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Abstract 
Activation of the adenosine monophosphate protein kinase (AMPK) signalling 
pathway is known to result in the inhibition of ATP-consuming anabolic mechanisms 
in the heart and is associated with prevention of cardiac myocytes loss. The multi-
tyrosine kinase inhibitor (TKI) Sunitinib has been associated with cardiotoxicity via 
the inhibition of AMPK signalling. In contrast, the agent Metformin, used for 
treatment of type-2 diabetes mellitus, is associated with cardioprotective properties 
with the activation of the AMPK signalling pathway. We aimed to demonstrate the 
potential use of Metformin with Sunitinib in order to prevent Sunitinib-induced 
cardiotoxicity. Sprague-Dawley (2/3 m/o, male) rat hearts were Langendorff 
perfused with vehicle control, Sunitinib (1 µM) ± Metformin (50 µM) ± AMPK-
associated inhibitor S-(4-Nitrobenzyl)-6-thioinosine (NBTI) (1 µM) for 155 minutes, 
following 20 minutes of stabilisation. Haemodynamic parameters were measured 
for heart rate (HR), left ventricular developed pressure (LVDP) and coronary flow 
(CF). Dismounted hearts were used for triphenyltetrazolium chloride (TTC) staining 
for infarct percentage or Western blot SDS page analysis for protein levels for 
phosphorylated-AMPK (Thr172), total-AMPKα and GAPDH. Isolated primary cardiac 
myocytes were obtained from Sprague-Dawley (2/3 m/o, male) rat hearts following 
Langendorff perfusion. HepG2 and HL60 cells were incubated with Sunitinib (0.1-
100 µM) ± Metformin (50 µM) ± NBTI (1 µM) for (3-(4,5-Dimethylthiazol-2-yl)-2-5-
Diphenyltetrazolium Bromide (MTT) analysis. Sunitinib administration (1 µM) 
demonstrated a significant increase in infarct percentage of Sprague-Dawley rat 
hearts using the Langendorff model, compared to vehicle control. Sunitinib 
administration further demonstrated a significant decrease in LVDP compared to 
vehicle control at selected time-points. Co-administration of Sunitinib with Metformin 
(50 µM) attenuated the increase in infarct percentage (co-treatment 20 ± 2 % vs. 
Sunitinib 31 ± 2 %) and attenuated the Sunitinib-induced decrease in LVDP at 
selected time-points (145 minute; Sunitinib 64 ± 5 % vs. co-treatment 80 ± 6 %, 160 
minute; Sunitinib 57 ± 6 % vs. co-treatment 75 ± 3 %, 175 minute; Sunitinib 58 ± 6 
% vs. co-treatment 74 ± 3 %). Live cell population of cardiac myocytes was 
decreased during Sunitinib administration (1 µM). Co-administration of Metformin 
(50 µM) with Sunitinib attenuated Sunitinib-induced decrease of live cell population 
of isolated cardiac myocytes (co-treatment 41 ± 3 % vs. Sunitinib 12 ± 2 %). 
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Metformin-induced activation of AMPK and Metformin-induced cardioprotection was 
abolished during co-administration of Sunitinib and Metformin with NBTI (1 µM). 
Sunitinib demonstrated a dose-dependent decrease in cell viability in HepG2 and 
HL60 cells, co-administration of Sunitinib (0.1-100 µM) with Metformin (50 µM) 
demonstrated an increase in EC50 concentration in HepG2 and HL60 cells (HepG2 
cells; co-treatment 34.7 µM vs. Sunitinib 15.4 µM., HL60 cells; co-treatment 18.2 
µM vs. Sunitinib 10 µM). The addition of NBTI (1 µM) with Sunitinib (0.1-100 µM) 
and Metformin (50 µM) demonstrated an increase in EC50 concentration in HepG2 
(43.3 µM) and HL60 cells (33.3 µM).  
We demonstrated for the first time Metformin-induced cardioprotection against 
Sunitinib-induced cardiotoxicity in an ex-vivo Langendorff-based model. 
Furthermore, Western blot analysis determined that Metformin-induced 
cardioprotection is associated with an increase in phosphorylation of AMPK, an 
effect that was abolished upon AMPK inhibition with NBTI. Moreover, we 
demonstrated the adjunctive treatment in human cancer cell lines of HepG2 and 
HL60, that Metformin co-administration resulted in an increase in EC50 
concentration compared to Sunitinib administration alone, however Metformin did 
not inhibit Sunitinib’s anti-proliferative properties. 
In conclusion, this study demonstrates the cardioprotective properties of Metformin 
during co-administration with Sunitinib and the role of AMPK signalling. This study 
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Statement of significance  
Early detection of symptoms associated with drug-induced cardiotoxicity can 
prevent the onset of ischaemia, heart failure as well as drug discontinuation. 
Screening with human cancer cell lines can reveal if potential adjunctive therapy 
drugs interfere with and prevent the anti-cancer activity of chemotherapy agents. 
Sunitinib has been associated with cardiotoxicity with the involvement of the AMPK 
signalling pathway, whilst Metformin, used for treatment of type-2 diabetes mellitus, 
is associated with cardioprotective properties with the activation of the AMPK 
signalling pathway. We demonstrated for the first time the potential use of Metformin 
with Sunitinib in an ex-vivo Langendorff-based model. We demonstrated for the first 
time in the described model that Metformin protects against Sunitinib-induced 
cardiotoxicity. Metformin-induced cardioprotection was correlated with an increase 
in phosphorylated-AMPK signalling following Western blot analysis, an effect that 
was attenuated following AMPK inhibition. The proposed activation of AMPK acts 
to counter loss of ATP levels, highlighted by current literature, corresponding to 
events of ischaemia, and the prevention of the activation of apoptosis and necrosis, 
preventing the loss of cardiac myocytes and coronary tissue.  
Contents from this thesis was submitted / published as following: 
Kuburas, R., Gharanei, M., Haussmann, I., Maddock, H., and Sandhu, H. (2019) 
‘Metformin Protects Against Sunitinib-Induced Cardiotoxicity via the Activation of 
AMPK Signalling’. Submitted to British Journal of Pharmacology 
Sandhu, H. and Kuburas, R. (2015) 'Insulin Resistance in Women with Polycystic 
Ovary Syndrome: Optimizing Treatment by Implementing an in Vitro Insulin 
Resistance Organ Culture Model'. Clinics Mother Child Health 12, e107. 
Kuburas, R., Gharanei, M., Haussmann, I., Maddock, H., and Sandhu, H. (2018). 
‘P37 the Assessment of the Cardioprotective Properties of Metformin during 
Sunitinib-Induced Cytotoxicity’ A14-A14.  
 
 
11 | P a g e  
 
Kuburas, R., Gharanei, M., Haussmann, I., Maddock, H., and Sandhu, H. (2017) 
'The Early Assessment of the Cardioprotective Properties of Metformin during 
Sunitinib-Induced Cytotoxicity'. Journal of Pharmacological and Toxicological 





















12 | P a g e  
 
Contents 
Certificate of Ethical Approval ................................................................................ 3 
Candidates Declaration .......................................................................................... 4 
Turnitin Report Summary ....................................................................................... 6 
Acknowledgements ................................................................................................ 7 
Abstract .................................................................................................................. 8 
Statement of significance ..................................................................................... 10 
List of Figures and Tables .................................................................................... 16 
Abbreviations ........................................................................................................ 18 
Chapter One: General Introduction ...................................................................... 24 
1.1. General overview ....................................................................................... 24 
1.2. Epidemiology of heart disease ................................................................... 25 
1.3. Pathophysiology of drug-induced cardiotoxicity and ischaemic injury ........ 26 
1.4. The role of the adenosine monophosphate protein kinase pathway .......... 29 
1.5. Myocardial cell death ................................................................................. 30 
1.6. Apoptosis and Necrosis ............................................................................. 31 
1.7. Multi-tyrosine kinase inhibitors and Sunitinib-induced cytotoxicity ............. 35 
1.8. Sunitinib treatment-associated cardioavascular effects and potential 
adjunctive treatment, the role of AMPK and mTOR signalling .......................... 46 
1.9. Metformin therapy and Metformin-induced cardioprotection ...................... 58 
1.10. The anticancer properties of Metformin. ................................................... 63 
1.11. AMPK-dependent activation during Metformin–induced cardioprotection. 72 
1.12. Role of mTOR in Metformin cardioprotection. .......................................... 80 
1.13. mTOR involvement in cancer and hypoxia. .............................................. 84 
1.14. Role of Adenosine and hENT1 in AMPK signalling .................................. 85 
1.15. Ex-vivo modelling for drug-induced ischaemic heart disease. .................. 90 
1.16. Aims and objectives. ................................................................................ 92 
Chapter Two: Materials and Methods. .................................................................. 93 
2.1. Drug concentration rationale and introduction ............................................ 93 
2.2.1. Materials ................................................................................................. 95 
2.2.2. Animals and cells. ................................................................................... 96 
2.3.1. Langendorff experiment and isolated perfused heart preparation–
normoxic study. ................................................................................................. 97 
13 | P a g e  
 
2.3.2. Triphenyl-tetrazolium chloride staining. ................................................... 98 
2.4. Western blot analysis SDS Page. ............................................................ 100 
2.5. Methylthiazolydiphenyl-tetrazolium bromide assay for HepG2 and HL60 cell 
viability ............................................................................................................ 101 
2.6.1. Cardiac myocyte isolation. .................................................................... 104 
2.6.2. Cardiac myocyte isolation-Trypan blue staining. ................................... 105 
2.7. Statistical Analysis. .................................................................................. 106 
Chapter Three: Metformin Attenuates Sunitinib-Induced Cardiotoxicity in Sprague-
Dawley Rat Hearts using the Langendorff System. ............................................ 107 
3.1. Introduction .............................................................................................. 108 
3.2. Methodology............................................................................................. 112 
3.2.1. Chemicals ............................................................................................. 112 
3.2.2. Isolated perfused heart preparation and Langendorff protocol. ............. 113 
3.2.3. Statistical Analysis. ............................................................................... 114 
3.3.1. Results. ................................................................................................. 115 
3.3.2. The effects of Sunitinib in the absence and presence of Metformin on 
haemodynamic parameters in SD rat hearts. .................................................. 116 
3.3.3. The effects of Sunitinib in the absence and presence of Metformin on 
infarct percentage in SD rat hearts.................................................................. 122 
3.4. Discussion ................................................................................................ 124 
3.5. Conclusion. .............................................................................................. 138 
Chapter Four: Inhibition of the human equilibrative nucleoside transporter prevents 
Metformin-induced cardioprotection in Sunitinib-induced cardiotoxicity, the role of 
AMPK activation. ................................................................................................ 139 
4.1. Introduction .............................................................................................. 141 
4.2. Methodology............................................................................................. 146 
4.2.1. Chemicals. ............................................................................................ 146 
4.2.2. Isolated perfused heart preparation. ..................................................... 147 
4.2.3. Langendorff protocol. ............................................................................ 148 
4.2.4. Isolated cardiac myocyte protocol. ........................................................ 149 
4.2.5. Trypan Blue staining for percentage live cell population of cardiac 
myocytes. ........................................................................................................ 150 
4.2.6. Western blot detection of phosphorylated-AMPK (Thr172), AMPKα and 
GAPDH. .......................................................................................................... 151 
4.2.7. Statistical Analysis. ............................................................................... 152 
14 | P a g e  
 
4.3. Results. .................................................................................................... 153 
4.3.1. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI on haemodynamic parameters in SD rat hearts. .................................... 154 
4.3.2. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI on infarct percentage in SD rat hearts. .................................................. 160 
4.4. The effects of Sunitinib in the absence and presence of Metformin and NBTI 
on live cell population of isolated cardiac myocytes using trypan blue staining.
 ........................................................................................................................ 162 
4.5. The effects of Sunitinib in the absence and presence of Metformin and NBTI 
in SD rat hearts using western blot analysis for phosphorylated-AMPKα, AMPKα 
and GAPDH. ................................................................................................... 164 
4.6. Discussion. ............................................................................................... 168 
4.7. Conclusion. .............................................................................................. 183 
Chapter Five: The effect of Metformin co-administration during Sunitinib-induced 
cytotoxicity in cancer cell lines. ........................................................................... 184 
5.1. Introduction. ............................................................................................. 185 
5.2. Methodology............................................................................................. 193 
5.2.1. Chemicals. ............................................................................................ 193 
5.2.2. MTT Assay for HepG2 and HL60 Cell Viability. ..................................... 194 
5.2.3. Statistical Analysis. ............................................................................... 195 
5.3.1. Results. ................................................................................................. 196 
5.3.2. The effects of Sunitinib on cell viability of HepG2 cells. ........................ 197 
5.3.3. The effects of Sunitinib on cell viability of HL60 cells. ........................... 198 
5.3.4. The effects of Metformin on cell viability of HepG2 cells. ...................... 199 
5.3.5. The effects of Metformin on cell viability of HL60 cells .......................... 200 
5.3.6. The effects of Sunitinib in the absence and presence of Metformin on cell 
viability of HepG2 cells .................................................................................... 201 
5.3.7. The effects of Sunitinib in the absence and presence of Metformin on cell 
viability of HL60 cells ....................................................................................... 202 
5.3.8. The effects of NBTI on cell viability of HepG2 cells ............................... 204 
5.3.9. The effects of NBTI on cell viability of HL60 cells .................................. 205 
5.3.10. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI on cell viability of HepG2 cells ............................................................... 206 
5.3.11. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI on cell viability of HL60 cells .................................................................. 208 
 ........................................................................................................................ 208 
15 | P a g e  
 
5.4. Discussion ................................................................................................ 210 
5.5. Conclusion ............................................................................................... 218 
Chapter Six: General Discussion. ....................................................................... 219 
6.1. Summary of findings ................................................................................ 219 
6.2. Considerations and concluding remarks .................................................. 221 
6.2.1. Mechanism of Sunitinib-induced cardiotoxicity ...................................... 221 
6.2.2. Considerations for Metformin use ......................................................... 222 
6.2.3. Concluding remarks .............................................................................. 223 
Chapter Seven: Appendix .................................................................................. 224 
7.1. The effects of Sunitinib ± Metformin ± NBTI on haemodynamics in 7-8 
months female SD rat hearts. ......................................................................... 224 
7.2. The effects of Sunitinib ± Metformin ± NBTI on infarct percentage in 7-8 
months female SD rat hearts. ......................................................................... 230 
















16 | P a g e  
 
List of Figures and Tables  
Figures 
Figure 1. ............................................................................................................... 33 
Figure 2. ............................................................................................................... 36 
Figure 3. ............................................................................................................... 39 
Figure 4 ................................................................................................................ 40 
Figure 5 ................................................................................................................ 45 
Figure 6 ................................................................................................................ 48 
Figure 7 ................................................................................................................ 59 
Figure 8 ................................................................................................................ 71 
Figure 9 ................................................................................................................ 74 
Figure 10 .............................................................................................................. 88 
Figure 11 .............................................................................................................. 99 
 
Figure 12a .......................................................................................................... 116 
Figure 12b .......................................................................................................... 118 
Figure 12c .......................................................................................................... 120 
Figure 13………………………………………………………………………………..123 
 
Figure 14a .......................................................................................................... 154 
Figure 14b .......................................................................................................... 156 
Figure 14c .......................................................................................................... 158 
Figure 15 ............................................................................................................ 161 
 
Figure 16 ............................................................................................................ 163 
 
Figure 17 ............................................................................................................ 165 
 
Figure 18 ............................................................................................................ 166 
 
Figure 19 ............................................................................................................ 167 
 
Figure 20 ............................................................................................................ 188 
 
Figure 21a .......................................................................................................... 197 
Figure 21b .......................................................................................................... 198 
 
Figure 22a .......................................................................................................... 199 
Figure 22b .......................................................................................................... 200 
 
17 | P a g e  
 
Figure 23a .......................................................................................................... 201 
Figure 23b .......................................................................................................... 202 
 
Figure 24a .......................................................................................................... 204 
Figure 24b .......................................................................................................... 205 
 
Figure 25a .......................................................................................................... 206 
Figure 25b .......................................................................................................... 208 
 
Tables  

















18 | P a g e  
 
Abbreviations  
%  Percentage 
µM Micromole 
4E-BP1 Elongation factor-4E binding protein 1 
5’-ITU 5’-iodotubercidin 
8-SPT 8-p-sulfophenyltheophylline hydrate 
ABL Abelson 
ACC Acetyl-coenzyme A carboxylase 
Acetyl-CoA Acetyl-coenzyme A 
ADP Adenosine diphosphate 
Akt Protein kinase B 
AICAR Aminoimidazole carboxamide ribonucleotide 
AIF Apoptosis-inducing factor 
AMP Adenosine monophosphate 
AMPK Adenosine monophosphate protein kinase 
ANT Adenine nucleotide translocase 
Apaf Apoptosis protease activating factor 
ATCC American Type Culture Centre 
ATM Ataxia telangiectasia mutated 
ATP Adenosine triphosphate 
BAD Bcl2-antagonist of cell death 
Bax Bcl2-associated X protein 
BclXL B cell lymphoma–XL 
19 | P a g e  
 
BCR Break-point cluster region 
BMI Body mass index 
BMP Bone morphogenic protein 
cAMP Cyclic AMP 
CAMKK Calmodulin-dependent protein kinase 
CHD Coronary heart disease 
CF Coronary flow 
cIAP  Cellular inhibitor of apoptosis 
CNT Concentrative nucleoside transporter 
CPT Carnitine palmitoyl transferase  
CRTC2 cAMP response element-binding protein-regulated transcription 
coactivator 2 
CSF1R Colony-stimulating factor 1 receptor 
CVD Cardiovascular disorder 
CyPD Cyclophillin D 
DDIT4 DNA-damage-inducible transcript 4 
DISC Death-inducing signalling complex 
DMSO Dimethyl sulfoxide  
DMEM Dulbecco’s Modified Eagle Medium 
ECG Electrocardiogram 
EEF2 Eukaryotic elongation factor-2 
EGFR Epidermal growth factor receptor 
ENT Equilibrative nucleoside transporter 
20 | P a g e  
 
EPC Endothelial progenitor cell 
Erk Extra-cellular signal-regulated kinase 
EIF2α Eukaryotic translation initiation factor 2α 
FADD FAS-associated death domain protein 
FAK Focal adhesion kinase 
FBPase Fructose-1, 6-biphosphatase 
FBS Fetal bovine serum 
FLIP FLICE-like inhibitory protein 
FLT FMS-like tyrosine kinase-3 
FOCO1 forkhead box-O1 
GADD45 Growth arrest and DNA damage–inducible 45 
GIST Gastro-intestinal stromal tumours 
GTP Guanosine triphosphate 
hENT Human equilibrative nucleoside transporter 
HF Heart failure 
HIF Hypoxia-inducible factor 
HR Heart rate 
IAP Inhibitors of apoptosis 
ICAD Inhibitor of caspase activated DNase 
ICAM Intercellular adhesion molecule 
IGF Insulin–like growth factor 
IKr Rapid delayed rectifier potassium current 
IKs Slow delayed rectifier potassium current 
21 | P a g e  
 
IL Interleukin 
IRE1 Inositol-requiring enzyme 1 
IRS Insulin receptor substrate 
JAK Janus-kinase 
JNK Jun-N-terminal kinase 
KH Krebs Henseleit 
LDH Lactate-dehydrogenase 
LV Left ventricular 
LVDP Left ventricular developed pressure 
LVEF Left ventricular ejection fraction  
LKB1 Liver kinase B1 
MAPK Mitogen-activated protein kinase 
MCT4 Mono carboxylate transporter 4 
MI Myocardial infarction 
mg/d Milligram per day 
mg/dl Milligram per decilitre 
mg/kg Milligram per kilogram 
mg/ml Milligram per milter  
MLC Myeloid cell leukaemia protein 
mmHg Millimetre of mercury 
mPTP Mitochondrial permeability transition pore 
mRNA Messenger RNA 
MTT 3-(-4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium  
22 | P a g e  
 
 bromide                                                      
mTOR Mammalian transporter of rapamycin 
mTORC1 Mammalian transporter of rapamycin complex 1 
NADPH Nicotinamide adenine dinucleotide phosphate 
NBTI S-(4-Nitrobenzyl)-6-thioinosine 
NO Nitric oxide  
NFκB Nuclear factor–κB 
NT-proBNP N-terminal pro-brain natriuretic peptide 
OCT1 Organic cation transporter 1 
PAT1 Proton-assisted amino acid transporter 1 
PBS Phosphate buffered saline 
PDGFR Platelet-derived growth factor receptor 
PERK Protein kinase RNA-like endoplasmic reticulum kinase 
PGC-1α PPARγ co-activator 1α 
PI3K Phosphatidylinositol-3-OH kinase 
PKC Protein kinase C 
PPAR Peroxisome proliferator-activated receptor 
PTEN Phosphatase and tensin homolog 
PTPN11 Tyrosine protein phosphate non-receptor type 11 
RAG Recombination activating gene 
ROS Reactive oxygen species 
RSK Ribosomal S6 kinase 
RISK Reperfusion injury salvation kinase 
23 | P a g e  
 
S6K1 Ribosomal protein S6 kinase 1 
SD Sprague-Dawley 
siRNA Small interfering RNA 
SIRT1 NAD(+)-dependent histone/protein deacetylase sirtuin 1 
SREBP Sterol regulatory element-binding protein 
STAT Signal transducer and activator of transcription  
T2DM Type-2 diabetes mellitus 
TDP Torsade de pointe 
Thr172 Threonine 172 
TK Tyrosine kinase 
TKI Tyrosine kinase inhibitor  
TRAIL TNF related apoptosis-inducing ligand 
TSC tuberous sclerosis complex 
TNF Tumour necrosis factor 
TTC 2, 3, 5 triphenyltetrazolium chloride 
TTF Triphenyltetrazolium formazan 
ULK-1 Unc-51 like autophagy activating kinase 
VCAM Vascular cell adhesion molecule 
VDAC Voltage–dependent anion channel 
VEGFR Vascular endothelial growth factor receptor 
VHL  von Hippel-Lindau 
XIAP X–linked inhibitor of apoptosis protein 
 
24 | P a g e  
 
Chapter One: General Introduction 
1.1. General overview 
The experimental work carried out in this thesis aimed to investigate the potential 
intracellular pathway and molecular markers associated with the cardioprotective 
effects of Metformin when used in adjunctive therapy with Sunitinib. This was carried 
out in order to potentially reduce or prevent Sunitinib-induced cardiotoxic effects 
during an ex-vivo Langendorff perfused rat heart model, with a further aim to 
examine the effects of co-treatment of adjunctive therapy with Metformin in cancer 
cell models.  
The introductory chapter provides general information on the issue of drug-induced 
heart disease, the cardiotoxic mechanism of Sunitinib, the potential mode of 
cardioprotection by Metformin and the emphasis on the role of the AMPK pathway 
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1.2. Epidemiology of heart disease  
The World Health Organisation estimate that over 17.7 million individuals died from 
cardiovascular disease (CVD) in 2015, whilst 7.4 million died due to coronary heart 
disease (CHD) and 6.7 million due to stroke (World Health Organisation 2017). 
Moreover, the British Heart Foundation reported that CVD results in over 25 % of 
all deaths within the United Kingdom in 2016–2017, with over 80 % dying in England 
compared to the United Kingdom overall (British Heart Foundation 2018). 
Furthermore, 7 million individuals are known to be living in the United Kingdom with 
CVD, with approximately 200,000 reported hospital visits in the UK resulting from 
myocardial infarction (MI), typically defined as a heart attack caused by the blockade 
of the coronary artery preventing the heart from receiving oxygenated blood (British 
Heart Foundation 2018). Moreover, the National Heart, Lung and Blood Institute 
(2018) highlighted risk factors to include high blood pressure-blood pressure 
consistently greater than systolic 140 mmHg / diastolic 90 mmHg (National Heart, 
Lung and Blood Institute 2018), high blood cholesterol–non-high density lipoprotein 
greater than 130 mg/dl (National Heart, Lung and Blood Institute 2014), smoking, 
being overweight or obese–BMI greater than 25.0 (Centres for Disease Control and 
Prevention 2016), low physical activity as well as having a family history of heart 
disease and preeclampsia during pregnancy (National Heart, Lung and Blood 
Institute 2017). Diabetes is also a risk factor for heart disease and heart failure (HF) 
(van Melle et al. 2010). The prevalence of patients with diabetes and HF is said to 
be rising, and in comparison to HF patients without diabetes, patients with diabetes 
are reported to have a poor prognosis and quality of life (de Boer et al. 2010, 
MacDonald et al. 2008). Patients with type-2 diabetes mellitus (T2DM) are reported 
to experience worse clinical outcomes following an incidence of MI compared to 
non-diabetic patients experiencing MI (Haffner et al. 1998, Malmberg et al. 2000, 
McGuire et al. 2000). Following this, the resulting development of HF and CVD are 
known to result in the development of myocardial ischaemia, resulting from an 
inadequate supply of oxygenated blood to the myocardium (Hurst and Lee 2003).  
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1.3. Pathophysiology of drug-induced cardiotoxicity and ischaemic injury  
As well as the discussed causes and contributors towards CVD, HF and MI 
discussed in Section 1.2., patients undergoing treatment, particularly 
chemotherapy, have been associated with the development and increased risk of 
developing cardiovascular adverse effects. Cardiovascular toxicity remains a 
serious issue in the clinical and pre-clinical phases of drug development, as well as 
contributing towards the withdrawal of agents post-approval. Safety issues account 
for approximately one third of all drug discontinuation (Ferri et al. 2013). Due to a 
very high attrition rate during in-man registration phases of development, the U.S 
federal drugs agency (FDA) approval of new drugs was lower in 2002 than at any 
other time in the previous decade (Ferri et al. 2013).  
Cardiotoxic effects may be induced in a predictable dose and time-dependent 
manner, whilst cardiotoxic agents may promote adverse consequences in patients 
with existing cardiovascular co-morbidities (Varga et al. 2015, Curigliano et al. 
2016). Certain agents have been associated with the onset of HF and cardiotoxicity, 
arising from the delay in ventricular depolarisation and repolarisation, resulting in 
an elevated QTc interval and QRS complex widening (Silke et al. 2002). The QT 
interval is the measuring of the beginning of the QRS complex to the end of the T 
wave on the electrocardiogram (ECG) surface, this represents a period from the 
onset of depolarisation to the completion of repolarisation of the ventricular 
myocardium (BMJ 2016). In summary, the P>Q interval defines the period of atrial 
depolarisation and ventricular filling, followed by the period of isovolumetric 
contraction defined as Q>S (BMJ 2016). From this, R>S>T periods results from the 
ejection period, whilst the T period occurs following isovolumetric and passive 
ventricular relaxation, the observed peaks are detected using the electrocardiogram 
(BMJ 2016).   
Prolonged or abnormal repolarisation, resulting from QT interval prolongation, long 
QT syndrome (LQTS) and/or abnormal T or T/U wave morphology, is known to 
result in the development of the condition known as “torsade de pointe” (TDP) (Yap 
and Camm 2003). Further TDP prolongation is known to result in ventricular 
fibrillation and sudden cardiac death and HF (Yap and Camm 2003). Within healthy 
individuals, QT interval is approximately 400 ms in men and 420 ms in women, QTc 
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values greater than 450 ms in men and greater than 470 ms in women is classed 
as ‘prolonged’ whilst QTc values greater than 500 ms are associated with 
arrhythmias and TDM (Huffman and Stern 2003, Glassman and Bigger 2001). As 
highlighted, many agents such as anti-arrhythmic agents and many non-cardiac 
agents are known to result in the prolongation of the QT and the development of 
TDP (Yap and Camm 2003). Therefore, understanding and identifying agents that 
have the potential to result in TDP and associated cardiotoxicity is key for patient 
survival.   
One explanation of the effects of drug-induced prolongation of the QTc interval can 
be hypothesised to be a direct result of the blockade of the delayed rectifier K+ 
current on the cardiac membrane, related to ventricular arrhythmia and can cause 
sudden cardiac arrest (Erbas and Yilmaz 2013). Repolarisation of cardiac myocytes 
result from the outward movement of K+ ions, K+ currents involved in ventricular 
repolarisation are subtypes of the delayed rectifier current and include the rapid 
activation of the delayed potassium rectifier channel (IKr) and the slow activation of 
the delayed potassium rectifier channel (IKs) (Yap and Camm 2003, Guo et al. 2011). 
Blocking of either of these potassium currents is said to be associated with the 
prolongation of action potential (Yap and Camm 2003). It has been mentioned by 
Yap and Camm (2003) that IKr is most susceptible to pharmacological influence and 
that the blockade is associated with pro-arrhythmic effects of prolonged QT interval 
and detection of T or U wave abnormalities on the surface ECG. Prolongation of 
repolarisation is associated with subsequent activation of an inward depolarisation 
current, referred to as an “early after-depolarisation”, promoting triggered activity 
and importantly when accompanied by the presence of a notably increased 
dispersion of repolarisation, the resulting action can induce re-entry and TDP (Yap 
and Camm 2003). It is known that voltage ion-gated channels are responsible for 
the generation of electrical activity within the human heart, the Na+, Ca+ and K+ 
channels are described as the most important for determining shape and duration 
of cardiac action potential (Brown et al. 2000). The direct opening of the K+ channel 
results in the movement of positively charged ions out of the cell and therefore 
terminating action potential and repolarising the myocardium (Brown et al. 2000). 
Drug-induced QTc interval prolongation can be detected using ECG, the 
prolongation is described to result from the prolonged action potential duration 
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within individual cardiac cells (Brown et al. 2000). As mentioned, the result of 
defective repolarisation can give rise to “early after-depolarisation” within cardiac 
cells; triggering arrhythmias as well as TDP (Brown et al. 2000). The administration 
of drugs can result in either the increase in influx of ions into cardiac myocytes 
during action potential or result in the reduction of efflux (Brown et al. 2000). Both 
alterations are known to result in the prolongation of after-depolarisation and the 
prolongation of the QTc interval (Brown et al. 2000).  
The proposed effects can contribute towards repolarisation of the myocardium and 
therefore contribute towards the potential inducing of CVD, including MI, congestive 
HF and CHD (Ferri et al. 2013). The use of in-vivo and ex-vivo experiments of 
animal heart models can assist to monitor and predict these effects during 
preclinical and early stages of drug development, however direct causes of CVD 
are said to be continuously less reflected during pre-clinical trials and the outcomes 
are not often recognised until after the chemotherapeutic agent has been approved 
and used within a large population and long-term clinical outcomes have been 
investigated (Ferri et al. 2013). Drug-induced cardiotoxicity can induce pericardial 
and endocardial disorders, contributing towards tachycardia (abnormal heart rate) 
and tachypnea (abnormal rapid breathing) and can contribute towards the 
development of stroke within patients (Ferri et al. 2013, Song et al. 2012).  
As mentioned, drug-induced cardiotoxicity results in ischaemic stress which exhibits 
hallmarks of and occurs directly as a result of the activation of apoptosis within 
cardiac myocytes (Song et al. 2012). This was supported by evidence of apoptosis-
induced cardiac myocytes located in the region of ischaemia and zone of infarction, 
compared to fewer apoptosis-induced cardiac myocytes shown in non-infarct 
myocardium (Krijnen et al. 2002). Moreover, the event of ischaemia is known to 
result in metabolic changes such as the increase in reactive oxygen species (ROS), 
calcium overload and the depletion of adenosine triphosphate (ATP) availability 
(Sanada et al. 2011, Eltzschig and Eckle 2011). Furthermore, ischaemia-
reperfusion injury can target the mitochondria for cell death, this results in defecting 
the electron transport chain and oxidative phosphorylation and further contributes 
to the deprivation of energy availability within the myocardium (Murphy and 
Steenbergen 2008, Camara et al. 2010).  
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1.4. The role of the adenosine monophosphate protein kinase pathway  
The perturbations in energy metabolism during pathological states such as 
ischaemia and cardiac hypertrophy, as described in Section 1.3., is said to result in 
the activation of the adenosine monophosphate (AMP)-protein kinase (AMPK) 
(Hardie and Carling 1997). Activation of AMPK inhibits ATP-consuming anabolic 
pathways to conserve ATP (Arad et al. 2007, Dyck and Lopaschuk 2006). During 
these events, ATP consumption exceeds the production, resulting in an increase in 
adenosine diphosphate (ADP) (Qi and Young 2015). Adenylate kinase acts to 
convert two ADPs to AMP and ATP, increasing cytosolic concentration of AMP and 
resulting in the activation of AMPK via the binding to the regulatory nucleotide 
binding domain of the AMPKγ subunit (Qi and Young 2015). AMPK is a 
heterotrimeric serine/threonine kinase responsible for cellular metabolic control and 
consists of a catalytic α subunit as well as regulatory β and γ subunits (Shaw et al. 
2004, Jones and Thompson 2009, Hardie 2011, Viollet et al. 2010). Phosphorylation 
occurs at the threonine 172 (Thr172) phosphorylation site within the α subunit, whilst 
the β subunit contains binding site for myristoylation, phosphorylation and glycogen 
(Warden et al. 2001, Hudson et al. 2003, Polekhina et al. 2003, Arad et al. 2007). 
AMPK acts to regulate cellular energy homeostasis within cardiac muscles, and 
other organ systems, by regulating AMP via the phosphorylation of upstream liver 
kinase B1 (LKB1) and calmodulin-dependent protein kinase kinase (CAMKK) 
(Heidrich et al. 2010, Arad et al. 2007). AMPK remains inhibited by high 
concentrations of ATP at rest during normal aerobic metabolism, due to ATP binding 
at the γ subunit (Wang et al. 2003, Hardie 2011). Depletion of ATP levels, and 
events such as stress, hypoxia and ischaemia-reperfusion-induced injury can 
contribute towards an increasing AMP:ATP ratio, enhancing the stimulation of 
AMPK via the activation of α subunits at Thr172 by kinases LKB1 and CAMKKβ 
(Frederich and Balschi 2002, Dyck and Lopaschuk 2006, Baron et al. 2005, Shaw 
et al. 2004, Jones and Thompson 2009, Hardie 2011, Viollet et al. 2010). Two 
isoforms of the α and β subunits, and three γ isoforms exist within the mammalian 
genome, human α2 and β2 subunits are expressed within the heart and skeletal 
muscles, mediating AMPK functions for intracellular localisation (Cheung et al. 
2000, Arad et al. 2007). The AMPK pathway is discussed in greater detail from 
Section 1.8. 
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1.5. Myocardial cell death 
Cardiotoxicity results in cardiac myocyte death and necrotic cell death during events 
such as ischaemia (Piper et al. 1998). Cardiac myocytes require and utilise high 
amount of ATP for energy-consuming contractile state, during which malfunctioning 
mitochondria are replaced by newly synthesised organelles required for the 
production of ATP (Fischer et al. 2012). Mitochondria are required for the production 
of ATP therefore agents that interfere with the physiological myocardial 
mitochondrial function are known to induce a depletion of the ATP pool and 
myocardial dysfunction (Varga et al. 2015).  
During an event such as ischaemia, within mitochondria altered cytosolic Ca2+ 
regulation induces structural fragility and excessive contractile activation results in 
necrotic cell death via mitochondrial permeability transition pore (mPTP) opening 
(Inserte et al. 2002, Siegmund et al. 1994, Bhamra et al. 2008).  Opening of the 
mPTP channel mediates cardiac myocyte death via uncoupling oxidative 
phosphorylation and swelling of the mitochondria (Hausenloy and Yellon 2003). 
mPTP has further been described as a non-specific pore within the mitochondrial 
membrane that opens in the first minutes of myocardial reperfusion in response to 
ATP depletion and oxidative stress (Griffiths and Halestrap 1995, Javadov et al. 
2003, Kim et al. 2006, Ruiz-Meana et al. 2006). Mitochondrial Ca2+ overload has 
been shown to result in mPTP opening (Argaud et al. 2004), adding to the 
understanding that mitochondrial Ca2+ uptake during reperfusion has an important 
role in cell death by bringing mitochondria closer to the threshold at which mPTP 
opening occurs during reperfusion, known as mitochondrial priming (Weiss et al. 
2003). Following cardiac myocyte, neutrophil and ischaemic zone endothelial cell 
injury the generation of oxygen free radicals is known to exacerbate membrane 
damage, calcium loading and releasing inflammatory mediators all contributing 
towards microvascular obstruction and the ‘no-flow’ phenomenon in the reperfused 
myocardium (Buja 2005). The “no-flow” phenomenon is defined as the inadequate 
myocardial perfusion through a segment of the coronary circulation without 
angiographic evidence of mechanical vessel obstruction; therefore, re-opening of 
the coronary artery following obstruction may not result in improved tissue perfusion 
(Kloner et al. 1974, Ramjane et al. 2008).  
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1.6. Apoptosis and Necrosis 
As mentioned, ischaemic myocardial cell injury results in programmed cell death 
(apoptosis) and the rapid loss of cellular homeostasis (necrosis) cell death 
(Hausenloy and Yellon 2013). Apoptosis is pivotal in determining infarct size within 
in-vivo animal models and ex-vivo models of ischaemia-reperfusion injury and drug-
induced toxicity (Fliss and Gattinger 1996, Bäcklund et al. 2004). As summarised in 
Figure 1, apoptosis has been described as the highly ordered process displaying 
nuclear fragmentation and condensation, cytoplasmic shrinkage, blebbing of the 
plasma membrane, as well as exposure of phosphatidylserine (Yuan, Lipinski and 
Degterev 2003). Following apoptosis, dead cells fragment into membrane-bound 
apoptotic bodies for phagocytosis via macrophages and surrounding cells without 
inducing an inflammatory response (Yuan, Lipinski and Degterev 2003). Apoptosis 
occurs via the loss of oxygen supply and constrained mitochondrial 
phosphorylation, thereby initiating the loss of the major source of ATP production 
for energy metabolism (Buja 2005). Initiating anaerobic glycolysis for ATP 
production accumulates hydrogen ions and lactate, contributing to intracellular 
acidosis and glycolysis inhibition via mitochondrial fatty acid and residual energy 
metabolism (Buja 2005). The resulting impairment in contraction in the sarcolemma 
establishes the milieu for ventricular arrhythmias (Buja 2005). In comparison to 
apoptosis, necrosis results in the progressive loss of cytoplasmic membrane 
integrity, the rapid influx of Na+, Ca+ and water causes cytoplasmic swelling, 
mitochondrial cellular fragmentation, release of lysosomal and granular contents 
into the extracellular space (Bhatia 2003, Barros and Castro 2001). The resulting 
effects of necrosis is followed by an inflammatory response to the cellular content 
released and can further result in tissue damage (Barros and Castro 2001).    
An event such as ischaemia and/or ischaemia-reperfusion is said to activate anti-
apoptotic pro-survival kinase signalling cascades such as phosphatidylinositol-3-
OH kinase (PI3K), protein kinase B (Akt) and p42/44 extra-cellular signal-regulated 
kinases (Erk) 1-2 (Hausenloy and Yellon 2004). All are said to be implemented in 
cellular survival through recruitment of anti-apoptotic protection pathways 
(Hausenloy and Yellon 2004). However, the PI3K/Akt signalling cascade 
phosphorylates pro-apoptotic proteins Bcl2-antagonist of cell death (BAD), Bcl2-
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associated X protein (Bax), Bim and p53 as a result of ischaemia-reperfusion injury 
(Hausenloy and Yellon 2004, Cross et al. 2000). Moreover, Erk 1-2 regulates cell 
proliferation by mediating cellular apoptosis via inhibiting cytochrome-c induced 
caspase activation (Hausenloy and Yellon 2004). As highlighted in Figure 1, the Bax 
protein is known to accelerate apoptosis via inducing mitochondrial cytochrome-c 
release, resulting in mPTP formation, thus initiating cellular apoptosis (Yamaguchi 
and Wang 2001, Tsuruta et al. 2002, Marzo et al. 1998, Hausenloy and Yellon 
2004). The Bcl-2 and apoptosis protease activating factor (Apaf) family proteins are 
said to constitute the core apoptotic mechanism. During cell death the pro-apoptotic 
Bcl-2 family members: tBid, Dp-5, Bim, Bax, Bak and BAD antagonise anti-apoptotic 
Bcl-2 family proteins in order to induce mitochondrial damage (Yuan, Lipinski and 
Degterev 2003). The resulting release of cytochrome-c from the damaged 
mitochondria is known to recruit caspase-9 and Apaf-1, resulting in the formation of 
an apoptosome (Yuan, Lipinski and Degterev 2003). The active caspase-9 acts to 
cleave and activate caspase-3, which further cleaves cellular substrates inhibitor of 
caspase activated DNase (ICAD) and initiating ICAD-induction of DNA laddering, 
whilst the release of apoptosis-inducing factor (AIF) and EndoG to facilitate DNA 
fragmentation and Smac/Diablo to facilitate caspase activation resulting in DNA 
damage (Yuan, Lipinski and Degterev 2003). Apoptosis is known to be an energy 
consuming process, and if the energy demand exceeds supply cells are often 
defaulted to necrotic death (Yuan, Lipinski and Degterev 2003, Ankarcrona et al. 
1995). The cell deletion process of apoptosis has a pivotal role in cardiovascular 
diseases including MI, reperfusion injury and the development of HF (Bae et al. 
2010, Kang and Izumo 2003, Logue et al. 2005). Within the mitochondria, AIF and 
cytochrome-c play an important role in cell viability, however upon release both can 
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Figure 1: Apoptotic pathway in mammalian cells. Activation of apoptosis results in 
pro-apoptotic Bcl-2 family member proteins: tBid, Dp-5. Bax, Bak, and BAD 
antagonise Bcl-2 family proteins to induce mitochondrial damage. Following 
mitochondrial damage, cytochrome-c is released and recruits apoptosome-forming 
proteins caspase-9 and Apaf-1. Active caspase-9 cleaves and activates caspase-3 
resulting in the cleaving of ICAD which initiates ICAD-induction of DNA laddering. 
This further releases AIF and EndoG and initiates DNA fragmentation following 
Smac/Diablo activation for caspase activation and DNA damage (Yuan, Lipinski and 
Degterev 2003).   
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As described, AIF has an essential down-stream signalling effect in cell death (Bae 
et al. 2010). The nuclear enzyme peroxisome proliferator-activated receptor 
(PPAR)-1 has been shown to facilitate both the release of AIF from mitochondria 
and AIF nuclear translocation, as evidenced by PPAR-1 inhibition in the attenuation 
of Doxorubicin-induced AIF release from mitochondria (Piper et al. 1999, Bae et al. 
2010). Caspases play an integral role in apoptotic cell death (Alnemri et al. 1996). 
Upon mitochondrial damage, cytochrome-c is released and forms an oligomeric 
complex with dATP or apoptotic proteases, resulting in the activation of Apaf-1 and 
caspases-9, -3, -6 and -7 (Earnshaw et al. 1999, Li et al. 1997,). Caspase-8 however 
is shown to be activated via plasma membrane receptors: Fas receptor and tumour 
necrosis factor (TNF) receptor, also activating downstream caspases -3 and -7 
(Earnshaw et al. 1999).  
During apoptosis, caspases become cleaved from the existing zymogens form, 
rendering them active and are capable of permitting caspase-dependent apoptosis; 
studies have demonstrated the importance of regulating Bcl-2 family proteins and 
caspase-3 for myocardial protection (Kim et al. 2008, Liu et al. 2011). The 
mitochondrial outer membrane permeabilisation has been described to initiate the 
caspase-dependent apoptotic cascade and caspase-3 was shown to be a pivotal 
caspase in the mechanism leading to apoptotic death (Earnshaw et al. 1999, Li et 
al. 1997). Further to this, ischaemic injury leads to the increase of calcium ions and 
oxidative stress, resulting in rapid ATP depletion and rupturing the outer 
mitochondrial membrane, thus initiating apoptosis (Hausenloy et al. 2002, Halestrap 
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1.7. Multi-tyrosine kinase inhibitors and Sunitinib-induced cytotoxicity   
As mentioned in Sections 1.2.–1.5., certain agents have been associated with the 
onset of HF and drug-induced apoptosis and necrosis of myocardial tissue 
stemming from cardiac myocyte cell death. An area of particular interest is involving 
the use of chemotherapeutic agents such as the tyrosine kinase (TK) inhibitors 
(TKI). A summary of chemotherapy-induced apoptosis is presented in Figure 2. It 
has been described by Schlessinger (2000) how under normal conditions and 
disease states such as cancer, TKs are required to modulate proliferation, 
metabolism, differentiation and apoptosis. Receptor TKs remain active via mutation 
or translocation and are the main drivers of cancer cell proliferation and survival, 
whilst TKIs act to catalyse the transfer of phosphate from ATP on a protein 
substrate, from this the kinases act as a mediator of cellular signal transduction 
(Gschwind et al. 2004). Following this, kinases have become a key therapeutic 
target within oncology.  
From this, phosphorylation of the insulin receptor, epidermal growth factor receptor 
(EGFR), platelet-derived growth factor receptor (PDGFR) and vascular endothelial 
growth factor receptor (VEGFR) are essential for cellular homeostasis and the 
modulation of gene expression in intercellular and intracellular signalling pathways 
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Figure 2: Chemotherapy-induced apoptosis. Key: green = anti-apoptotic proteins, 
red = pro-apoptotic proteins. During treatment, apoptosis can be activated via the 
intrinsic or extrinsic pathway. Bcl-2 family proteins and the mitochondria are known 
to regulate the intrinsic pathway, whilst the binding of pro-apoptotic ligands such as 
TNF related apoptosis-inducing ligand (TRAIL) or Fas act to regulate the extrinsic 
pathway. Upon activation of apoptosis by chemotherapeutic agents and TKIs, the 
caspase activated cascade occurs and can act on both extrinsic and intrinsic 
pathways. The extrinsic pathway results from the binding of pro-apoptotic ligands to 
cell surface death receptors of the TNF receptor family present on the cell surface 
or are secreted into the extracellular space, described to belong to the extended 
cytokine TNF superfamily. Binding results in each receptor forming a death-inducing 
signalling complex (DISC), recruiting the adaptor protein FAS-associated death 
domain protein (FADD), caspase-8 and caspase-10. Release of both caspase-8 
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and caspase-10 into the cytoplasm initiates a subsequent activation of effector 
caspases to activate apoptosis. The FLICE-like inhibitory protein (FLIP) is known to 
act to suppress caspase-8 activation. The intrinsic pathway is regulated by Bcl-2 
family proteins and mitochondria and is activated via stresses such as DNA 
damage. Upon activation, p53 transmits death signals via inducing the expression 
of BH3-only proteins, for the activation of Bax and Bak, resulting in the formation of 
the mitochondrial outer membrane permeabilisation and releasing mitochondrial 
apoptogenic proteins; cytochrome-c, SMAC/Diablo and AIF. Cytochrome-c is said 
to promote the formation of the apoptosome and the activation of caspase-9 to 
antagonise the inhibitors of apoptosis (IAP) family proteins, whilst AIF and EndoG 
promote DNA degradation (Zhang and Yu 2013, Ashkenazi 2008, Bagnoli et al. 
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TKs of the VEGF receptor are a prime target for the inhibition of angiogenesis for 
established treatment for the inhibition of tumour growth and metastatic progression 
of cancer (Figure 3). Treatment options include pyrimidines (e.g. Imatinib, Dasatinib, 
Nilotinib and Pazopanib), pyrroles (e.g. Sunitinib) and pyridines (e.g. Sorafenib), 
however therapy is associated with adverse effects such as TDP, hypertension, 
cardiac toxicity and renal toxicity (Kappers et al. 2010). TKs are also involved in the 
development of certain cancer types. One example of clear-cell renal cell carcinoma 
involves the inactivation of the von Hippel-Lindau (VHL) gene during VHL disease, 
resulting in the accumulation of hypoxia-inducible factor (HIF)-1, causing the 
expression of hypoxia-inducible genes including VEGF and PDGF (Cockman et al. 
2000, Kaelin Jr 2004, Kim and Kaelin 2004). VHL disease is known to affect several 
parts of the body, including the development of renal and pancreatic tumours 
(Oxford University Hospitals 2014). Binding of growth factors to their respective TK 
receptors, results in cell migration, proliferation and survival, whilst overexpression 
of VEGF and PDGF is implicated in tumour angiogenesis, growth and metastasis 
(Krause and Van Etten 2005). Tumour development arises from several pathways 
and therefore multi-targeted inhibition is considered an effective approach for anti-
angiogenic renal cell carcinoma therapy when compared with single-targeted 
therapy (Oudard et al. 2005). However, as summarised in Figure 4, receptor TK 
signalling is involved in multiple pathways such as the focal adhesion kinase (FAK), 
PI3K and mitogen-activated protein kinase (MAPK) are involved in non-cancerous 
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Figure 3: Signalling pathway of receptor TKs involved in cancer. Ligand binding to 
the extracellular domain of the receptor TKs results in dimerisation, 
autophosphorylation and activation of the intracellular dimerisation kinase domain. 
This results in the recruitment of enzymes, such as PI3K and signal transducer and 
activator of transcription 3 (STAT3), as well as adaptor molecules and the activation 
of downstream signalling pathways Akt and Janus-kinase (JAK)-STAT. The 
enzymes act to regulate transcription, translation, metabolism, cell-proliferation, 
mortality and survival. Genetic mutations or an overexpression of the described 
effects, are said to cause malignant proliferation disorders and cancer (Grimminger 
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Figure 4: Receptor TK signalling in cardiac myocytes. It has been described that 
within cardiac myocytes, receptor TK signalling is involved in the hypertrophic 
response to stretch. Integrin signalling acts to activate FAK and SRC, thereby 
activating PI3K and MAPK signalling cascades following stress (Grimminger et al. 
2010). MAPK is also said to be activated via transactivation of EGFR by G protein-
coupled receptor. Moreover, cytokines released during biochemical stress is said to 
activate the JAK-STAT pathway. The signalling pathways act to suppress 
apoptosis, increase protein translocation and transcription of hypertrophy response 
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The TKI Sunitinib (Sunitinib malate, SUTENT, SU11248, Pfizer) is described as a 
multi-targeted TKI that is currently approved in the United States and European 
Union (Pfizer 2014). Sunitinib was designed to treat pancreatic cancer, 
gastrointestinal stromal tumours and renal cell carcinoma, after disease progression 
or intolerance to Imatinib, by inhibiting VEGF 1-3, platelet-derived growth factor 
receptor α and β, c-KIT, FMS-like tyrosine kinase (FLT)-3, colony-stimulating factor 
1 receptor and RET kinase (Chow and Eckhardt 2007). Furthermore, in 2006 
Sunitinib received accelerated approval for the treatment of renal cell carcinoma as 
well as approval for gastrointestinal stromal tumours (GIST), it is noted that the 
accelerated approval regulation allows for the approval of drugs used to treat life-
threatening illnesses based upon a surrogate end-point considered to be 
‘reasonably likely to predict clinical benefit’ if the drug is an improvement compared 
to existing therapy (Goodman et al. 2007). GIST patients who developed disease 
progression during Imatinib treatment or patients who were intolerant to Imatinib, 
no standard treatment was available prior to Sunitinib’s production (Goodman et al. 
2007).  
Sunitinib has been reported to demonstrate clinical activity in solid tumours 
including breast, neuroendocrine, colorectal, thyroid, melanoma and non-small-cell 
lung cancer (Chow and Eckhardt 2007). Sunitinib has been able to prolong survival 
within patients with certain carcinomas including renal cell carcinoma and 
gastrointestinal stromal tumour after disease progression or intolerance to Imatinib 
(Motzer et al. 2006, Demetri et al. 2006, Faivre et al. 2006). Sunitinib’s further mode 
of action is known to involve targeting foetal liver TK receptor 3, PDGRF α and β, c-
KIT stem cell receptors, ret oncogene product colony-stimulating factor 1 receptor 
(CSF1R) and RET receptor TKs (Branca 2005, Jain et al. 2006, Mendel et al. 2003, 
Morabito et al. 2006, Faivre et al. 2006, Abrams et al. 2003).  
In-vitro metabolism studies demonstrated that Sunitinib is metabolised via 
cytochrome CYP3A4 and results in the formation of the N-desethyl metabolite 
SU012662, shown to be potent towards VEGFR, PDGFR and KIT (Baratte et al. 
2004). SU012662 was concluded to be the major plasma metabolite in mice, rats 
and monkeys in in-vivo experiments, whilst the N-oxide metabolite SU012487 was 
concluded to be the major metabolite in dogs; however, this was said to be 
infrequently observed in humans (Faivre et al. 2006). Radio-labelling of orally 
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administered Sunitinib demonstrated that primary excretion was over 71 % for rats 
and 84 % for monkeys (Faivre et al. 2006). Animal studies have indicated that target 
plasma concentrations of Sunitinib and SU012662 were capable of inhibiting 
PDGFR-β and VEGFR-2 phosphorylation at concentrations 50–100 ng/ml (Abrams 
et al. 2003, Mendel et al. 2003, Murray et al. 2003). These results were said to be 
similar to those observed in Sunitinib-administered patients with acute myeloid 
leukaemia, of which sustained inhibition of FLT3 phosphorylation in blast cells was 
observed (O’Farrell et al. 2003).  
The 4-week-on, 2-week-off schedule of Sunitinib administration was said to allow 
patients to recover from potential bone marrow and adrenal toxicity, which was 
observed in animal models (Faivre et al. 2006). Following Sunitinib standard dosage 
of 50 mg/day for 4 weeks with 2 weeks off-treatment, peak plasma concentration is 
reached within 6–12 hours (Pfizer 2012). Sunitinib is known to demonstrate linear 
pharmacokinetics whilst having a long half-life of 40–60 hours (Minkin et al. 2009). 
Following pharmacokinetic analysis, it has been described that dose adjustments 
are not required for weight, age, gender, race, creatine clearance or Eastern 
Cooperative Oncology Group Performance Status (EMA nd). The dose range of 50–
150 mg/d (15-59 mg/m2) was assessed in 28 patients with advanced malignancies, 
for 4 weeks every 6 weeks in the phase I study by Faivre et al. (2006), and reported 
dose-limiting toxicities at doses greater than 75 mg/d, to include reversible grade-3 
fatigue, grade-3 hypertension and grade-2 bullous skin toxicity, indicating the 
recommended dose of 50 mg/d. At this selected dose, manageable toxicities were 
reported to include sore mouth, edema and thrombocytopenia (Faivre et al. 2006).    
Following this, the current dosage of 50 mg once-daily of Sunitinib was assessed 
for efficacy and safety in patients with cytokine-refractory renal cell carcinoma in 
two phase II trials (Motzer et al. 2006, Motzer et al. 2007). The first phase II trial 
involved 63 patients, where 25 patients achieved a partial response in solid 
tumours, thereby resulting in an objective response rate of 40 %, whilst a further 17 
patients achieved a stable disease state over 3 months (Motzer et al. 2006). The 
second phase II trial involved 105 patients, where 33 % obtained a partial response 
(Motzer et al. 2007 (1)). At plasma concentrations of 50-100 ng/ml Sunitinib is able 
to inhibit the phosphorylation of multiple receptor TKs in tumours, whilst also 
inhibiting tumour growth, inhibiting metastases and tumour regression in 
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experimental models of cancer, however it has been highlighted that no minimally 
effective dose has been established for Sunitinib (Goodman et al. 2007). 
The non-receptor TK FAK is believed to be involved in the pathogenesis of cardiac 
remodelling and hypertrophy via the mediating the first phase of the hypertrophic 
response to stretch in cardiac myocytes (Torsoni et al. 2003). FAK is thought to 
regulate the activation of myocyte enhancer factor 2 and JNK-Jun pathways in the 
early activation of the hypertrophic genetic programme (Nadruz et al. 2005). The 
tyrosine protein phosphate non-receptor type 11 (PTPN11) is thought to negatively 
regulate the growth of cardiac myocytes via downregulation of the mammalian 
transporter of rapamycin (mTOR) pathway (Marin et al. 2008). Nevertheless, 
cardiovascular events and cognitive HF were still demonstrated with GIST patients 
receiving Sunitinib (Chu et al. 2007). Further studies reported adverse effects on 
cardiac function and the development of HF with Sunitinib treatment (Khakoo et al. 
2008, Telli et al. 2008).   
It has been highlighted that a significant number of patients developed cardiotoxicity 
following Sunitinib administration, demonstrating congestive HF and 
electrocardiographic abnormalities (Chu et al. 2007, Hall et al. 2013, Telli et al. 
2008). Patients were recorded as not experiencing symptoms of cardiotoxicity until 
after 2 years of treatment with Sunitinib treatment, however approximately 20% of 
clinical patients experienced significant declines in LV ejection fraction, whilst 47 % 
of patients were recorded as experiencing hypertension and 8 % developed HF 
(Chu et al. 2007, Motzer et al. 2007, Henderson et al. 2013). Sunitinib has also been 
associated with a 1.4 % risk of arterial thrombosis and a 2.69-fold increase in 
congestive HF (Choueiri et al. 2010, Zamorano et al. 2016, Motzer et al. 2013, Qi 
et al. 2014, Ghatalia et al. 2015). Furthermore, Sunitinib-induced cardiotoxicity was 
found to be more prevalent in patients with a history of heart disease, hypertension 
or previous treatment with other cardiotoxic agents such as Imatinib, this is 
particularly concerning as Sunitinib is prescribed following prior-resistance to 
Imatinib treatment (Henderson et al. 2013). 
Within animal models Sunitinib upregulated the expression of hypoxia-induced 
cardiac prolyl-hydroxylase domain-containing protein which is an upstream 
regulator of HIF-1α, continuous activation of HIF contributes towards congestive HF 
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(Eschenhagen et al. 2011, Moslehi et al. 2011). Sunitinib has the potential to 
activate apoptosis via the release of pro-apoptotic proteins such as cytochrome-c, 
in doing so it has been reported that Sunitinib inhibits AMPK, with overexpression 
of an activated mutant AMPK ameliorates Sunitinib-induced cardiac myocyte 
cytotoxicity (Kerkela et al. 2009). Moreover, the study by Laderoute et al. (2010) 
demonstrated Sunitinib directly binding to and inhibiting AMPK phosphorylation. 
This further reinforces the importance of investigating the direct role of AMPK 
involvement, with the possibility of designing adjunctive therapy in order to maintain 
the activation of AMPK. 
As summarised in Figure 5, the inactivation of ribosomal S6 kinase (RSK) by 
Sunitinib is thought to lead to the release of the pro-apoptotic factor BAD (Force et 
al. 2007). This leads to the activation of Bax and cytochrome-c release, further 
resulting in the activation of the intrinsic apoptotic pathway and ATP depletion as 
highlighted by Force et al. (2007). It was also mentioned by Force et al. (2007) that 
within the setting of energy deficiency or loss of ATP, AMPK would inhibit the energy 
consuming process during protein translation and lipid biosynthesis via inhibition of 
eukaryotic elongation factor-2 (EEF2), mTOR and acetyl-coenzyme A (acetyl-CoA) 
carboxylase (ACC). The inhibition of ACC results in the reduction in malonyl-CoA 
levels and thereby inhibits carnitine palmitoyltranserase-1 which is responsible for 
the stimulation of fatty acid oxidation by controlling the entry of long-chain fatty acid 
molecules into the mitochondria (Dyck et al. 1999, Kudo et al. 1996, Musi et al. 
2005, Saddik and Lopaschuk 1991). Inactivation of AMPK by Sunitinib results in the 
release of EEF2, mTOR and ACC from inhibition; this further exacerbates ATP 
depletion (Force et al. 2007). The study by Laderoute et al. (2010) further 
investigated the direct role of Sunitinib on AMPK inactivation. Laderoute et al. 
demonstrated the ability for sunitinib to directly bind to and inhibit AMPK 
phosphorylation in PC3 human prostate cancer cells when incubated at 
concentrations of 5 µM and 20 µM for 6 hours. The effects were said to be similar 
to that of Compound C. It was proposed by Laderoute et al. (2010) that Sunitinib 
binds via a structurally-dependent basis to the ATP site of the AMPKα catalytic 
domain. Moreover, as AMPK signalling is considered vital in response to cells in 
hypoxic conditions, cardiac myocyte survival may be affected by Sunitinib within 
settings of which hypoxia occurs, notably during ischaemia. The increased activity 
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of EEF2 and mTOR, in the presence of Sunitinib, would promote hypertrophy, which 
is further triggered via cardiac myocyte loss and left ventricular (LV) dysfunction 
(Force et al. 2007). 
Figure 5: The potential mechanism of action of Sunitinib-induced cardiotoxicity 
involving the release of BAD, Bax, cytochrome-c, and the inhibition of AMPK 
activation as summarised by Force et al. (2007). Sunitinib is mentioned to result in 
the inactivation of RSK signalling, resulting in the release of pro-apoptotic proteins 
BAD, Bax as well as cytochrome c release. As mentioned, the proposed inhibition 
of AMPK signalling via Sunitinib is hypothesised to result in the release of EEF2, 
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1.8. Sunitinib treatment-associated cardiovascular effects and potential 
adjunctive treatment, the role of AMPK and mTOR signalling 
It was estimated that 2.5 million people 2015 were living with cancer in the UK, it 
has been reported that the number of people who have survived 5 years or more 
since diagnosis has increased by 260,000 and the number of projected survivors in 
the UK is estimated to increase by 1 million per decade from 2010–2040 (Maddams 
et al. 2012, Macmillan Statistics Fact Sheet 2017). Chemotherapeutic agents are 
known to contribute towards cardiotoxicity, particularly leading to HF, MI, 
arrhythmias, hypertension and thromboembolism (Bovelli et al. 2010). 
Chemotherapy treatment has been suggested to contribute towards CV damage via 
direct damage caused by the treatment or via contributing towards accelerated 
atherosclerosis due to chemotherapy-related CVD risk factors (De Haas et al. 2011, 
Aleman et al. 2014).  
Improvements in treatment and earlier diagnosis have both contributed towards this 
increased survival rate for patients, however chemotherapy carries the risk of late 
effects including CVD that can lead to significant mortality and morbidity accounting 
for 30–50 % of all deaths within developed countries (Borchmann et al. 2012, Clarke 
et al. 2005, Darby et al. 2011, Aleman et al. 2014, Hodgson 2011). It is therefore 
crucial to detect cardiac injury at an early onset, thereby preventing further damage. 
It was mentioned by Force et al. (2007), the perspective of cancer treatment, the 
targeting of multiple TKs is described to make sense, however some agents have 
an increased risk of cardiotoxicity than more selective agents such as Imatinib.  
The selective TKI Imatinib mesylate (Gleevec), used for the treatment of chronic 
myeloid leukaemia, is associated with cardiotoxic events and there have been 
reported incidences of peripheral edema (Kerkela et al. 2006). Subclinical 
cardiovascular damage was demonstrated in patients receiving Imatinib, developing 
congestive HF and LV dysfunction, with similar effects demonstrated in mice 
following Imatinib treatment (Kerkela et al. 2007). Moreover, drug-induced toxicity 
may arise years after the end drug usage (Ewer and Ewer 2010), Maharsy et al. 
(2014) demonstrated the potential for Imatinib to cause a deleterious effect in 
cardiac myocytes in a time, dose and age dependent manner, highlighting the 
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importance in demonstrating the effects of drug-induced toxicity in a time-dependent 
and long–term manner.  
Imatinib acts to inhibit kinase activity of the oncogenic fusion protein break-point 
cluster (BCR)-abelson (ABL) BCR-ABL and shows marked effects in individuals 
with chronic-phase chronic myeloid leukaemia (Deininger et al. 2005). When 
investigated with cultured cardiac myocytes, and in mice involving the reproducible 
doses equivalent to that of a plasma concentration within humans, Imatinib 
demonstrated mitochondrial dysfunction with a loss of membrane potential, release 
of cytochrome-c into the cytosol, a reduction in ATP content and cell death (Kerkela 
et al. 2006, Force et al. 2007). However, the 5-year follow-up study by Druker et al. 
(2006) involving 553 patients with chronic myeloid leukaemia receiving Imatinib 
treatment, only a single patient was recorded to have developed drug-related 
coronary HF (Druker et al. 2006). Supporting this, a 6-year follow-up study involving 
patients with GIST reported no cardiac events attributed to Imatinib treatment 
(Hochhaus et al. 2008). Studies involving cardiac myocytes demonstrated that 
Imatinib increased calcium-opening of the mPTP in mitochondria isolated from rat 
hearts and caused significant mitochondrial dysfunction with a loss of membrane 
potential, declines in ATP and release of cytochrome-c, all associated with cell 
death via apoptosis (Figure 6) (Dyck and Lopaschuk 2006, Yuan et al. 2003, 
Ankarcrona et al. 1995). As cardiac myocytes require large amounts of ATP, due to 
their contractile role, they are known to be highly sensitive to perturbations in energy 
generation (Dyck and Lopaschuk 2006). The opening of mPTP plays a significant 
role in myocardial injury and therefore blocking the opening of the pore should result 
in cardioprotection, interestingly however the mPTP is said to remain closed during 
ischaemia and opens at the onset of reperfusion (Suleiman et al. 2001, Weiss et al. 






48 | P a g e  
 
Figure 6: The role of Imatinib in cardiac myocyte-activation of apoptosis. The BCR 
gene and ABL gene kinase inhibitor Imatinib is described to induce extracellular-
regulated stress by activating protein kinase RNA-like endoplasmic reticulum kinase 
(PERK) and inositol-requiring enzyme 1 (IRE1) pathways, whilst over expressing 
protein kinase C (PKC)-delta (PKCδ). It has been described that following sustained 
extracellular stress, IRE1 activates Jun-N-terminal kinases (JNKs) and as part of 
the protective response PERK phosphorylates the eukaryotic translation initiation 
factor 2α (EIF2α), all contributing towards the release of Bax and mitochondrial 
depolarisation, ATP depletion, cytochrome-c release and further potential features 
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Following Imatinib resistance in patients undergoing treatment for chronic myeloid 
leukaemia, the second generation multi-TKI Sunitinib malate was produced (Liang 
et al. 2013). Imatinib resistance is reported to develop from a failure to reach 
complete haematological response and major molecular response, equivalent to a 
reduction in BCR-ABL transcripts less than 0.1 %, within an allocated duration of 
time (Milojkovic and Apperley 2009). It was reported that a loss of previously 
obtained response to Imatinib occurs in 20–25 % of patients that reach a complete 
haematological response (Milojkovic and Apperley 2009). Sunitinib is known to 
result in the inhibition of several off-target kinases within patients; this was 
demonstrated involving the testing of the binding affinity of several small-molecule 
inhibitors to 119 tyrosine and serine/threonine kinases (Fabian et al. 2005). Sunitinib 
was shown to inhibit normal variants or tyrosine kinases among non-cancerous 
cells, despite being designed to inhibit kinases that are mutated or over-expressed 
in cancer cells (Chu et al. 2007). Clinical studies in patients treated for 
gastrointestinal stromal tumours or renal cell carcinoma demonstrated evidence 
towards Sunitinib-associated cardiotoxicity via HF, LV systolic dysfunction and 
hypertension (Chu et al. 2007, Telli et al. 2008).  
The phase III trial involving Sunitinib vs interferon-α in patients with previously 
untreated metastatic renal cell carcinoma, reported that Sunitinib was associated 
with a 2 % grade-3 decline in LV ejection fraction (LVEF), in comparison to a 1 % 
grade-3 decline during treatment with interferon-α, this cardiac dysfunction was said 
to be reversible upon discontinuation or dose lowering of Sunitinib (Motzer et al. 
2007). LV dysfunction is defined as an absolute decline in LVEF greater than 10 % 
to a resultant value of less than 50 % (Narayan et al. 2017, Cardinale et al. 2006, 
Piccart-Gebhart et al. 2005). The study by Narayan et al. (2017) reported that 
patients undergoing Sunitinib treatment for multiple renal cell carcinoma 
demonstrated “very modest” declines in LVEF, whilst approximately 10 % of 
patients demonstrated a more substantial decline in LV function, however recovery 
was demonstrated. However, the report by Catino et al. (2018) reported that no 
statistically significant association was shown between vascular and systolic 
dysfunction and LVEF, during Sunitinib treatment in patients with metastatic renal 
cell carcinoma. Moreover, the authors concluded that Sunitinib did result in early, 
significant increases in blood pressure, arterial stiffness and resistive and pulsative 
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load during treatment. Sunitinib was further demonstrated to induce apoptosis of 
human umbilical vein endothelial cells in in-vitro and adrenal toxicity in rats, and 
bone marrow depletion affecting the pancreas in rats and monkeys (Mendel et al. 
2003, Faivre et al. 2006). It was shown in monkeys that Sunitinib resulted in an 
increase in arterial blood pressure and QT interval at doses that were deemed high 
(Mendel et al. 2003, Faivre et al. 2006).   
The study by Chu et al. (2007) focussed on cardiac adverse effects in 75 patients 
with Sunitinib treatment and indicated the potential for cardiac adverse events such 
as HF and MI in the Dana-Farber Cancer Institute, an early Phase II clinical trial. In 
contrast, the study by Demetri et al. (2006) reported no systematic mean decreases 
on LVEF during a Phase III clinical trial in GIST patients. However, Motzer et al. 
(2007) reported modest declines in LVEF without clinical sequelae in renal cell 
carcinoma patients. Following this, the study by Chu et al. (2007) was able to identify 
that 11 % of patients, with Imatinib-resistant metastatic GIST, treated with Sunitinib 
developed cardiac adverse events. Patients were shown to demonstrate a decrease 
in LVEF and an increase in blood pressure and 47 % of patients developed 
hypertension (Chu et al. 2007). The associated cardiac dysfunction from Sunitinib 
administration was associated in individuals with histopathology involving myocyte 
hypertrophy as well as alterations in mitochondrial structure, without inflammatory 
or fibrotic changes (Chu et al. 2007). The study involved a median time to 
development of all cardiac adverse events at 30.5 weeks, unlike the study by 
Demetri et al. (2006) that contained a median of 10 weeks, suggesting that follow-
up studies are required in order to determine if the longer exposure to Sunitinib 
treatment allowed for patients to develop cardiovascular sequelae (Chu et al. 2007).  
As highlighted, studies have reported that Sunitinib-treated patients developed LV 
dysfunction, declines in LVEF, overt HF and the development of symptomatic grade 
3-4 HF, however the associated effects by Sunitinib were shown to be reversible 
after drug discontinuation (Telli et al. 2008, Motzer et al. 2007). Moreover, the 
manufacturers of SUTENT (Sunitinib) have reported that Sunitinib demonstrated 
grade 1 or 2 toxicity in most events of renal cell carcinoma whilst also including 
reports of grade 3–4 drug-related adverse events (Pfizer 2012, Telli et al. 2008). 
The National Cancer Institute have defined grade I toxicity as any drop in LVEF 
below normal for LV systolic dysfunction, whilst any reduction below 50 % 
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represents a grade 2 toxicity for LV systolic dysfunction (CTCAE 2006). Despite 
reports of LV dysfunction, many studies display few or very little alterations in these 
haemodynamics, and therefore the underlying mechanisms of cardiotoxicity by 
Sunitinib are unclear.  
As well as cardiac myocytes, mice treated with Sunitinib (40 mg/kg) highlighted the 
targeting of the pericyte via Sunitinib, inducing microvascular abnormalities and 
cardiac dysfunction, a result that was not shown during Doxorubicin-induced toxicity 
(Chintalgattu et al. 2013). The authors indicated that the targeting of pericytes by 
Sunitinib is specific to cardiac muscle, and indicated Sunitinib-induced binding to 
PDGFR-β. The PDGFR signalling pathway was important in the pro-survival 
signalling pathway for pericytes (Chintalgattu et al. 2013). Inhibition of PDGFR-β 
signalling was shown to induce similar effects as that shown by Sunitinib, indicating 
the involvement of the PDGFR-β signalling pathway during Sunitinib treatment 
(Chintalgattu et al. 2013). Moreover, the cytotoxic effect of Sunitinib was inhibited 
via Thalidomide, as Thalidomide was shown to result in the restoration of pericytes 
during co-administration, thereby preventing cardiac toxicity and coronary 
microvascular dysfunction in normal mice and tumour-bearing mice (Chintalgattu et 
al. 2013). However, pericytes are needed to be studied in more detail to understand 
the precise mechanism impact on coronary microvascular function, as the induced 
phenotype was reversed following Sunitinib withdrawal (Chintalgattu et al. 2013).  
Sunitinib’s induction of apoptosis via direct anti-VEGFR and PDGFR effects on 
endothelial cells was demonstrated during the Phase I study by Faivre et al. (2006) 
which demonstrated skin toxicities in patients subjected to doses greater than 75 
mg/d, this was hypothesised to result from Sunitinib’s ability to induce dermal vessel 
alteration. Moreover, Sunitinib demonstrated the ability to induce endothelial cell 
apoptosis in in-vitro and in animal tumour models (Rouffiac et al. 2004). 
Furthermore, asymptomatic subungual splinter haemorrhages were observed in 
patients, this was said to be associated with macroangiopathy (Robert et al. 2005, 
Faivre et al. 2006). The resulting thrombosis observed in some patients was 
associated to result from the increased susceptibility of endothelial cells to damage, 
this was demonstrated during exposure to the TKI SU5416 (Semaxinib), a similar 
VEGF inhibitor, in combination with Cisplatin and Gemcitabine (Kuenen et al. 2003, 
Faivre et al. 2006). This reinforces the hypothesis that VEGF has a role in 
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endothelial cell protection (Faivre et al. 2006). PDGFRs are expressed in cardiac 
myocytes, whilst overexpression can signal cardiac myocyte survival (Hsieh et al. 
2006). Exogenous PDGFR agonists were shown to have no pulmonary toxicity 
effect (Hsieh et al. 2006), therefore indicating the apparent Sunitinib-induced 
cardiotoxicity may be as a result of an off-target effect, it was highlighted that the 
RSK family and AMPK could be potential candidates towards the off-target effects 
of cardiotoxicity (Hsieh et al. 2006, Force et al. 2007). It can be hypothesised that 
the inhibition of AMPK results from the inhibition of the pro-survival signals within 
the heart. The inhibition of the RSK, which acts to signal survival via the inhibition 
of phosphorylating proapoptotic factor BAD, is said to be responsible for Sunitinib-
induced cardiotoxicity (Hasinoff et al. 2008, Force et al. 2007, Dyck and Lopaschuk 
2006, Terai et al. 2005). RSK is described to act to signal survival via inhibiting 
phosphorylation of the pro-apoptotic factor BAD, whilst AMPK is involved in the 
transducing of pro-survival signalling within the heart (Dyck and Lopaschuk 2006, 
Terai et al. 2005, Hsieh et al. 2006, Force et al. 2007). The inhibition of RSK and 
AMPK by Sunitinib could be potentially seen in studies involving relevant 
concentrations of 25 mg/kg/day and in-vitro relevant concentrations of 8–10 µM 
(Kerkela et al. 2009, Fabian et al. 2005, Cohen et al. 2011).  
Additional concerns exist regarding the inhibition of VEGFR signalling in the heart. 
It was highlighted that during poorly controlled hypertension in patients receiving 
Sunitinib, studies demonstrated that VEGF-VEGFR signalling was disrupted 
during the imposition of a pressure load on the heart, moreover capillary density 
was shown to be reduced (Shiojima et al. 2005, Izumiya et al. 2006). This was 
associated with contractile dysfunction, fibrosis and HF (Shiojima et al. 2005, 
Izumiya et al. 2006). This therefore indicated that an angiogenic response is 
necessary when maintaining a normal response of cardiac myocytes to pressure 
overload, moreover when this does not occur the heart transitions rapidly from 
compensatory hypertrophy to HF (Shiojima et al. 2005, Izumiya et al. 2006). 
Furthermore, the inhibition of the angiogenic response to pressure overload was 
demonstrated to be mediated via the upregulation of the tumour suppressor p53, 
therefore suggesting p53 activity within the heart to be important in hypertensive 
patients (Sano et al. 2007, Ventura et al. 2007). The study by Sano et al. (2007) 
demonstrated that p53 accumulation is required for the transition from cardiac 
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hypertrophy to HF, the inhibition of p53 was said to demonstrate beneficial 
functions following MI.  
As highlighted, therapy targeting apoptotic pathways that are regulated by TKs 
can cause cardiac dysfunction; this includes the non-receptor TK JAK2 and KIT.  
In leukaemia cell mutations within JAK2 activates members of the STAT3 
transcription factors: STAT3 and STAT5 (Lin et al. 2000). However, the JAK-STAT 
signalling pathway is believed to be cardioprotective in the heart, highlighted by 
the inhibiting of JAK2 in reducing apoptosis in rat models of MI (Negoro et al. 
2000). Mice engineered to lack STAT3 demonstrated increased susceptibility to 
cardiac injury via MI and were more susceptible to Doxorubicin-induced 
cardiotoxicity, however overexpression of STAT3 protected against Doxorubicin-
induced cardiotoxicity (Hilifiker-Kleiner et al. 2005, Hilifiker-Kleiner et al. 2004, 
Kunisada et al. 2000). Following this, STAT3 is said to be vital in maintaining 
cardiac capillary density via mechanisms such as direct regulation of VEGF 
expression, the induction of pro-angiogenic cytokines and the suppression of anti-
angiogenic activity within the heart (Force et al. 2007). However possible 
cardiotoxicity of JAK2 inhibitors has been flagged, noting the potential of these 
inhibitors to have activity against several JAK family kinases (Force et al. 2007). In 
clinical development, the most advanced JAK2 inhibitor Lestaurtinib (CEP-701) 
demonstrated no significant cardiotoxicity in Phase I–II clinical trials in patients 
with acute myeloid leukaemia and activating FLT-3 mutations (Smith et al. 2004).   
Sunitinib is known to inhibit the stem cell receptor KIT, expressed on 
hemangioblasts for haematopoietic stem cells and endothelial progenitor cells 
(EPCs) (Liang et al. 2013). Correct functioning of the KIT receptor is necessary for 
the mobilisation of EPCs towards sites of injury such as MI (Liang et al. 2013). 
Using a mouse model of a heterozygote allele deletion (KITW/W-ν) and reduced 
kinase activity subjected to MI, demonstrated impaired post-MI repair and survival 
(Liang et al. 2013).  This was attributed to a failure to recruit pro-angiogenic bone 
marrow-derived stem/progenitor cells (Ayach et al. 2006, Fazel et al. 2006). 
Following this, concerns were mentioned regarding KIT inhibition, this was 
attributed to pathological remodelling of the heart following MI and prevent repair, 
the inhibition of KIT was said to prevent beneficial homing to areas of injury within 
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the heart, potentially relevant to patients treated with KIT inhibitors (Force et al. 
2007).   
In summary, Sunitinib was shown to result in abnormalities within the heart including 
the development of LV dysfunction, declines in LVEF, overt HF and the 
development of symptomatic grade 3-4 HF. Sunitinib further demonstrated grade 1 
or 2 toxicity and was reported to result in grade 3–4 adverse events. The resulting 
effects are associated with Sunitinib’s pro-apoptotic properties as well as Sunitinib’s 
ability to inhibit VEGFR, PDGFR and KIT signalling, as well as mentioned RSK, 
AMPK and JAK STAT signalling pathway involvement of Sunitinib. For this study, 
our focus was on the role of AMPK signalling.   
The study by Inoki et al. (2003) demonstrated AMPK to phosphorylate tuberous 
sclerosis complex (TSC)-2, thereby increasing the ability of the TSC complex to 
inhibit the mTOR pathway and inhibiting cell growth to protect against apoptosis 
during glucose starvation. Growth factors and amino acids activate the mTOR 
pathway, stimulating translation and cell growth via the activation of ribosomal 
protein S6 kinase (S6K1) and stimulates the initiation of translation by increasing 
phosphorylation of elongation factor-4E binding protein 1 (4E-BP1) (Carrera 2004). 
The serine/threonine protein kinase mTOR is known to regulate cell growth, 
proliferation and angiogenesis, and is located downstream of AMPK and Akt/PKB, 
however inhibition of mTOR leads to a feedback activation of Akt/PKB and thereby 
regulates apoptosis and proliferation as well as cell growth (Larkin et al. 2009).  
Following this, the inhibition of mTOR has been a common route of renal cell 
carcinoma treatment however significant toxicity has been reported following 
inhibition of VEGF and mTOR pathways, particularly with Sunitinib in combination 
with Temsirolimus, an inhibitor of the mTOR signalling used for treatment of renal 
cell carcinoma (Patel et al. 2009). During the Phase I trial by Patel et al. (2009) with 
Sunitinib at 25 mg (oral, daily) and Temsirolimus 15 mg (Intravenous, weekly) 
combination resulted in 2 out of 3 patients suffering from severe acneiform 
erythematous rash and gout/cellulitis requiring hospitalisation. Both doses were 
lower than the required administration doses of Sunitinib 50 mg and Temsirolimus 
25 mg (Pfizer 2014, Torisel 2007). The authors described that these effects may 
herald from the synergistic effect of the drugs used, as concomitant treatment could 
55 | P a g e  
 
result in additive or synergistic effects on overlapping toxicities, potentially inhibiting 
compensatory mechanisms that interfere with the development of drug-induced 
toxicity that is not seen clinically with single agents (Patel et al. 2009).   
Further studies exist demonstrating the potential for mTOR and TKI inhibition as 
conjunctive therapy to enhance the antitumor effects. The study by Park et al. (2014) 
investigated the synergistic interaction between the PI3K and mTOR dual inhibitor 
NVP-BEZ235 and Sunitinib in castration-resistant prostate cancer cells with 
Docetaxel resistance. The author concluded that the combination of NVP-BEZ235 
and Sunitinib resulted in a significant synergistic antitumor effect in the dose-ranges, 
whilst the half-maximal inhibitory concentrations of both treatments were reduced 
7.8 and 6.6-fold (Park et al. 2014). It was stated that the combination therapy caused 
an induction of caspase-dependent apoptosis in Docetaxel-resistant cells; however, 
Sunitinib did not produce an additional effect on the NVP-BEZ235-mediated 
inhibition of PI3K/Akt/mTOR phosphorylation (Park et al. 2014).   
As highlighted, there is a growing concern regarding drug-induced cardiotoxicity and 
the potential use of adjunctive therapy with Sunitinib treatment. Current studies such 
as the ASSURE (adjunctive Sorafenib or Sunitinib for unfavourable renal cell 
carcinoma) study attempted a three-arm randomised trial comprising 1 year of 
adjunctive therapy with Sorafenib vs. Sunitinib vs. placebo within patients (Porta 
and Chiellino 2016). The ASSURE study failed to demonstrate a significant 
difference in disease-free survival in the three treatment arms, whilst the author’s 
indicated a rationale against the use of Sunitinib and suggested kidney cancer may 
be independent of angiogenesis (Porta and Chiellino 2016). Furthermore, the 
STRAC trial aimed to compare the disease-free survival time and safety of Sunitinib 
with placebo for 1 year as a form of adjunctive therapy for patients at a high risk of 
recurrent kidney cancer following surgery (Porta and Chiellino 2016). The STRAC 
study demonstrated positive results, of which there was an increase disease-free 
survival (Porta and Chiellino 2016). Therefore, TKIs are an area of interest, 
particularly humanised monoclonal antibodies and small-molecule inhibitors against 
TK receptors, as summarised in Table 1 (Krause et al. 2005).  
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Table 1 Summary of existing TKIs and associated toxicity  
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Table 1: Summary of existing TKIs and TK-targeting agents which have been 
associated with cardiotoxicity; QT prolongation, prolongation of the QT interval on 
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1.9. Metformin therapy and Metformin-induced cardioprotection   
With the vast amount of TKIs and similar agents being associated with 
cardiovascular events, it is important to prevent these associated symptoms in 
patients, one approach is to develop an adjunctive or synergistic approach to using 
TKIs, particularly with other non-competitive agents. A large epidemiological trial 
involving 4075 patients with T2DM with Metformin treatment improved 
cardiovascular prognosis in comparison to glucose-lowering agents 
Chlorpropamide, Glibenclamide or insulin and was able to reduce the incidence of 
MI within patients by 39 % (UK Prospective Diabetes Study 1998). Several studies 
have highlighted the cardioprotective properties of Metformin treatment, particularly 
in ischaemia-reperfusion studies (Paiva et al. 2009, Paiva et al. 2010, Bhamra et al. 
2008, Barreto-Torres et al. 2012).  
The biguanide Metformin hydrochloride, is currently prescribed for the treatment of 
insulin resistance, T2DM and impaired glucose intolerance at oral dosages of 500 
mg twice a day or 850 mg once a day (Figure 7) (Giannarelli et al. 2003, FDA nd). 
Metformin is prescribed to over 100 million patients worldwide and has been in 
clinical use for over 50 years (Rena et al. 2013) and has been in use since 1957 in 
Europe and since 1995 in the USA (Pernicova and Korbonits 2014). Metformin 
decreases hepatic glucose production and intestinal absorption of glucose, whilst 
improving insulin sensitivity by increasing peripheral glucose uptake and utilisation 
(FDA nd). 500 mg oral dosage of metformin, under fasting conditions, has an 
absolute bioavailability of 50–60 %, whilst food has been described to decrease the 
extent of and slightly delay absorption, approximately a 40 % lower mean peak 
concentration (CMAX), 25 % lower area under the plasma concentration versus time 
curve, 35 minute prolongation of time to peak plasma concentration (TMAX) following 
administration of a single 850 mg tablet with food compared to the administration 
during fasting (FDA nd).   
Metformin’s mode of action has been described to reduce insulin levels and promote 
improved receptor activity, both direct and indirect effects via insulin action and 
steroidogenic enzymatic activity and improve nitric oxide (NO) vasodilator effects in 
the endothelium (Giannarelli et al. 2003, Traub 2011). It has been hypothesised that 
Metformin principally acts on the liver, inhibiting hepatic gluconeogenesis, as well 
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as binding to ACC activity and suppressing fatty acid production (Giannarelli et al. 
2003), whilst optimising hepatic glucose metabolism by enhancing the AMPK 
signalling pathway, suppressing hepatic gluconeogenesis (Inzucchi et al. 1998). 
Furthermore, Metformin acts upon skeletal muscle and adipose tissue to inhibit lipid 
production and stimulate glucose transport and uptake (Yuan et al. 2003, Guigas et 
al. 2004). Metformin has been suggested to reduce lipid uptake or synthesis in the 
intestine and in the hepatocytes, during therapy the observed improvement of 
obesity, abdominal obesity, with a subsequent decreased release of free fatty acids 
from adipose tissue could help to explain the improvement of lipid profile during 
Metformin treatment (Shaker et al. 2010). Serum concentrations of insulin HOMA 
and HOMA-beta-cell % were decreased significantly after three months of treatment 
(Shaker et al. 2010). It was suggested that the reduction in hyperinsulinemia 
observed may be due to improvements in hepatic extraction and insulin sensitivity 
during therapy with Metformin (Shaker et al. 2010). It was also observed that 
Metformin reduced basal levels of free fatty acids, which have a role in reducing 
glucose disposal in skeletal muscle, leading to impaired insulin sensitivity (Shaker 
et al. 2010). Furthermore, a study by Ferreira et al. (2013) was able to highlight an 
increase in PI3K and GLUT4 expression among cells cultured with Metformin for 24 
and 48 hours. Following this, reports have further indicated Metformin to be able to 
activate Rab4, involved in translocation of intracellular GLUT4 to the cell membrane 
(Lee et al. 2011).  
 
 
Figure 7: Metformin Hydrochloride N-dimethylimidodicarbonimidic diamide 
hydrochloride, C14H11N5HCl, molecular weight 165.63, pH of a 1 % aqueous solution 
of metformin hydrochloride is 6.68, pKa 12.4, (FDA nd).   
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Metformin’s properties are believed to stem from the involvement on cellular ATP 
levels (Rena et al. 2013), it was deduced that Metformin was able to suppress 
hepatic glucose output, with the inhibition of complex I within the mitochondrial 
electron transport chain (Figure 9) (Owen et al. 2000, El-Mir et al. 2000). Further to 
this, when compared to the complex II substrate Succinate, that can bypass 
complex I inhibition, Metformin was shown to inhibit mitochondrial oxidation of 
glutamate more effectively (Owen et al. 2000, El-Mir et al. 2000). The magnitude of 
inhibition of gluconeogenesis is believed to be correlated to the extent of inhibition 
of the respiratory chain, suggesting that the change in energy results in the 
insufficient flux of ATP for gluconeogenesis (Owen et al. 2000). The inhibition of 
gluconeogenesis and mitochondrial inhibition may be contributed by ATP-, ADP- 
and AMP-independent effects on pyruvate carboxylase (Owen et al, 2000). 
Mitochondrial inhibition is further known to result in the accumulation of lactate from 
glycolysis, contributing to respiratory chain inhibition (Owen et al, 2000). 
Mitochondrial oxidation of glutamate and malate inhibition by Metformin, was 
suggested to result from a time-dependent and concentration-dependent inhibition 
of the respiratory chain to restrain hepatic gluconeogenesis and increase glucose 
utilisation in peripheral tissue suggesting Metformin to be less toxic than other 
complex I inhibitors and the reduced rate of lactic acidosis (Owen et al, 2000).  
Metformin was shown to reduce the risk of MI in overweight patients with T2DM in 
comparison to diet therapy in overweight diabetic patients (UKPDS 1998). 
Moreover, Metformin consists of vasoprotective as well as cardioprotective 
properties following the results of the United Kingdom Prospective Diabetes study 
which demonstrated Metformin to reduce all-cause mortality by 36 %, mortality 
associated with type-2 diabetes by 42 %, myocardial infarction by 39 % and stroke 
by 41 % respectively (UKPDS 1998). Metformin was also shown to reduce all-cause 
mortality and CV mortality in T2DM patients in comparison to Sulphonylurea therapy 
(Johnson et al. 2002) and has been described to show beneficial changes in blood 
rheology, serum lipid profile and anti-ischaemic effects (Anfossi et al. 2010). 
However, in contrast to this, two meta-analyses have failed to determine the benefit 
of Metformin therapy on all-cause or cardiovascular-related mortality, or on 
diabetes-relates macrovascular complications, contributing towards the debate 
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regarding Metformin’s ability to reduce the occurrence of cardiovascular disorders 
(Boussageon et al. 2012, Selvin et al. 2008).  
Metformin was shown to modulate inflammation by suppressing interleukin (IL)-1β-
induced IL-8 production, cyclic AMP (cAMP)-induced mRNA expression and 
aromatase activity, limiting the development of endometriosis (Takemura et al. 
2007). Metformin was stated to exert an anti-inflammatory role by reducing pro-
inflammatory cytokine secretion, and potentially inhibiting endometriosis by 
suppressing both ovarian and local production of oestrogen as exhibited by 
Metformin’s ability to suppress cAMP-stimulated aromatase activity in endometriotic 
stromal cells (Takamura et al. 2007). Metformin treatment improved lipid profiles, 
vascular-smooth-muscle, hypercoagulation, and platelet function (Kirpichnikov et al. 
2002), whilst improving relaxation and calcium handling within rat cardiac myocytes 
during hyperglycaemia (Ren et al. 1999) and reduce the generation of ROS (An et 
al. 2006, Kukidome et al. 2006, Rosen and Wiernsperger 2006).  
The mechanism of cardioprotection by Metformin has only recently been 
investigated. It was reported that Metformin inhibits the opening of the mPTP during 
reperfusion by activating the protein kinase Akt (Bhamra et al. 2008), whilst 
protecting cells against calcium and oxidative stress (Detaille et al. 2005, Guigas et 
al. 2004). Therefore, efforts have been concentrated towards preventing the 
opening of mPTP channel, with studies highlighting the resulting effect to reduce 
infarction size (Hausenloy et al. 2002, Hausenloy et al. 2004). Metformin was shown 
to be dependent on the activation of AMPK; the phosphorylation of AMPK was 
shown to be mediated by the increase in the cytosolic AMP concentration (Zhang 
et al. 2007). Metformin was further shown to promote interaction between the 
upstream activating kinase LKB1 and AMPK, for AMPK activation (Zou et al. 2004). 
The stimulation of the adenosine receptor was shown to be an important mechanism 
in infarct size-limiting effects of ischaemic pre- and post-conditioning (Yellon and 
Downey 2003), whilst adenosine receptor stimulation was shown to activate Akt 
(Yang et al. 2004) and inhibit the opening of mPTP (Hausenloy et al. 2002). The 
survival protein kinase Akt is known to contribute towards the reperfusion injury 
salvage kinase pathway, reducing MI size (Hausenloy and Yellon 2004).  
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A study involving Metformin treatment in T2DM and normal-glycaemic rat hearts 
was able to indicate the reduction in MI infarct size, when administered at the time 
of reperfusion (Bhamra et al. 2008). Metformin-treated ischaemia-reperfusion 
hearts were shown to improve respiration and respiratory control index, an effect 
that ischaemia-reperfusion depletes as a result of decreasing efficiency of 
respiratory coupling and ATP synthesis (Barreto-Torres et al. 2012). Furthermore, 
Metformin demonstrated cardioprotective effects during treatment in perfused rat 
hearts and rat cardiac myocytes via the phosphorylation of Akt (Bhamra et al. 2008). 
Studies have shown that Metformin is able to exert cardioprotection in rat models 
following ischaemia-reperfusion via activation of PPARα (Barreto-Torres et al. 2012, 
Oidor-Chan et al. 2016). PPARα is highly expressed in the heart as well as other 
organs, and PPARα ligands were shown to reduce myocardial ischaemia-
reperfusion injury in mice models (Yue et al. 2003). PPARα was suggested to 
prevent mPTP formation via directly interacting with mPTP components, voltage–
dependent anion channel (VDAC), adenine nucleotide translocase (ANT) and/or 
cyclophilin D (CyPD) and could also indirectly by activating signalling pathways 
PI3K/Akt and NO production (Barreto-Torres et al. 2012, Bulhak et al. 2009). 
Metformin was further able to decrease cardiac myocyte apoptosis and increase 
NO (Gundewar et al. 2009), improving endothelial function whilst maintaining 
myocardial energy production during ischaemia (Hardie 2003). In addition to this, 
clinical studies demonstrated Metformin’s ability to reduce plasma dipeptidyl 
peptide-4 activity and increase circulating levels of GLP-1, associated with 
cardioprotective effects (Maida et al. 2011). Metformin was shown to decrease 
myocardial damage in cultured myocytes, via inhibiting apoptosis (Sasaki et al. 
2009), whilst LV fractional shortening and LV end-diastolic pressure were improved 
in dogs treated with Metformin, however another study demonstrated cleaved 
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1.10. The anticancer properties of Metformin.  
As well as the discussed cardioprotective properties, Metformin has anti-cancer 
properties. Metformin-treatment is associated with a decrease in incidences of 
cancer and cancer-related mortality in diabetic patients (Bowker et al. 2006, Evans 
et al. 2005, Janjetovic et al. 2011). Since 2005 Metformin has been associated with 
a reduced incidence of cancer, following this, over 173 clinical trials involving 
Metformin and cancer have been reported (U.S. National Library of Medicine nd). 
Metformin was reported to reduce this risk of cancer development and cancer–
related mortality when compared to other diabetes treatment such as sulfonylureas 
(Evans et al. 2005, Bowker et al. 2006, Monami et al. 2009, Wright and Stanford 
2009, Giovannucci et al. 2010). Metformin’s ability to act on the liver to lower 
systemic glucose levels and improve secondary hyperinsulinemia has been 
associated with preventing tumour growth and progression, hyperinsulinemia itself 
is associated with an adverse prognosis in breast, colon and prostate cancer (Pollak 
2012). This results in Metformin being able to affect insulin-sensitive neoplastic 
tissue without accumulating cancer cells (Pollak 2012). Metformin was further said 
to demonstrate cell proliferating inhibition properties, reducing colony formation and 
result in partial cell cycle arrest in cancer cell lines (Zakikhani et al. 2006, Alimova 
et al. 2009, Liu et al. 2009). In contrast, the population-based study involving 
diabetic patients with breast cancer, aged 65 years and older, failed to demonstrate 
an association between improved survival and Metformin use (Lega et al. 2013). 
Metformin’s ability to attenuate tumour genesis and chemoprotective properties are 
poorly understood, especially as concentrations used in in-vitro experiments are not 
able to be translated into patients (Pollak 2012). Further limitations include the 
varying degree of tissue expression of transporters mediating Metformin uptake, in 
normal and tumour cells, which can be influenced by drugs including antibiotics 
(Nies et al. 2012). The poor uptake into target cells may limit the therapeutic ability 
of Metformin in cancer (Nies et al. 2012).  
The population study by Bowker et al. (2006) demonstrated that cancer-related 
mortality was shown to be 3.5 % (245 out of 6,969) for patients treated with 
Metformin compared to patients not receiving Metformin, and suggested that 
Metformin has the ability to decrease the incidence of cancer and cancer-related 
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mortality in diabetic patients (Bowker et al. 2006, Evans et al. 2005, Janjetovic et al. 
2011). Moreover, the study by Keizman et al. (2016) demonstrated an increase in 
overall survival for renal-cell carcinoma patients receiving Metformin compared to 
patients not receiving Metformin. Metformin is suggested to have anti-neoplastic 
properties by affecting cancer cells by either decreasing insulin levels or inhibiting 
cancer cell proliferation and apoptosis (Margel et al. 2013), via the activation of 
AMPK to inactivate enzymes associated with ATP consumption and the inhibition 
of mTOR/mTOR complex 1 (mTORC1) pathway in tumourigenesis (Zakikhani et al. 
2006, Vazquez-Martin et al. 2009). From this, it can be suggested that AMPK 
activation may be having a potential anti-cancer and cardioprotective properties.   
The activation of AMPK is known to inhibit mTOR activity; mTOR is regulated by 
cellular energy levels, nutrients, oxygen and growth factors (Hay and Sonenberg 
2004). The dysregulation of mTOR, and mTOR-associated signalling pathways, is 
said to result in uncontrolled cell growth and proliferation (lagan and Manning 2016). 
PI3K3CA mutations or loss of expression of the tumour suppressor phosphatase 
and tensin homolog (PTEN) can lead to uncontrolled mTOR activity in breast cancer 
(Neshat et al. 2001, Bjonsti and Houghton 2004).  Following this, inhibiting pathways 
of AMPK activation and mTOR inhibition has been an area of interest to prevent 
and inhibit cancer cell growth. Studies have demonstrated Metformin’s ability to 
inhibit growth of breast cancer cells in in-vitro and tumours in-vivo (Buzzai et al. 
2007, Dowling et al. 2007, Zakikhani et al. 2006). Patients receiving neoadjuvant 
chemotherapy for breast cancer demonstrated that diabetic patients with breast-
cancer and receiving Metformin during treatment had a greater pathological 
complete response rate than diabetic patients not receiving Metformin (Jiralerspong 
et al. 2009). Patients receiving Metformin demonstrated a pathological response 
rate of 24 % compared to 8 % for patients not receiving Metformin (Jiralerspong et 
al. 2009). It was proposed that the activation of AMPK leads to the suppression of 
metabolic processes requiring high amounts of ATP as well as the exerting inhibitory 
effects on the mTOR pathway; phosphorylating TSC2 and Raptor (Gonzalez-
Angulo and Meric-Berstam 2010).  
In-vivo experiments involving orally administered or intraperitoneal Metformin in 
mice demonstrated a tumour growth inhibition of up to 55 % (Ben Sahra et al. 2010, 
Gonzalez-Angulo and Meric-Berstam 2010). Metformin was further shown to inhibit 
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growth of MCF-7 human breast cancer cell lines, administration of growth inhibitory 
concentration of Metformin was suggested to decrease protein synthesis, blocking 
growth and proliferation via AMPK activation and mTOR inhibition (Zakikhani et al. 
2006, Dowling et al. 2007). Moreover, Metformin was shown to enhance the 
antiproliferative ability of Doxorubicin during co-administration in non-stem and 
cancer stem cell lines, whilst also reducing tumour mass and prolonged remission 
in a xenograft mouse model, in comparison to Doxorubicin administration alone 
(Hirsch et al. 2009).  
A summary of Metformin’s anticancer ability is presented in Figure 8. The proposed 
mechanism of action of Metformin is believed to stem from Metformin-induced 
activation of the AMPK pathway in tumour cell lines, resulting in growth inhibition 
via potentially inhibiting protein synthesis (Dowling et al. 2007, Zakikhani et al. 2006, 
Alimova et al. 2009, Liu et al. 2009). Metformin’s other suggested anti-neoplastic 
properties may result from Metformin’s ability to either decrease insulin levels or 
inhibiting cancer cell proliferation and apoptosis, via the activation of AMPK to 
inactivate enzymes associated with ATP consumption and the inhibition of 
mTORC1 pathway in tumourigenesis (Zakikhani et al. 2006, Vazquez-Martin et al. 
2009). Although the mechanisms outlining the direct role of AMPK in anticancer 
treatment is not fully established, studies have suggested Metformin to have a direct 
action on cancer cells, involving AMPK-dependent and AMPK-independent 
mechanisms, whilst AMPK is suggested to interfere with cancer cell growth by 
activating HIF-1α, tumour protein p53 and DICER1 (Pierotti et al. 2013, Bar-Peled 
et al. 2012, Pernicova and Korbonits 2014). AMPK has further been suggested to 
act as a mediator towards the nuclear factor–κB (NFκB)/IL-6 pathway, delaying the 
malignant transformation via attenuating the inflammatory feedback loop (Pernicova 
and Korbonits 2014).  
As described, the mTOR pathway is able to be suppressed via an AMPK-dependent 
manner, a potential anti-neoplastic effect of Metformin (Wang et al. 2011). 
Metformin is shown to reduce types of neoplasm with the reductions being 
associated with reductions in the level of mTORC1 (Rogalska et al. 2016). The 
mTOR pathway is known to contribute towards the progression and proliferation of 
tumours (Chiang and Abraham 2007). In reference to cancer, the mTOR inhibition 
is described to interfere with protein synthesis and tumour cell proliferation, with loss 
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of LKB1 shown to be frequent in cancer (Wang et al. 2011). As mTOR is the catalytic 
subunit of mTORC1 and mTORC2, these complexes are important in regulating 
cellular growth, whilst integrating the input from hormonal signalling and energy-
sensing pathways, such as insulin–like growth factor (IGF)-1-2 and AMPK (Inoki et 
al. 2002). The activation of TSC1 and TSC2 creates an mTOR-inhibiting complex, 
thereby down-regulating mTORC1, in an AMPK-dependent manner (Gwinn et al. 
2008).  
As touched upon, IGF-1 insulin signalling is inhibited by Metformin via AMPK-
dependent phosphorylation of insulin receptor substrate (IRS)-1, which is known to 
transmit signals from insulin and IGF-1 receptor to the P13K-Akt pathway, 
potentially down regulating mTOR signalling (Ning and Clemmons 2010). In 
contrast to this cascade, reports have highlighted multiple regulatory feedback loops 
that counteract the antitumor effect during Metformin exposure (Vazquez-Martin et 
al. 2009). AMPK targets the tumour suppressor protein p53, which is able to activate 
genes for the inhibition of Akt and mTORC1 pathways; however, the role of 
Metformin in p53 activation is not fully established (Liang et al. 2007). Metformin is 
further known to induce the expression DICER1, involved in microRNAs synthesis, 
loss of function mutation is known to result in the complex tumour syndrome 
(Blandino et al. 2012). As tumours, inflammatory cells and other rapidly dividing 
cells favour glycolysis to oxidative phosphorylation as an energy source for 
metabolism, this promotes fatty acid synthesis and intermediates for proliferation, 
including mTORC1-activated HIF-1α, thereby promoting the expression of GLUT-1 
and mono carboxylate transporter 4 (MCT4) for lactic acid transport (Thomas et al. 
2006). The activation of AMPK was shown to inhibit the proto - oncogenic c-MYC 
and HIF-1α (Blandino et al. 2012). In summary, the proposed mechanism of 
Metformin results in the inhibition of the PI3K-Akt-mTOR pathway, moreover AMPK 
phosphorylates TSC2 which inhibits mTORC1, thereby decreasing in protein 
synthesis and cell growth (Yoshida et al. 2011, Patel et al. 2015). 
Within T2DM patients, variation of the glycaemic response to Metformin was 
associated with the presence of a common genetic variant of the ataxia 
telangiectasia mutated (ATM) gene locus (Zhou et al. 2011). From this, ATM 
activation was said to be involved in Metformin-dependent signalling, as ATM 
encodes the tumour suppressor protein component of the DNA-damage response 
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for DNA repair and cell-cycle control (Zhou et al. 2011). The ATM mutation was 
indicated to be present in ataxia telangiectasia (Zhou et al. 2011). This 
neurodegenerative condition has been associated with the predisposition to cancer, 
insulin resistance and T2DM, whilst both AMPK-dependent and -independent 
mechanisms were suggested to be involved in the ATM-mediated reparatory effect 
(Zhou et al. 2011). For this, the cellular stressor effects of Metformin are involved in 
activating the repertory process, a protective effect against pre-malignant to 
malignant transformation (Vazquez-Martin et al. 2011). AMPK acts to inhibit the 
rate-limiting steps during lipogenesis, including sterol regulatory element-binding 
protein (SREBP)-1 via mTOR in hepatic cells, thereby decreasing lipid deposition 
(Scot et al. 2004). Repressing AMPK is not only known to prevent the described 
effects but also accelerates fatty liver developments (Scot et al. 2004). ATP 
depletion results in AMPK activation of catabolic pathways to generate ATP and 
switch-off ATP-consuming mechanisms (Hardie and Hawley 2001). Metformin is 
known to improve hepatic steatosis via increasing AMPK phosphorylation (Zhou et 
al. 2001), whilst constitutively active AMPK can potentially inhibit the expression of 
lipid synthesising gene SREBP-1 and attenuating oleic acid-induced lipid deposition 
in rat hepatocytes (Jung et al. 2011).  
Targeting the activation of the LKB1-AMPK axis is an area of interest in cancer, in 
particular Metformin is used to activate AMPK via an LKB1-dependent mechanism 
(Green et al. 2011). As we mentioned, Metformin inhibits the mitochondrial 
respiratory chain complex 1, resulting in the generation of ROS which activates 
PKC, inducing LKB1 phosphorylation, required for LKB1 nucleo-cytoplasmic 
translocation and AMPK activation (Memmott et al. 2009, Dowling et al. 2007). The 
LKB1–AMPK-mTOR signalling pathway links cellular metabolism and energy status 
in the signal transduction pathway required for cell growth, proliferation and 
autophagy (Shackelford and Shaw 2009). The LKB1-AMPK axis is shown to be 
functional in hematopoietic cancers such as myeloid leukaemia (Green et al. 2011). 
LKB1 is a key upstream activator of AMPK in low ATP conditions, upon an increase 
in AMP/ATP ratio, AMP binding results in an allosteric change of AMPK and 
exposes AMPKα Thr172 residue for phosphorylation via LKB1 and activates AMPK 
(Green et al. 2011). AMPK acts as a tumour suppressor kinase via the p53-
dependent regulation of cell cycle (Tiainen et al. 2002, Jones et al. 2005). 
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Metformin was reported to improve cancer responses during radiation therapy, 
during the investigation of MCF-7 human breast cancer cells in combination with 
ionising radiation (Song et al. 2012).  Another study using Metformin in combination 
with ionising radiation on non-small cell lung cancer cells, demonstrated that 
Metformin inhibited cell and tumour growth whilst also sensitising cells to ionising 
radiation (Storozhuk et al. 2013). Metformin was also shown to improve pathologic 
complete response rate in patients undergoing rectal cancer treatment, of which 
patients taking Metformin demonstrated a 35 % increase in pathological complete 
response rate, as well as an increase in disease-free and overall survival compared 
to patients not taking Metformin (Skinner et al. 2013).  
Metformin’s ability was hypothesised to result from the downregulation of the 
hyperactive PI3K-Akt-mTOR pathway (Song et al. 2012). It contrast to studies 
demonstrating the inability of Metformin in co-treatment studies, Metformin was 
shown to enhance apoptosis induced by chemotherapy agents Paclitaxel and 
Cisplatin in endometrial cancer, the authors highlighted the involvement of 
glyoxalase 1 expression but were unable to conclude the direct mechanism (Dong 
et al. 2012). Metformin was shown to successfully induce cell death amongst cancer 
stem cells in mouse xenograft cancer models, whilst further prolonging tumour 
remission in combination with chemotherapy agents, via possible regulation of the 
inflammatory pathways (Iliopoulos et al. 2011, Hirsch et al. 2009). Moreover, 
Metformin is believed to inhibit cancerous transformation via attenuation of the 
inflammatory feedback loop (Hirsch et al. 2013). This signalling cascade is known 
to be mediated by the transcription factor NFκB with the down-stream cytokine IL-6 
(Hirsch et al. 2013). However, this inhibitory effect remains more effective in cancer 
stem cells than non-cancer stem cells, as the degree of sensitivity of the 
transformed cell lines to Metformin is said to be reliant upon the degree of immune 
cell-mediated tumour inflammation, reflected by IL-6 levels (Hirsch et al. 2013). This 
suggests Metformin’s ability to activate AMPK varies upon whether there is a 
metabolic difference between cancer stem cells and regular stem cells (Anastasiou 
2013). The study by Misirkic et al. (2012) demonstrated that an autophagic response 
is triggered via AMPK-dependent manner in U251 human glioblastoma cell lines, 
whilst also inhibiting Simvastatin-induced apoptosis, suggests a cytoprotective role 
of AMPK-activation of autophagic response during statin-mediated apoptosis. 
69 | P a g e  
 
AMPK-induced activation of autophagy was followed by Raptor activation with 
subsequent decreases in mTOR and S6K phosphorylation (Misirkic et al. 2012). 
Furthermore, the authors concluded that siRNA-mediated downregulation of AMPK 
prevented inhibition of mTOR and S6K activation via Raptor, however Akt 
phosphorylation was said to not be affected by AMPK siRNA. The authors 
concluded that this result excluded the role of Akt inhibition in early AMPK-
dependent induction of autophagy. 
The in-vitro study by Janjetovic et al. (2011) demonstrated the use of Metformin in 
combination with Cisplatin cotreatment, in HL60 human leukaemia cancer cell lines. 
Janjetovic et al. (2011) indicated the role of serine/threonine Akt-activation, 
inhibiting apoptosis via phosphorylation and inactivation of targets BAD, forkhead 
transcription factors, c-Raf and caspase-9 (Datta et al. 1997, Brunet et al. 1999, 
Zimmermann and Moelling 1999, Cardone et al. 1998). The components of the 
PI3K/Akt pathway are said to be amplified in tumours sensitive to chemotherapy 
(Yuan and Cantley 2008, Janjetovic et al. 2011). With the knowledge that ROS are 
involved in some chemotherapy-induced cell death, Metformin-mediated activation 
of Akt was demonstrated to decrease ROS production in Cisplatin-treated cells 
(Janjetovic et al. 2011). Akt has been associated with protecting mPTP opening 
against oxidative stress (Bhamra et al. 2008, Wang et al. 2009, Muders et al. 2009). 
Although AMPK is involved in VEGF-induced Akt phosphorylation in breast cancer 
cells (Levine et al. 2007), Metformin was not able to increase Cisplatin-induced 
AMPK activation, with AMPK activators also failing to mimic Metformin-mediated 
Akt activation and cardioprotection, Akt-mediated anti-apoptotic action of Metformin 
was deduced to be independent of AMPK (Janjetovic et al. 2011). The finding 
suggest that Metformin has the ability to reduce ROS-induced cell death and 
apoptosis, potentially preventing cardiac myocyte death and protecting the 
myocardium from drug-induced toxicity.  
The study by Shi et al. (2012) demonstrated co-administration of Metformin with 
Doxorubicin was able to enhance lymphoma cell response, the authors stated that 
combined treatment triggered lymphoma cell autophagy. Autophagy is described as 
the cellular self-digestive process, and can play a role in cell death, whilst the mTOR 
pathway is said to regulate cell autophagy under stress conditions, including in 
response to anticancer agents (Shi et al. 2012, Hanahan and Weinberg 2011). In 
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particular inhibition of mTOR is known to result in the activation of autophagic 
responses (He et al. 2009, Meijer and Codogno 2004). In relation to this, Metformin 
is considered to target tumour cells by amplifying chemotherapy-induced AMPK 
activation and inducing tumour cell apoptosis, as well as inhibiting tumour 
development via autophagy (Shi et al. 2012, Rocha et al. 2011, Tomic et al. 2011). 
Autophagy is important as it plays an alternative route of apoptosis towards cell 
death, whilst activation is considered to improve chemotherapy-sensitising effects 
of certain anticancer agents (Shi et al. 2012, Lin et al. 2010). mTOR is considered 
to act as a negative regulator of autophagy, therefore inhibition of mTOR by AMPK 
activation stimulates autophagy, via phosphorylation of downstream targets Raptor 
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Figure 8: Summary of Metformin’s antiproliferative properties. Metformin is 
proposed to inhibit the mTOR pathway directly and indirectly. Upon AMPK 
activation, processes requiring high amounts of ATP are surpassed, inhibiting the 
transcription of gluconeogenesis genes in the liver as well as increasing glucose 
uptake in skeletal muscle, reducing circulating levels of glucose and increasing 
insulin sensitivity and reducing hyperinsulinemia. Within the cancer cell, 
dysregulated mTOR signalling promotes cell growth and proliferation; TORC1 
directly regulates cell growth and contains Raptor and PRAS40 required for the 
suppression of mTOR activity. AMPK activation, following low levels of ATP, 
switches off mTOR signalling over positive effects of amino acids or growth factors 
via phosphorylation of TSC2, stimulating Ras homolog enriched in brain (Rheb)-
GAP activity. In the absence of TSC2, AMPK activation occurs through Raptor 
phosphorylation by Metformin, directly effecting mTOR kinase activity Gonzalez-
Angulo and Meric-Berstam 2010).  
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1.11. AMPK-dependent activation during Metformin–induced 
cardioprotection. 
As highlighted, the AMPK is known to be a critical energy sensor and regulator of 
energy homeostasis (Zhou et al. 2001, Hardie et al. 2012). ATP depletion results in 
AMPK activation of catabolic pathways to generate ATP and switch-off ATP-
consuming mechanisms. This results in the increase in cellular ADP: ATP and 
AMP:ATP ratios, via decreasing the catabolic production of ATP, through nutrient 
depression and exposure to mitochondrial toxins, or via promoting ATP 
consumption through muscle contraction (Hardie et al. 2012).  
Zhou et al. (2001) highlighted that Metformin stimulated AMPK activation, whilst the 
stimulation was associated with the inhibition of glucose production in rat 
hepatocytes. Metformin was shown to have an indirect effect on AMPK, by 
increasing the AMP: ATP and ADP:ATP ratios in engineered cell lines expressing 
AMPK complexes with either wild-type γ2 isoform or Arg531>Gly mutation, thusly 
expressing γ2 complexes insensitive to the effects of AD and AMP phosphorylation 
(Hawley et al. 2010). Furthermore, AMPK activation was reduced with liver-specific 
LKB1 knockout hyperglycaemic mice, with Metformin failing to produce glucose-
lowering effects in these mice models due to the absence of LKB1 (Shaw et al. 
2005). It was proposed that LKB1-AMPK signalling regulates the expression of 
gluconeogenic genes via the regulation of transcription coactivator cAMP response 
element-binding protein-regulated transcription coactivator 2 (CRTC2) (Shaw et al. 
2005, Altarejos and Montminy 2011). CRTC2 is in a dephosphorylated state, 
localised in the nucleus, and enhances gluconeogenic genes such as PPARγ 
coactivator-1α (Rena et al. 2013). Insulin intake is known to switch-off glucose 
production via inhibiting gluconeogenic gene programmes, CRTC2 and forkhead 
box-O1 (FOCO1) proteins (Lin et al. 2011). Metformin is known to switch-off 
gluconeogenesis, independent of insulin/Akt signalling via the LKB1-AMPK 
pathway (Shaw et al. 2005).   
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Metformin administration in AMPKα1/α2 Prkaa1/2 or LKBI knock-out mice 
demonstrated a glucose-lowering effect, compared to controls; highlighting 
Metformin’s effect on gluconeogenesis in the liver is mainly mediated through 
AMPK-dependent kinases (Foretz et al. 2010). Furthermore, hepatocytes lacking 
AMPK were treated with Metformin and displayed inhibition of glucose production, 
with hepatocytes lacking LKB1 were found to have higher rates of basal-
unstimulated and cAMP-stimulated glucose production (Foretz et al. 2010). 
However, when considering knock-out mice studies, inactivation of critical metabolic 
genes could result in compensatory adaptations in alternate pathways in 
maintaining glucose homeostasis (Rena et al. 2013), indicating the importance of 
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Figure 9: The anti-hyperglycaemic effect of Metformin and activation of AMPK on 
the liver cell (Modified figure from Rena et al. 2013). Metformin is transported into 
hepatocytes via organic cation transporter-1 (OCT1) inhibiting the mitochondrial 
respiratory chain complex 1 formation. The deficit in energy production is known to 
be balanced by a reduction in energy consumption by the cell, including 
gluconeogenesis within the liver. This results in the decrease in ATP and increase 
in AMP concentration, further contributing to the inhibition of gluconeogenesis due 
to the ATP deficit. The increase in AMP concentration acts as a signalling mediator 
to inhibit cAMP-PKA signalling via suppressing adenylate cyclise. The increase in 
AMP concentration further acts to inhibit the gluconeogenic enzyme fructose-1, 6-
biphosphatase (FBPase), whilst also activating AMPK, all leading to the inhibition 
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Metformin stimulates the insulin-induced component of glucose uptake into both 
skeletal muscle and adipocytes (Klip and Leiter 1990). This demonstrated 
significant increase in diabetic patients, indicating that the drug has an enhanced 
effect in a hyperglycaemic state (Klip and Leiter 1990). Metformin further increases 
the insulin-dependent portion of glucose oxidation, whilst elevating the uptake of 
non-metabolisable analogues of glucose and increasing glucose-analogue 
transport independently of insulin (Klip and Leiter 1990). The antihyperglycaemic 
effects shown by Metformin are observed in many but not all guanidine-containing 
compounds, however guanidine itself was shown to be toxic for clinical use 
(Watanabe 1918), as well as diguanides such as Synthalin A and B (Bischoff et al. 
1928), before attention was shifted to Metformin Rena et al. 2013). The inhibition of 
the mitochondrial complex I is known to reduce NADH oxidation, thereby lowering 
the proton gradient through the inner mitochondrial membrane and the proton-
driven ATP synthesis, this shifts the ATP: ADP: AMP equilibrium towards the 
increased AMP synthesis via adenylate kinase, reducing the energy charge of the 
cell (Owen et al. 2000). The raised AMP levels are known to inhibit adenylate 
cyclise, preventing the converting of ATP to cAMP, thereby ultimately reducing 
cAMP levels, as shown in Figure 9 (Miller et al. 2013). The resulting effect reduces 
levels of PKA activity and inhibits glucagon-dependent glucose output from 
hepatocytes, ultimately inhibiting gluconeogenesis (Miller et al. 2013). The 
stimulation of PKA phosphorylates protein targets to increase hepatic glucose 
output (Miller et al. 2013).      
AMPK is known to be activated by pathological intracellular stress that depletes 
cellular ATP, including metabolic poisoning, oxidative stress, hypoxia and nutrient 
deprivation (Hardie 2004). AMPK is also known to inhibit energy consuming 
pathways, particularly within the heart this can be an issue due to the high demand 
in ATP, however AMPK activation can lead to an increase in glucose and fatty acid 
metabolism during this demand in ATP (Dyck and Lopaschuk 2006). Little energy 
reserves are present within the heart, therefore if ATP production were ceased the 
ATP supply within the heart is said to be exhausted (Dyck and Lopaschuk 2006). 
With this, cardiac AMPK is activated during ischaemia, the activation leads to the 
stimulation of glucose uptake, glycolysis and fatty acid oxidation (Dyck and 
Lopaschuk 2006). However, during ischaemia these metabolic effects can be 
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harmful as ischaemia is known to induce apoptosis in the heart, whilst AMPK is 
suggested to result in either pro- and anti-apoptotic effects (Capano and Crompton, 
Hickson-Brick et al. 2000, Russell et al. 2004, Shibata et al. 2005, Dyck and 
Lopaschuk 2006). Further to this, AMPK is involved in the cardiac hypertrophic 
process and acts to inhibit protein synthesis, whilst mutations for activating and 
inactivating AMPK are suggested to contribute to cardiac hypertrophy (Dyck and 
Lopaschuk 2006). Moreover, AMPK activation can also be via hormonal regulation, 
such as insulin, however it is unclear how insulin inhibits AMPK whilst this is 
hypothesised to be mediated via Akt activation and AMPK acts to inhibit insulin 
signalling (Kovacic et al. 2003, Longnus et al. 2005).  
Activation of AMPK during a state of intracellular stress, such as ischaemic injury, 
requires and involves increases AMP and the activation of upstream AMPK kinases, 
suggesting the possible role of AMP as a control mechanism of AMPK activation 
within the heart (Dyck and Lopaschuk 2006). The study by Frederich and Balaschi 
(2002), involving a P-NMR approach investigating the calculating of AMP 
concentrations, demonstrated that cardiac AMPK can be activated via AMP 
concentrations within the low micromolar range. This suggests that lowering of AMP 
concentrations can be used to activate AMPK in the absence of ischaemia, such as 
in the response to an increased workload (Frederich and Balaschi 2002). Within the 
heart AMPK phosphorylation is key to controlling AMPK activation, whilst 
phosphorylation of threonine within the activation loop of the α1 and α2 subunit via 
upstream AMPK kinases is known to be a key mechanism to activate AMPK during 
metabolic stress (Hardie and Carling 1997, Dyck and Lopaschuk 2006). AMPK 
kinases LKB1 and CAMKK are identified within the heart; with CAMKK expressed 
at low levels and LKB1 being highly expressed in the heart, however data regarding 
the role of both in AMPK phosphorylation is limited (Dyck and Lopaschuk 2006, 
Hawley et al. 2003, Hawley et al. 2005). LKB1 is a serine/threonine kinase that is 
involved in several pathways including AMPK activation by responding to anoxic 
stress via phosphorylation of the α subunit at the Thr172 residue, independently of 
AMP concentration (Baron et al. 2005, Hawley et al. 2003, Hawley et al. 2005). 
However, it is worth noting that during events of ischaemia LKB1 acts to 
phosphorylate the α2 subunit and not the α1 subunit, highlighting the possible 
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differential regulation and physiological roles of catalytic complexes and upstream 
kinases (Arad et al. 2007, Sakamoto et al. 2006). 
In healthy hearts large amounts of ATP are produced and sustained by 
mitochondrial oxidative metabolism and glycolysis. Within the heart, ATP is primarily 
produced via oxidation of fatty acids and pyruvate from either glycolysis or lactate, 
by the mitochondria (Dyck and Lopaschuk 2006). It is estimated that 10-40 % of 
ATP is produced via pyruvate oxidation; while 60-90 % of ATP is derived from fatty 
acid oxidation (Dyck and Lopaschuk 2006). AMPK can also have an important role 
in fatty acid and glucose metabolism and is known to regulate malonyl CoA, which 
acts to inhibit carnitine palmitoyl transferase (CPT)-1 on the mitochondria 
membrane (Dyck and Lopaschuk 2006). During events of ischaemia and ischaemic 
heart injury, mitochondrial oxidative metabolism decreases whilst ATP production 
is also decreased (Dyck and Lopaschuk 2006). During mild ischaemia energy 
demand is greater than the supply from mitochondrial glucose and fatty acid 
oxidation, resulting in glycolysis acceleration to compensate for the ATP supply 
(Dyck and Lopaschuk 2006). Moreover, during ischaemia ATP production is 
primarily via glycolysis however glycolysis becomes uncoupled from glucose 
oxidation, resulting in accumulation of by-products lactate and protons within 
cardiac cells (Dyck and Lopaschuk 2006). This results in the re-direction of ATP 
from myocardial contraction and towards clearing glycolytic by-products, decreasing 
cardiac function and efficiency (Dennis et al. 1991, Liu et al. 1996, Dyck and 
Lopaschuk 2006). AMPK is activated during myocardial ischaemia, occurring to 
restore myocyte ATP levels, and activating ATP generating pathways for glucose 
and fatty acid metabolism (Dyck and Lopaschuk 2006). AMPK activation results in 
the increase in cardiac glucose utilisation, promoting the translocation of GLUT4 to 
the sarcolemma of the myocyte and promoting glucose uptake, whilst also 
phosphorylated and activating phosphofructokinase 2, thereby phosphorylating 
fructose-2,6-biphosphate, stimulating glycolysis, and benefiting the heart via 
increasing glucose utilisation and anaerobic ATP synthesis (Russell et al. 2004, Li 
et al. 2005, Marsin et al. 2000, Young et al. 1966, Merrill et al. 1997, Marsin et al. 
2000).  
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AMPK is highly expressed within the heart and can be activated by pressure 
overload hypertrophy, endogenous AMPK activation was able to protect cardiac 
myocytes against hypoxic injury via attenuation of endoplasmic reticulum stress, the 
endoplasm reticulum-dependent apoptotic pathway was said to be a mechanism of 
hypoxic injury in cardiac myocytes (Terai et al. 2005, Stapleton et al. 1996, Hardie 
et al. 1997, Sambandam and Lopaschuk 2003, Tian et al. 2001, Xing et al. 2003). 
Terai et al. (2005) demonstrated hypoxia activation of AMPK in cultured cardiac 
myocytes, whilst pretreatment with the AMPK-activator AICAR was able to further 
activate AMPK attenuating hypoxic injury. It has been previously indicated that 
hypoxia can regulate AMPK activity, with and without the presence of cytosolic AMP 
(Frederich et al, 2005, Terai et al. 2005). The study by Frederich et al, (2005) used 
potassium-arrested hearts perfused with varying oxygen content and demonstrated 
the α-subunit of Thr172 phosphorylation increased in the presence of oxygen 
concentrations ≤ 21%, whilst measured AMP was recorded at ≤ 0.3µM concertation, 
highlighting that oxygen concentrations ≤ 21% increased AMPK phosphorylation 
and activity independently of cytosolic AMP. It was mentioned by Frederich et al, 
(2005) that the hypoxic increase in AMPK activity may result from direct 
phosphorylation of Thr172 via an upstream kinase or a reduction in the A0.5 for 
cytosolic AMP. Following this, AMPK has been suggested to play a role in mild 
ischaemia without a global change in high-energy phosphate homeostasis (Terai et 
al. 2005).  
Cardioprotection by AMPK focuses on downstream targets on mitochondria, 
including PPAR-α and PPARγ co-activator 1α (PGC-1α) contributing to the cascade 
of coordinate energy metabolism within the heart, particularly as PPARs are nuclear 
hormone receptors that act as central regulators of cardiac fatty acid metabolism 
(Ingwall 2004, Barreto-Torres et al. 2012, Vega et al. 2010, Mu et al. 2001, 
Schreiber et al. 2003). Whilst three PPAR isoforms exist (α, β/δ and γ), PPARα was 
shown to be the main isoform within the heart and is the primary regulator of fatty 
acid metabolism (Barreto-Torres et al. 2012), whilst being indicative in 
cardioprotection (Bulhak et al. 2009, Yue et al. 2003, Ingwall 2004). PGC-1α acts 
as an integrator of the transcriptional network for regulating cardiac mitochondrial 
biogenesis, whilst also regulating genes required for the cellular uptake of fatty acids 
and fatty acid oxidation via activating PPARs and oestrogen-related receptors (Huss 
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and Kelly 2004, Kelly and Scarpulla 2004). AMPK activation results in the 
upregulation of mitochondrial biogenesis and increases the expression of the 
electron transport chain enzymes via phosphorylation of PGC-1α (Jager et al. 
2007). Further to this, cardiac fibrosis was inhibited via AMPK activation involving 
PPARα activity (Fujita et al. 2008). The study by Fujita et al. (2008) demonstrated 
adiponectin enhanced PPARα activity though the activation of the AMPK signalling 
pathway in cardiac fibroblasts. The activation of AMPK was further shown to 
suppress Erk 1/2 activity, from this the author’s concluded that adiponectin-AMPK–
PPARα pathway is potentially involved in pathogenesis for cardiac fibrosis (Fujita et 
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1.12. Role of mTOR in Metformin cardioprotection. 
As mentioned in Sections 1.9. and 1.11., Metformin is associated with 
cardioprotective properties by interfering with cellular pathways associated with 
ROS signals and DNA damage responses, cellular energy homeostasis and amino 
acid availability, converging in restrained mTORC1 signalling (Melnik and Schmitz 
2014). mTORC1, composed of proteins mTOR, Raptor and mLST8, functions as a 
key regulator of cell growth and cellular proliferation, whilst Raptor acts to interact 
with substances for mTOC1-mediated phosphorylation (Sarbassov et al. 2005, 
DeYoung et al. 2007). mTORC1 is a multi-domain protein consisting of 
serine/threonine protein kinase domain at the C-terminus related to PI3K, within 
mammalian cells it is known that two functional complexes exist: mTORC1 and 
mTORC2 (Melnik and Schmitz 2014, Inoki et al. 2005, Sengupta et al. 2010, 
Laplante and Sabatini 2012). As mentioned, AMPK is a critical regulator of 
mTORC1, whilst the serine/threonine kinase LKB1 is considered to be the major 
kinase involved in phosphorylating the AMPK activation loop during energy stress 
(Shaw 2009, Xu et al. 2012, Shaw et al. 2005, Hardie 2007). AMPK suppresses 
mTORC1 via phosphorylating TSC2 and Raptor, upon activation during energy-
deficient conditions and the rise in AMP levels (Gwinn et al. 2008, Pikiou et al. 
2015). The inhibition activates autophagy via initiation of the Unc-51 like autophagy 
activating kinase (ULK-1), whilst hexokinase-II binds to mTORC1, decreasing 
mTORC1 activity during glucose deprivation (Egan et al. 2011, Shang et al. 2011, 
Roberts et al. 2014, Rabinowitz and White 2010).  
mTORC1 is known to control the G1/S transition and G2/M progression of the cell 
cycle as well as playing a role in sensing ATP levels and ROS signals involved in 
regulating cell growth and proliferation (Melnik and Schmitz 2014, Wang and Proud 
2009). It has been suggested that the involvement of the aberrant mTORC1 
signalling is associated with the onset and progression of obesity, T2DM and certain 
cancers, whilst enhanced mTORC1 signalling has been shown to stimulate 
adipogenesis and the increased expression of key adipogenesis transcription 
factors PPARγ and SREBP1 (Zoncu et al. 2011, Dazert and Hall 2011, Cornu et al. 
2013, Dann et al. 2007, Mieulet and Lamb 2010, Proud 2011, Takahara and Maeda 
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2013, Laplante and Sabatini 2013, Hara et al. 1998, Lynch et al. 2001, Lynch 2001, 
Pham et al. 2000, Kim and Chen 2004, Melnik and Schmitz 2014).   
The attenuation of mTORC1 overexpression signalling is hypothesised to aid in the 
prevention of the onset of T2DM, HF and cancer. mTORC1 regulates protein and 
lipid synthesis, nucleoside synthesis, cell cycle progression and couples nutrient 
availability to cell growth and cancer (Melnik and Schmitz 2014, Hsieh et al. 2012, 
Wang and Proud 2009, Efeyan and Sabatini 2010, Ekim et al. 2011, Robitaille 2013, 
Ben Sahra et al. 2013, Thoreen et al. 2012, Clohessy et al. 2012). From this, the 
dysregulation of elements of the mTORC1 pathway have been reported in cancers, 
this includes PI3K amplification/mutation, loss of PTEN function and overexpression 
of Akt (Populo et al. 2012, Nardella et al. 2009, Vadlakonda et al. 2013, Mita et al. 
2003, Barrett et al. 2012, Beauchamp and Platanias 2013).  
ATP levels play a role in maintaining genomic stability, particularly as the mTORC1 
pathway can be regulated by oxidative stress that down-regulates mTORC1 
signalling (Lavin and Khanna 1999, Alexander et al. 2010). Metformin primarily acts 
on the liver; however, OCT1 is also found on cancer cell surfaces and plays an 
important role in antiproliferative action of Metformin in cancer cells (Segal et al. 
2011). Upon uptake via OCT1, Metformin is believed to alter cellular energy 
metabolism associated with direct and indirect stimulation of AMPK in cancer cells, 
inhibiting mTOR and mTORC1 release (Pernicova and Korbonists 2014). Activation 
of LKB1 phosphorylates and activates the catalytic α-subunit of AMPK, loss of LKB1 
was shown to increase mTORC1 signalling in LKB1+ mice with intestinal tumours, 
detected by the phosphorylation of the major downstream targets of p70 ribosomal 
S6 kinase and eukaryotic translation initiation factor 4B binding protein 1 (4E-BP1) 
(Shaw et al. 2005, Zhou et al. 2001, Rena et al. 2013, Shaw et al. 2005).  
Following the inhibition of mitochondrial complex-1 activity, Metformin was shown 
to enhance the expression of fibroblast growth factor 21; the increased expression 
as well as the inhibition of mTORC1 was associated with an increase in lifespan 
(Zhang et al. 2013, Zhang et al. 2012, Rallis et al. 2013, Mendelsohn and Larrick 
2012). The induced expression of fibroblast growth factor 21 is known to be 
mediated via activating transcription factor 4 and is associated with mTORC1 
inhibition (Zhang et al. 2013, Bruning et al. 2014). In response to stress conditions 
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the DNA-damage-inducible transcript 4 (DDIT4) acts to repress signalling through 
mTORC1 whilst also inhibiting mTORC1 signalling by stabilising the TSC1-TSC2-
TBC1D7 inhibitory complex (Yoshida et al. 2010). p53 is required for the induction 
of DDIT4 and the activation of the TSC complex to inhibit mTORC1 signalling 
(Ellisen et al. 2002, DeYoung et al. 2008, Cam et al. 2014). DDIT4 acts to suppress 
mTORC1 signalling by releasing TSC2 from Akt-mediated association with 
inhibitory 14-3-3 proteins, this is said to be a physiological mechanism in response 
to hypoxia (DeYoung et al. 2008, Cam et al. 2014). p53 was shown to be involved 
in suppressing carcinogenesis via the inhibition of mTORC1, in particular p53 is a 
target of AMPK, with AMPK acting to induce phosphorylation of p53 and AMPK-
dependent cell-cycle arrest (Akeno et al. 2014, Zhang et al. 2012, Jones et al. 2005). 
Mdmx is a negative regulator of p53, Metformin activation of AMPK results in the 
phosphorylation of and inactivation of Mdmx, resulting in p53 stabilisation and 
activation (Wade et al. 2010, He et al. 2014). p53 induces Sestrin 1 and 2, which 
are known to activate AMPK and phosphorylate TCS2, resulting in the inhibition of 
mTORC1 (Budanov and Karin 2008). Therefore, AMPK activation, p53 activation 
and Sestrin 1 and 2 expressions via Metformin are described to function as a feed-
forward loop to inhibit mTORC1 signalling (Hay 2011). AMPK is also a major 
downstream target of ATM, a member of the PI3K family and plays a role in 
activation of p53 (Sanli et al. 2010, Sun et al. 2009, Fu et al. 2008). Inhibition of 
ATM was demonstrated to result in the reduction of Metformin-stimulated 
phosphorylation of AMPK in rat hepatoma cells, highlighting the role ATM has during 
Metformin administration (Melnik and Schmitz 2014, Vazquez-Martin et al. 2011, 
Lee et al. 2012). It has been hypothesised that Metformin could sensitise cells 
against further damage following the activation of the ATM-mediated DNA damage 
response, said to be mimicking the precancerous stimulus which acts as an intrinsic 
barrier against carcinogenesis (Melnik and Schmitz 2014). Further to this, Metformin 
is also hypothesised to function as a tissue sweeper of pre-malignant cells prior to 
gaining stem cell or tumour initiating properties (Melnik and Schmitz 2014, 
Menendez et al. 2011).  
The exact mechanism of Metformin inhibition of guanosine triphosphate (GTP)-ases 
and the resulting suppression of mTORC1 signalling is still in debate (Melnik and 
Schmitz 2014, Kalender et al. 2010). It is known that proton-assisted amino acid 
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transporters interact with recombination activating gene (RAG)s and are required 
for mTORC1 activation (Melnik and Schmitz 2014, Ogmundsdottir et al. 2012, 
Goberdhan 2010). The proton-assisted amino acid transporter 1 (PAT1) has been 
established as the essential mediator of amino-acid-dependent mTORC1 activation 
in the function of the PAT1/RAG/Ragulator complex (Ogmundsdottir et al. 2012), 
the mTORC1-regulatory role of PATs said to be conserved in humans (Heublein et 
al. 2010). The activation of mTORC1 requires PAT1 and PAT4 and is elevated in 
PAT1-overexpressing cells (Heublein et al. 2010). PATs are hypothesised to 
modulate activity of mTORC1 by modulating the intracellular response to amino 
acids, as PAT1 and mTORC1 co-localise at the surface of the same intracellular 
compartments (Heublein et al. 2010). The over-expression of PAT1 enhanced the 
sensitivity of the mTORC1 response to amino acids in starved cells following 
refeeding, whilst the siRNA knock-down of the PAT1 gene inhibited mTORC1 
activation, thereby highlighting that suppression of PAT1 attenuates mTORC1 
signalling (Heublein et al. 2010). However, it was shown by Melnik and Schmitz 
(2014) that Metformin in excessive concentrations (10 mM) exhibited modest PAT1 
inhibition of L-[3H) proline uptake in Caco-2 cells, whilst only a few studies exist 
demonstrating the effects of biguanides on PAT4 activity, involved in the regulation 
of mTORC1 (Matsui and Fukuda 2013). It is worth investigating the effect of different 
Metformin concentrations on PAT1 and PAT4 expressing cells, to elucidate the 
potential inhibitory effect of Metformin on PAT/RAG/Ragulator/v-ATPase nutrisome-
mediated mTORC1 signalling (Melnik and Schmitz 2014).  
To conclude, Metformin administration is associated with cardioprotective 
properties via the inhibition of certain pathways, particularly the mTORC1-
assocaited pathway. Dysregulation of the mTOR and mTORC1-associated 
pathways is demonstrated in certain cancers as well as being associated with 
increases in ROS signalling and onset of HF. Metformin acts to phosphorylate TSC2 
and LKB1, inhibiting mTOR and mTORC1, as well as regulating key proteins such 
as ATM and p53. The importance of mTOR and mTORC1 is expanded in Section 
1.13.    
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1.13. mTOR involvement in cancer and hypoxia.  
As discussed in Section 1.12., the loss of control of mTORC1 activity is a key 
hallmark of malignant tumours, indicating the importance in tumourigenesis (Guertin 
and Sabatini 2007, DeYoung et al. 2007). TSC1/2 acts to inhibit the activity of 
mTORC1 (Hay and Sonenberg 2004), as well as functioning to integrate the cellular 
response to growth factor, nutrient and oxygen availability (Pan et al. 2004, 
DeYoung et al. 2007). Regulation of mTORC1 is known to involve growth factor 
signalling, promoting mTORC1 activity via inhibition of the TSC1/2 complex (Gao 
and Pan 2001, Potter et al. 2001, DeYoung et al. 2007).  
TSC2 is activated via phosphorylation of the LKB1/AMPK pathway, thereby 
contributing towards mTORC1 inhibition during energy deprivation and long-term 
hypoxic stress (Corradetti et al. 2004, Shaw et al. 2005, Liu et al. 2006, DeYoung 
et al. 2007). mTORC1 activity is shown to be inhibited during exposure to modest 
hypoxia (1 % O2) (Arsham et al. 2003) via a pathway involving the TSC1/2 complex 
and the REDD1 gene (Brugarolas et al. 2004, Reiling and Hafen 2004). Knowing 
that oxygen is an essential regulator of cellular metabolism, within hypoxic 
conditions cells are known to rapidly activate a variety of adaptive mechanisms to 
limit energy loss via inhibiting energy-intensive processes including protein 
translocation (Wouters et al. 2005, Liu et al. 2006, DeYoung et al. 2007). Is it 
suggested that a period of hypoxic stress occurs during tumourigenesis and that 
failure to suppress mTORC1 activity under hypoxia can contribute towards 
tumourigenesis (DeYoung et al. 2007). This highlights a potential role Metformin 
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1.14. Role of Adenosine and hENT1 in AMPK signalling 
Studies have demonstrated the cardioprotection of Metformin to be inhibited via 
adenosine receptor antagonism with 8-p-sulfophenyltheophylline hydrate (8-SPT) 
and the equilibrative nucleoside transporter (ENT) inhibitor nitrobenzylthioinosine 
(NBTI), inhibiting the AMPK and PI3K/Akt pathway (Figure 10) (Paiva et al. 2009, 
Bhamra et al. 2008). It was demonstrated that facilitated diffusion of adenosine 
through the human equilibrative nucleoside transporter (hENT) to the extracellular 
compartment occurs and stimulates the adenosine receptor to provide 
cardioprotection (Paiva et al. 2009). The use of NBTI indicates the importance of 
adenosine simulation by either increased intracellular or extracellular formation of 
adenosine, suggesting that Metformin has intracellular adenosine concentration 
increasing properties (Paiva et al. 2009). The administration of Metformin during 
reperfusion resulted in the significant reduction of myocardial infarction; the effect 
was abolished in the presence of an AMPK-inhibitor Compound C (Paiva et al. 
2010).  
It is known that extracellular adenosine activates adenosine receptors A1, A2A, 
A2B, A3, and A3AR on the membrane surface of cardiac myocytes, acting to 
regulate pacemaker activity, producing physiological responses (Linden 2005, Rose 
et al. 2010, Mubagwa and Flemeng 2001). Levels of adenosine within the cell are 
regulated by the presence of and activity of nucleoside transporters found on the 
surface of cell membranes (Linden 2005, Rose et al. 2010). The influx of adenosine 
across the cardiac myocyte cell membrane is known to be mediated via ENT1 and 
is known to be expressed at higher levels in heart tissue compared to other ENT 
isoforms, highlighting the role of ENT1 for adenosine transport (Rose et al. 2010, 
Lu et al. 2004, Pennycooke et al. 2001). This can be used to suggest the role of 
ENT1 for adenosine transport, required for AMPK and ATP production. However 
the use of AMPK and ENT1 signalling is still in debate, the study by Rose et al. 
(2010) failed to find evidence towards the role of ENT1 in the modulation of AMPK 
signalling via exogenous added adenosine, the authors went on to suggest that the 
mechanism of cardioprotection may involve other pathways aside from AMPK in 
mice with the ENT1 gene knocked out (Rose et al. 2010). The study further went on 
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to suggest that cardioprotection was offered in the absence of ENT1 in ENT1-null 
transgenic mice (Rose et al. 2010). 
Adenosine is known to be taken into mammalian cells via ENT and concentrative 
nucleoside transporter (CNT) (Baldwin et al. 2004, Gray et al. 2004, Pastor-Anglada 
et al. 2004, Aymerich et al. 2006). ENT1 and CNT2 are primarily responsible for this 
process, the expression of both transporters is said to be widespread and have 
demonstrated a Km value for adenosine in the physiological range of 40 µM for ENT1 
and 8 µM for CNT2 (Wang et al. 1997, Ward et al. 2000). Adenosine is reported to 
be present in peripheral blood at concentrations of 0.3-1 µM, moreover the 
concentration is considered to be higher in the intestinal lumen and the portal vein 
(Lasey et al. 1998, Pasini et al. 1996, Saadjian et al. 2002). Further to this, 
adenosine is known to be produced via ectonucleotidase action on nucleotides, 
contributing to higher local nucleoside concentrations (Che et al. 1997, Roman and 
Fritz 1999).  
The adenosine receptor system is said to enhance resistance to ischaemic injury 
under cellular and metabolic stress within the heart, the purine nucleoside 
adenosine functions to mitigate myocardial damage from ischaemia-reperfusion 
injury (Peart and Headrick 2007). Under ischaemic injury endogenous levels of 
adenosine are said to increase rapidly to mediate a response, adenosine is formed 
following dephophorylation of 5’AMP via intracellular and extracellular 5’-
nucleotidases and from S-adenosylhomocysteine and is taken into cells by the 
facilitative ENT (Headrick et al. 2003). Within cells the adenosine is de-aminated 
via adenosine deaminase or rephosphorylated to 5’AMP by adenosine kinase 
(Headrick et al. 2003). Small changes in intracellular AMP concentrations have 
demonstrated a modulating effect on AMPK activity in a synergistic manner 
(Aymerich et al. 2006). With the knowledge that adenosine is taken into mammalian 
cells via ENT, it was demonstrated that extracellular adenosine was able to activate 
AMPK within epithelial cells, this was said to involve adenosine transport and 
resulted in an increase in the AMPK intracellular pool (Aymerich et al. 2006). Using 
this information, it can be suggested that inhibiting extracellular adenosine, required 
for AMPK activation, would result in the decrease or inactivation of AMPK.  
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The study by Aymerich et al. (2006) demonstrated that the prevention of adenosine 
phosphorylation resulted in an increase yield in AMP signalling, using the inhibitor 
of adenosine kinase 5’-iodotubercidin (5’-ITU) following pre-treatment of IEC-6 cells. 
The study further demonstrated the inhibition of increased intracellular AMP 
concentrations after adenosine addition, and a marked decrease in ADP 
concentration, the authors concluded that the generation of AMP from extracellular 
adenosine was required for AMPK activation (Aymerich et al. 2006). Further to this, 
the role of ENT-type transporters on the adenosine-triggered activation of AMPK 
was investigated by Aymerich et al. (2006) using 1 µM NBTI, prior to adenosine 
addition to cultured cells. The authors concluded that the ENT-related transport 
function was inhibited by approximately 80 % (Aymerich et al. 2006). The authors 
concluded that extracellular adenosine was able to activate AMPK via a mechanism 
requiring adenosine transport, resulting in an increase in the AMP intracellular pool 
(Aymerich et al. 2006). The same study further demonstrated that partial inhibition 
of extracellular adenosine, via the inhibition of CNT2, resulted in a significant 
blockade of the AMPK pathway and by using 1 µM adenosine a consistent and 
significant increase in AMPK was achieved (Aymerich et al. 2006). The addition of 
extracellular adenosine was shown to enhance ACC phosphorylation, which was 
otherwise abolished following CNT2 inhibition (Aymerich et al. 2006).  
Endogenous adenosine demonstrated cardioprotective properties during 
ischaemia-reperfusion studies, reducing the infarct size and delaying the onset of 
ischaemic contracture by reducing the rate of ATP catabolism (Ely and Berne 1992). 
Adenosine further demonstrated cardioprotection involving cardiac myocytes via 
inhibiting platelet aggregation, preventing adhesion of inflammatory cells to the 
endothelium and reducing the production of superoxide via neutrophils (Ely and 
Berne 1992, Mubagwa et al. 1996). The administration of exogenous adenosine is 
said to be effective in ischaemic and pharmacological preconditioning (Wang et al. 
2002). However, it was said that the uses of adenosine receptor agonists are difficult 
to use in clinical settings due to complicated side effects of drugs on extra cardiac 
tissue and by progressive desensitisation of receptors to high doses of adenosine 
(Maddock et al. 2002). The high level of extracellular adenosine during ischaemia 
can potentially reduce the efficacy of adenosine receptor agonists (Van der Heide 
and Reimer 1996, Matherne et al. 1997). 
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Figure 10: The proposed mechanism of Metformin-induced cardioprotection with 
the involvement of adenosine for the activation of AMPK (Bromage and Yellon 
2015). Key: Ado: Adenosine.  
The study by Maddock et al. (2002) demonstrated that the activation of adenosine 
A3 receptors, after administrating the A3 receptor agonist 2-CL-IB-MECA, was able 
to reduce the infarct percentage increase after ischaemia-reperfusion in isolated 
perfused rat hearts, whilst further exerting an anti-apoptotic and anti-necrotic effect 
in cardiac myocytes. Adenosine A3 receptor activation was hypothesised to mediate 
both cell protection and cell death depending on the degree of receptor activation, 
moreover the threshold for A3 mediated decrease in apoptotic injury is said to be 
mild (Maddock et al. 2002, Abbracchio and Cattabeni 1999, Gao et al. 2001, 
Shneyvays et al. 2001, Von et al. 2001, Yao et al. 1997). However, concentrations 
of 2-CI-IB-MECA greater than 10 μM are said to trigger necrosis or apoptosis of cell 
death (Maddock et al. 2002, Abbracchio and Cattabeni 1999, Shneyvays et al. 
2000, Shneyvays et al. 1998). From this, the concentration of 1 nM for A3 agonism 
was said to be ideal, particularly as higher concentrations of 30 and 100 nM were 
said to not demonstrate a reduction in infarct percentage following ischaemia-
Some materials have been removed from this thesis due to Third Party Copyright. Pages where 
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reperfusion of isolated rat hearts, whilst concentrations below 1 nM were also said 
to not demonstrate any reduction in infarct percentage (Maddock et al. 2002). This 
was further stated to demonstrate similar profiles of apoptosis and necrosis of rat 
cardiac myocytes (Maddock et al. 2002). With this information regarding the role of 
adenosine signalling in cardioprotection, Metformin was demonstrated to reduce 
ischaemic heart damage via adenosine receptor activation (Paiva et al. 2009).  
Studies have also demonstrated that Metformin can increase adenosine signalling 
in in-vivo and ex-vivo contractile models involving penile strips from high-fat diet-
induced animal, of which in-vivo and ex-vivo administration of Metformin resulted in 
an increase in adenosine receptor relaxation via the interference of NO and 
increase in adenosine signalling (Vignozzi et al. 2014). However, a blinded-endpoint 
study involving healthy middle-aged participants failed to demonstrate if Metformin 
was able to protect against endothelial ischaemia–reperfusion injury (El Messaoudi 
et al. 2014). However, it must be noted that the study involved the use of forearm 
ischaemia and Metformin was administered as a form of short-term pre-treatment 
and not during the event of ischaemia or reperfusion. The authors mentioned the 
hypothesis was driven following studies by Paiva et al. (2009), Bhamra et al. (2008), 
Calvert et al. (2008) and Gundewar et al. (2009), however only Calvert et al. (2008) 
of the aforementioned studies involved pre-treatment of Metformin prior to 
ischaemia, the others focussed on Metformin administration throughout the course 
of ischaemia or during reperfusion following the initiation of a form of ischaemia.  
Moreover, unlike El Messaoudi et al. (2014), Calvert et al. (2008) demonstrated that 
Metformin was able to limit the extent of myocardial damage following pre-treatment 
of Metformin in non-diabetic mice hearts. Using this, it can be suggested that 
Metformin administration during an event of ischaemia could result in the prevention 
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1.15. Ex-vivo modelling for drug-induced ischaemic heart disease.  
Investigating Sunitinib-induced cardiotoxicity and Metformin-induced 
cardioprotection can be performed using the Langendorff technique for both 
normoxic and ischaemia-based experiments, using animal hearts. The Langendorff 
system can be used to stimulate the effects of perfusion of compound into the heart, 
the technique allows the heart to be perfused by cannulating the aorta whilst 
perfusion buffer flows retrogradely down the aorta, opposite normal physiological 
flow (Bell et al. 2011). This can allow for both Sunitinib and Metformin to be 
retrogradely perfused directly into the heart. During perfusion, haemodynamic 
parameters such as left ventricular developed pressure (LVDP), heart rate (HR) and 
coronary flow (CF) as well as further parameters can be measured (Bell et al. 2011). 
Furthermore, isolated heart tissue following Langendorff perfusion can be used to 
measure infarct percentage by using the 2, 3, 5 triphenyltetrazolium chloride (TTC) 
staining technique. TTC is used to visually detect infarcted area of the animal heart 
following Langendorff perfusion, TTC is reduced to triphenyltetrazolium formazan 
(TTF), TTF allows for the distinguishing between intact myocardium (brick-red 
colour) where dehydrogenase activity is preserved, and infarct myocardium (pale 
colour) where enzymes are inactivated or reduced (Kokimoto et al. 2013). 
The Langendorff technique and TCC staining will allow for the measuring of drug–
induced changes to haemodynamic parameters as well as measuring potential 
drug–induced damage to the heart. The Langendorff system is described as a highly 
reproducible and neither time-consuming or technically demanding (Skzypiec-
Spring et al. 2006). However, when using the Langendorff system, the system 
needs to be tailored appropriately for the desired organ used and the animal model. 
Perfusion pressure is typically between 70 and 80 mmHg as described by Bell et al. 
(2011), whilst coronary flow remains dependent on the size of the heart being used, 
typical figures are 2 ml/min for mouse, 20 ml/min for rat and 40 ml/min for rabbit 
(Bell et al. 2011). The column of perfusate is above a certain height above the 
perfusion cannula tip, therefore pressure at the cannula should be the same as 
throughout the Langendorff apparatus, however once flow is established restriction 
to the delivery circuit, including the diameter of tubing, coil heat exchanges, tubing 
connectors, sintered glass in line filters and the presence of air bubbles or debris, 
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can lead to a significant drop in perfusion pressure (Bell et al. 2011). In particular, 
cannula design is 3 mm in outer diameter when using rat hearts (Bell et al. 2011). 
Isolated hearts are perfused with a physiological salt solution containing 
bicarbonate similar to the ionic content of plasma originally defined by Krebs and 
Henseleit following replacement of animal blood as used originally by Langendorff 
and must be delivered at 37 oC whilst continuously gassed with 5 % CO2 and 9 5% 
O2, pH 7.4 (Langendorff 1898, Taegtmeyer 1995, Skzypiec-Spring et al. 2006, 
Doring 1990, Sutherland and Hearse 2000, Ytrehus 2000). Following this, we 
propose the use of the Langendorff system to monitor the potential cardiotoxic and 
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1.16. Aims and objectives.  
Taking into consideration of all information discussed in Section 1, we aim to 
investigate the following aims and hypothesis:  
1. Sunitinib malate will demonstrate properties of cardiotoxicity when 
administered at a clinical dose as highlighted by existing research studies, 
we propose that the anti-diabetic agent Metformin hydrochloride will 
demonstrate potential properties of cardioprotection when administered 
together with Sunitinib. 
2. Sunitinib-induced cardiotoxicity may result from the inhibition of AMPK 
inactivation, equally Metformin-induced cardioprotection may result from the 
activation of AMPK. This will be demonstrated using the AMPK-associated 
inhibitor S-4-Nitrobenzyl)-6-thioinosine (NBTI), administered with Metformin 
and Sunitinib.  
3. We aim to investigate the anti-cancer properties of Metformin and Sunitinib 
co-administration in cancer cell lines of HepG2 liver cancer and HL60 human 
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Chapter Two: Materials and Methods. 
2.1. Drug concentration rationale and introduction  
Metformin at a 50 µM concentration was selected to be used in the ex-vivo 
Langendorff model and the in-vitro cancer cell-based models. Metformin 
administration at very high concentrations (5 mM) was shown to induce apoptotic 
death (An et al. 2006) and therefore maximum plasma concentration of Metformin 
administration was recommended to be 100 µM (Wood et al. 1996). Taking this into 
consideration the cardioprotective properties of Metformin were demonstrated at 50 
µM (Bhamra et al. 2008, Paiva et al. 2009). The use of PI3K inhibitors further 
demonstrated Metformin’s cardioprotective effects to be independent of 
hypoglycaemic and insulin-sensitising effects, in isolated perfused rat hearts and 
cardiac myocytes (Bhamra et al. 2008). The ex-vivo concentration of 50 µM is 
believed to be slightly greater than the average plasma concentration after 
administration of a single dose of 850 mg in patients (Sambol et al. 1996). Very few 
studies exist regarding the use of Metformin administration alone in normoxic 
conditions of the Langendorff system without use of prior-induced injury or 
ischaemia-reperfusion; however existing ischaemia-reperfusion studies have used 
Metformin at concentrations of 25 µM, 50 µM and 75 µM in isolated perfused rat 
heart models. Metformin at concentrations of 50 µM and 75 µM demonstrated a 
reduction in infarct size when administered at reperfusion following ischaemia, 
however 25 µM Metformin failed to demonstrate a cardioprotective effect (Bhamra 
et al. 2008). Metformin is indicated to achieve a plasma concentration of 10-20 μM/l 
in patients, Hawley et al. (2002) was able to demonstrate a significant activation of 
AMPK in H4IIE cells at a Metformin concentration of 50 μM, whilst activation was 
said to be two-fold greater following 72 hours of incubation. It was said that higher 
doses of Metformin are not required for maximal AMPK activation to achieve a 
beneficial therapeutic effect (Hawley et al. 2002). Furthermore, in patients, greater 
doses of Metformin are said to result in gastrointestinal side effects, whilst also 
posing a risk for lactic acidosis, possibly resulting from the compound acting as an 
inhibitor of the respiratory chain at higher concentrations (Hawley et al. 2002, Owen 
et al. 2000).  
 
94 | P a g e  
 
The concentration of 1 µM for Sunitinib was selected to be used in the ex-vivo 
Langendorff model and the in-vitro cancer cell-based models. Sunitinib is reported 
to achieve a steady state blood concentration at 50 ng/ml in cancer patients, 
corresponding to 0.09-1 µM (Goodman et al. 2007, Henderson et al. 2013). 
Furthermore, Sunitinib drug solution was made to achieve a final dimethyl-sulfoxide 
(DMSO) concentration of 0.1 % or lower in all solutions, it is believed that there are 
no changes in contractility in cardiac ex-vivo experiments with <0.1 % DMSO in 
Krebs Henseleit (KH) bicarbonate buffer (Henderson et al. 2013).  
The concentration of 1 µM for NBTI was selected to be used in the animal and 
cancer cell-based models. As mentioned in Section 1.14., facilitated diffusion of 
adenosine through the hENT was shown to stimulate the adenosine receptor to 
provide cardioprotection via the activation of AMPK (Paiva et al. 2009). Metformin’s 
cardioprotective properties, via adenosine receptor stimulation was demonstrated 
after adenosine receptor stimulation was abolished via ENT inhibitor NBTI (1 µM), 
inhibiting AMPK and the PI3K/Akt pathway (Paiva et al. 2009, Bhamra et al. 2008). 
Moreover, similar results were shown at a concentration of 1 µM by Aymerich et al. 
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2.2.1. Materials 
Metformin hydrochloride (500 mg, MW 165.62 mg/mM) was purchased from Sigma 
Aldrich, Gillingham, UK. 500 mg of Metformin was dissolved in 30.184 ml ultra-pure 
RO water in order to bring to a final concentration of 0.1 M stock solution. The 
Metformin stock solution was stored at -20oC.  
Sunitinib Maleate (25 mg, MW 532.56 mg/mM) was purchased from Sigma Aldrich, 
Gillingham, UK. The 25 mg of Sunitinib was dissolved in 4.69 ml of DMSO in order 
to bring to a final concentration of 0.01 M stock solution. The Sunitinib stock solution 
was stored at -20oC and care was taken to avoid exposure to light and UV radiation.  
NBTI (S-4-Nitrobenzyl)-6-thioinosine, 100 mg, MW 419.41 mg/mM) was purchased 
from Sigma Aldrich, Gillingham, UK. NBTI was dissolved in 23.84 ml DMSO in order 
to bring to a final concentration of 0.01 M stock solution. The NBTI stock solution 
was stored at -20oC.  
AMPKα, Phospho-AMPKα (Thr172), GAPDH, and mAb Anti-rabbit antibodies were 
purchased Cell Signalling Technology® New England BioLabs, Hitchin, UK. Vials 
were aliquoted and stored at -20 oC. Mini-PROTEAN® TGX™ Precast 
polyacrylamide gels (4-10 %, mini-protein Stain-Free), and Trans-Blot® Turbo™ 
Midi PDVF Transfer Pack membranes were purchased form Bio-Rad, UK, and 
stored at 4oC. 
Penicillin-Streptomycin Solution (x100 concentration), Trypsin with EDTA (x10 
concentration) and L-Glutamine (200 mM, x100 concentration) were all purchased 
from LabTech International Ltd, East Sussex, United Kingdom. Foetal Bovine 
Serum (FBS, South American origin) and Dulbecco’s Modified Eagle Medium 
(DMEM) with high glucose and Sodium Pyruvate w/o HEPES were all purchased 
from ThermoFisher Life Technologies Ltd, Paisley, United Kingdom.  
3-(-4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) powder 
was purchased from Sigma Aldrich, Gillingham, UK.  
Remaining reagents were standard laboratory reagents from Sigma Aldrich and 
Fisher Scientific.  
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2.2.2. Animals and cells. 
Experiments were performed using Sprague-Dawley (SD) rats (2-3-month male, 
345-375 g b/w). Animals were obtained from Charles River research laboratories, 
Margate, UK. Experiments received ethical approval from Coventry University and 
all experiments were conducted in accordance with the Animal (Scientific 
Procedure) Act 1986 and Coventry University standards. SD rats were selected for 
use due to general purpose model and based on previous worked carried out at 
Coventry University by Sandhu et al. 2017, Cooper et al. 2018 and Maddock et al. 
2002. 
Experiments were performed using HepG2 and HL60 cell lines acquired from The 
American Type Culture Centre (ATCC) brought up from the Coventry University 
stock. Experiments received ethical approval from Coventry University and all 
experiments were conducted in accordance with the Animal (Scientific Procedure) 
Act 1986 and Coventry University standards.  
As Sunitinib is currently used in studies for the treatment of acute myeloid 
leukaemia, the HL60 cell line was deemed as a suitable model to investigate 
Sunitinib’s anti-proliferative properties. As described by ATCC, the HL60 cell line is 
described as a peripheral blood leukocyte promyelocytic cell line obtained from 
leukapheresis from a 36-year-old Caucasian female with acute promyelocytic 
leukaemia.  The HepG2 liver cancer cell line, derived liver tissue of a 15-year old 
male with hepatocellular carcinoma, was used to investigate the potential anti-
proliferative properties with Metformin. Moreover, the HepG2 cell line was deemed 
suitable for a comparison study with HL60 cells based on the use with numerous 
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2.3.1. Langendorff experiment and isolated perfused heart preparation–
normoxic study.   
Animals were sacrificed by cerebral dislocation, a schedule one home office 
procedure in accordance with The Guidance on the Operation of the Animals 1986. 
Hearts were rapidly isolated and placed into ice cold 4oC KH bicarbonate buffer. 
Hearts were immediately mounted onto the langendorff system, cannulated via the 
aorta with a 1.4 mm inner diameter, whilst being retrogradely perused with KH 
buffer. KH buffer was prepared in 10 litres ultra-pure Millipore/RO water containing 
(mM) NaCl 118.5, NaHCO3 25, KCL 4.8, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.7, 
glucose 11.  
KH buffer was gassed with 95 % O2 and 5 % CO2 and maintained at 37 ± 1 oC and 
pH 7.4 ± 0.2 at all times. The left atrium was trimmed away, and the latex isovolumic 
balloon was carefully introduced into the left ventricle and inflated up to 5–10 mmHg 
end diastolic pressure. Ex-vivo rat hearts were equilibrated and stabilised for 10–20 
minutes prior to starting the experiment. Functional recording was conducted using 
the physiological pressure transducer connected to a bridge amp and Powerlab (AD 
Instruments Ltd. Chalgrove, UK). LVDP, HR and CF were measured at regular 
intervals of 5 minutes for 20 minutes during stabilisation, intervals of 5 minutes for 
35 minutes during drug perfusion, and intervals of 15 minutes for 120 minutes (155 
minutes total drug perfusion) (Figure 11). 
Normoxic study involved the administration of Sunitinib at 1 µM concentration ± 
Metformin at 50 µM concentration ± NBTI at 1 µM concentration following 20 
minutes of stabilisation for each heart during the 155 minute drug perfusion (Figure 
11), (refer to Section 2.1. for drug rationale). Control study was carried out without 
the administration either Sunitinib or Metformin or NBTI. Hearts were divided into 2 
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2.3.2. Triphenyl-tetrazolium chloride staining. 
Following Langendorff perfusion, Section 2.3.1., hearts were dismounted and were 
weighed and frozen at -20 oC. Frozen hearts were sliced into 2mm thick transverse 
sections before being incubated in TTC solution (1% in phosphate buffer) at 37 oC 
for 10–12 minutes and fixed in 10 % formalin for a minimum of 4 hours. Heart slices 
were monitored for discolouration. Risk zone and infarct area were traced onto 
acetate sheets. Computerised ImagetoolTM software was used to analyse the 
percentage of infarct tissue. Infarct size was normalised to the total area of each 































Key:                Normoxic KH buffer perfusion                         Drug perfusion 
Figure 11: The treatment protocol used for the normoxic study for infarct size 








Infarct Size Assessment            
 





175 min perfusion with KH solution                          
Infarct Size Assessment            
 
Addition of Sunitinib (1 µM), Metformin (50 
µM), the combination of Metformin and 
Sunitinib, NBTI (1 µM) or the combination 
of Metformin and Sunitinib and NBTI.  
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2.4. Western blot analysis SDS Page. 
Following Langendorff perfusion, Section 2.3.1., hearts were dismounted and left 
atrium coronary organ tissue from the normoxic study was snap-frozen in liquid 
nitrogen. Tissue was homogenised in Protein Lysis Buffer (100 mM Tris-Base, 1 
mM EDTA, 10 % SDS, 0.1 M NaCl, 2 mM Sodium Pyruvate, 2 mM NaF, 2 mM β-
Glycerophosphate, 1 protease inhibitor cocktail tablet per 100 ml, 1 PhosSTOPTM 
tablet per 10 ml, ultra-pure RO water), using the homogeniser (IKA® T 25 ULTRA-
TURRAX).  
A total of 60 µg of protein concentration was determined using PierceTM BCA protein 
assay kit (ThermoFisher Scientific). Required quantities of each sample were mixed 
1:1 with Sample Buffer (1 M Tris-HCl, pH 6.8, SDS, glycerol, β-Mercapto-ethanol, 
Bromophenol blue, ultra-pure RO water) heated to 100oC for 10 minutes. Samples 
were diluted with the required quantity of Sample Buffer to achieve a 60 µg of protein 
concentration in a 15 µl well volume.  
Samples were loaded onto Mini-PROTEAN® TGXTM stain-free Gel (BioRad, USA) 
and run for approximately 1 hour at 130 V, following protocol optimisation. Gels 
were transferred onto membrane via electrophoresis with Tran-Blot Turbo (BioRad, 
USA). Immunoblots were incubated for 1 hour with blocking buffer (5 % milk powder, 
x1 concentration TBST). Immunoblots were analysed using primary antibodies: 
Phosphorylated AMPKα (p-AMPK, Thr172), total AMPKα and house-keeping protein 
GAPDH for overnight incubation in 4 oC, using a tube roller/orbital shaker. 
Immunoblots were exposed for 1 hour to specific secondary antibodies (Rabbit 
mAb). Proteins were visualised using enhanced chemiluminescence detection kit 
Super Signal West Femto Maximum Sensitivity Substrate (ThermoFisher Scientific, 
USA). Images were taken with ChemiDoc MP System (BioRad, USA). Density was 
analysed with BioRad software QuantityOne. Analysis of p-AMPK protein receptor 
bands was normalised to AMPKα (total AMPK) and GAPDH and quantified using 
computerised ImagetoolTM software analysis.  
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2.5. Methylthiazolydiphenyl-tetrazolium bromide assay for HepG2 and HL60 
cell viability  
The methylthiazolydiphenyl-tetrazolium bromide (MTT) assay with 3-(-4,5-Dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide was performed using HepG2 and 
HL60 cancer cells for control and treatment group: Metformin 6 µM, 10 µM, 30 µM, 
60 µM, 100 µM, 300 µM, 600 µM, 1000µM, Sunitinib 0.1 µM, 0.3 µM, 1 µM, 6 µM, 
10 µM, 30 µM, 60 µM and 100 µM, NBTI 0.1 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 25 
µM, 50 µM and 100 µM. Co-administration (co-treatment) of Sunitinib 0.1-100 µM 
was carried out with 50 µM Metformin, co-treatment and NBTI was carried out using 
Sunitinib 0.1-100 µM, 50 µM Metformin and 1 µM NBTI.  
HepG2 and HL60 cells were investigated for assessing cell metabolic activity 
including nicotinamide adenine dinucleotide phosphate (NADPH)–dependent 
cellular oxidoreductase enzymes to reduce tetrazolium dye MTT to the insoluble 
formazan product.  
Cancer cells were stored in a T75 cm2 flask containing 12 cm2 DMEM or RPMI cell 
growth media. Plates containing HepG2 cells were incubated at 37 oC, 5 % CO2 for 
48 hours, to allow attachment >60 % confluency. Plates containing HL60 cells were 
incubated at 37 oC, 5 % CO2 for 24 hours to allow for >60 % confluency 
Plates were incubated with Sunitinib 0.1-100 µM concentration or Metformin 0.1-
1000 µM concentration or NBTI 0.1-100 µM concentration at 37 oC, 5 % CO2 for 24 
hours. Following incubation with compounds, media was aspirated off and replaced 
with fresh media and 50 µl MTT media (concentration 5 mg/ml final concentration) 
for a total of 100 µl. The plate was incubated for 6 hours minimum at 37oC, 5% CO2. 
MTT-containing media was aspirated gently and replaced with 100 µl of DMSO. 
Plates were read on microtiter plate reader at 595 nm/492 nm, reference 690 nm. 
EC50 was generated from the dose-response curve for each sample using GRAPH 
PAD PRISM software.    
For HepG2 cells, media from cell culture flask was decanted into a 30 cm2 universal 
bottle; remaining cells were washed with 5 ml sterile Phosphate buffered saline 
(PBS) x1 concentration, cell suspension was left for 2 minutes with the flask being 
agitated gently at intervals during incubation. PBS, from cell suspension, was 
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discarded into a waste beaker. 2 ml Trypsin/EDTA solution, at x2 concentration, 
was added to the flask containing cells. Cells were incubated for 3–5 minutes at 37 
oC, 5 % CO2. Cell detachment was observed and recorded. Following cell layer 
detachment, 8-10 ml DMEM cell growth medium was added. Cell suspension was 
pipetted up and down, approximately 10 times, to dislodge cell clumps. Cells were 
centrifuged at 2,000–2,500 rpm for 5 minutes to remove dead cells, creating a 
visible pellet.     
For HL60 cells, the cell suspension with media from cell culture flask was decanted 
into a 30 cm2 universal bottle. Cells were centrifuged at 2,000-2,500 rpm for 5 
minutes to remove dead cells, creating a visible pellet.     
Supernatant was discarded into a waste beaker; the remaining visible pellet was 
resuspended in 10 ml fresh DMEM or RPMI cell growth medium. Approximately 10 
µl of cell suspension was transferred to the haemocytometer to determine the 
approximate total cell count with Trypan blue (1:1 dilution). Live/viable cells were 
characterised as “white” in colour, dead/non-viable cells were distinguished as 
blue/dark blue in colour due to cell permeability resulting in the absorption of the 
Trypan blue dye. 
Viability (%) was determined as the mean live cells/mean total cells or cells/cm3 x 
100 = Mean viable cell number per corner x 104. Calculation was carried out to 
produce 5x103 cells/ml per well of a 96-well plate. 
HepG2 cancer cells were plated 5x103 cells/well by adding 100 µl of the 5x103 
cells/ml cell suspension to each well of the 96-well tissue culture plate. Plate was 
incubated at 37oC, 5% CO2 for 48 hours to allow attachment and 40%-60 % 
confluency. DMEM Media was aspirated off and replaced with fresh media (100 µl) 
containing either Sunitinib at 0.1 µM, 0.3 µM, 1 µM, 6 µM, 10 µM, 30 µM, 60 µM and 
100 µM concentration or Metformin at 0.1 µM, 0.5 µM, 1 µM, 5 µM, 6 µM, 10 µM, 
30 µM, 50 µM, 60 µM, 100 µM, 300 µM, 500 µM, 600 µM and 1000 µM concentration 
or NBTI at 0.1 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 25 µM, 50 µM and 100 µM 
concentration. 2 rows were used as normoxic controls.   
HL60 cancer cells were plated 5x103 cells/well by adding 100 µl of the 5x103 cells/ml 
cell suspension to each well of the 96-well tissue culture plate. Cells were 
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immediately incubated with either Sunitinib at 0.1 µM, 0.3 µM, 1 µM, 6 µM, 10 µM, 
30 µM, 60 µM and 100 µM concentration or Metformin at 0.1 µM, 0.5 µM, 1 µM, 5 
µM, 6 µM, 10 µM, 30 µM, 60 µM, 100 µM, 300 µM, 600 µM and 1000 µM 
concentration, or NBTI at 0.1 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 25 µM, 50 µM and 
100 µM concentration. 2 rows were used as normoxic controls. Concentrations 0.1 
µM, 0.5 µM, 1 µM and 5 µM Metformin not presented in Section 5.1.-5.5. 
Plates were incubated at 37oC, 5 % CO2 for 24 hours with drug treatment. Following 
incubation with compounds, media was aspirated off and replaced with fresh media 
and 50 µl MTT media (concentration 5 mg/ml in PBS) for a total of 100 µl in each 
well. The plate was incubated for 6 hours minimum at 37oC, 5 % CO2. MTT-
containing media was removed gently, and samples were solubilised in 100 µl of 
DMSO. Plates containing purple formazan dye, converted from MTT by visible cells, 
were read and quantified on microtiter plate reader at 595 nm/492 nm, reference 
690 nm. Treatment groups were standardised to vehicle control for each plate. EC50 
was generated from the dose-response curve for each sample using PRISM 
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2.6.1. Cardiac myocyte isolation.  
SD rat (2-3 month old male, 345–375 g b/w, Charles River research laboratories, 
Margate, UK) left ventricular cardiac myocytes were isolated by conventional 
enzymatic dissociation (Maddock et al. 2012). Animals were sacrificed by central 
dislocation, following appropriate supervision and following Coventry University 
standards. 
Hearts were immediately isolated and mounted onto a modified langendorff 
apparatus. Hearts were perfused with modified KH bicarbonate buffer for 5 minutes 
followed by 8 minutes of perfusion with collagenase buffer. Modified KH buffer was 
prepared in 1 litre Millipore/RO water containing (mM) NaCl 116, KCl 5.4, 
MgSO47H2O 0.4, Glucose 10, Taurine 20, Pyruvate 5, NaHCO3, KH2PO4. Modified 
KH bicarbonate buffer was oxygenated with 95 % O2 and 5 % CO2 and maintained 
at 37 oC (pH 7.4). Collagenase buffer was prepared at pH 7.4 in 65 ml of modified 
KH buffer containing 0.03 g of 1 mg/ml Collagenase and 2.2 μl of 1 M CaCl2. 
During perfusion with collagenase buffer, effluent was collected and reused. After 
perfusion with collagenase, the heart was removed, and the atrium was cut away. 
Ventricles were teased apart and incubated with collagenase buffer in the sterile 
falcon tube (1) before being suspended. Solution from tube (1) was transferred to a 
sterile falcon tube (2) and centrifuged at 400 rpm for 2 minutes. Fresh collagenase 
was added to tube (1) (containing the existing heart tissue) and suspended. The 
tissue suspension containing digestion buffer, from tube (1), was aspired and was 
passed through a nylon mesh into a sterile falcon tube before being centrifuged at 
400 rpm for 2 minutes. The supernatant from each tube (1) and (2) was removed 
using a sterile pipette. The remaining pellet was redistributed in 25 ml restoration 
buffer. Restoration buffer was prepared in 200 ml of modified KH buffer at pH 7.4, 
containing 2 g of 1 % Bovine Serum Albumin, 2 ml of 1 % pen-strep, 0.131 g creatine 
and 100 μl CaCl2 of 100 mM CaCl2 (Hussain et al. 2014). Calcium concentration 
was gradually brought back to 1.25 mM before myocyte viability was assessed 
under light microscopy. Solution was discarded if cardiac myocyte viability was 
judged to be below 70 %.  
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2.6.2. Cardiac myocyte isolation-Trypan blue staining.  
Following successful cardiac myocyte isolation, Section 2.6.1., cardiac myocytes 
were seeded into a 6 well plate. Sunitinib 1 µM ± Metformin 50 µM ± NBTI 1 µM 
were added to each appropriate well in with vehicle control. Cardiac myocyte cell 
suspension was added to each appropriate well making each well final volume 1 ml. 
Cells were incubated for 4 hours in the normoxic condition chamber (37 oC) before 
undergoing trypan blue (0.4 % w/v in 1x PBS filtered, 1:1 dilution, 2x concentration) 
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2.7. Statistical Analysis. 
The data were expressed as mean ± SEM. LVDP, HR and CF were assessed for 
the statistical difference (p<0.05) using one-way analysis of variance (ANOVA) 
with LSD post hoc tests for each specific time point. The use of the two-way 
repeated measures (multi-parametric) ANOVA with Tukey HSD post hoc tests was 
used to assess the statistical significance (p<0.05) between time and time against 
treatment group for HR, LVDP and CF. The infarct size data was tested for group 
significant differences (p<0.05) using one-way ANOVA with LSD post hoc tests. p-
AMPKα expression was quantified against AMPKα and GAPDH expression and 
assessed for statistical difference (p<0.05) using one-way ANOVA with LSD post 
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Chapter Three: Metformin Attenuates Sunitinib-Induced Cardiotoxicity in 
Sprague-Dawley Rat Hearts using the Langendorff System. 
 
Data and contents in this chapter were published / presented as following: 
Conferences 
• British Toxicology Society Annual Conference (2016), Manchester, 
England. 
• Safety Pharmacology Society Annual Conference (2016), Vancouver, 
Canada. 
Abstract and poster presentation 
• Early Studies Assessing the Cardioprotective and Anticancer Properties of 
Metformin during Sunitinib-Induced Cytotoxicity, Safety Pharmacology 
Society Annual Conference 2016, Vancouver, Canada. 
• Early Studies Assessing the Cardioprotective Properties of Metformin 
during Sunitinib-Induced Cardiotoxicity, British Toxicology Society Annual 
Conference 2016, Manchester, England. 
Oral presentation  
• Early Studies Assessing the Cardioprotective Properties of Metformin 
during Sunitinib-Induced Cardiotoxicity, British Toxicology Society Annual 
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3.1. Introduction 
As discussed in Chapter 1, drug-induced cardiotoxicity, involving anticancer agents, 
has been defined as toxicity of the heart and vascular system through the adverse 
side-effects (Albini et al. 2010). Drug-induced cardiotoxicity can be attributed to one 
or more of the following: cardiomyopathy as a reduction in LVEF, symptoms 
associated with HF, signs associated with HF including S3 gallop, tachycardia or 
both, and reduction in LVEF from baseline in the range of less than or equal to 5 % 
to less than 55 % with symptoms of HF (Albini et al. 2010). This definition was further 
updated to include subclinical cardiovascular damage associated in response to 
chemotherapy agents (Albini et al. 2010). An example of this is involves tyrosine-
kinase inhibitors such as Imatinib mesylate (Gleevec) used for the treatment of 
chronic myeloid leukaemia; subclinical cardiovascular damage was demonstrated 
in patients developing congestive HF and LV dysfunction, with similar effects 
demonstrated in mice following Imatinib treatment (Kerkela et al. 2007). Moreover, 
drug-induced toxicity may arise years after the end drug usage (Ewer and Ewer 
2010), Maharsy et al. (2014) demonstrated the potential for Imatinib to cause a 
deleterious effect in cardiac myocytes in a time, dose and age dependent manner, 
highlighting the importance in demonstrating the effects of drug-induced toxicity in 
a time-dependent and long–term manner.  
The multi-TKI Sunitinib is associated with incidences of a decline in LVEF however 
the effect was reversible upon drug discontinuation (Motzer et al. 2007). The exact 
mechanism of Sunitinib-induced cardiotoxicity is not fully established. Sunitinib 
binds to VEGFR and PDGFR with both receptors being associated with a key role 
in renal-cell carcinoma pathogenesis (Abrams et al. 2003, Mendel et al. 2003, 
O'Farrell et al. 2003). ATP is an area of particular interest in regard to drug-induced 
cardiotoxicity. Multi-TKIs have been reported to bind to and occupy the kinase ATP-
binding sites as highlighted in the reviews by Krause and Van Etten (2005) and 
Roskoski (2016), a mechanism that is successful in inhibiting abnormally high 
kinase activity and abnormal cell proliferation in many forms of cancer. However, 
off-target effects as suggested by Alameddine et al. (2015) result in binding to 
PDGFR sites of cardiac myocytes within the heart, contributing to the limiting of ATP 
availability to cardiac myocytes and the potential initiation of apoptosis.  
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Within cardiac myocytes a signalling pathway of interest involves the role of ATP 
and the resulting activation of the AMPK pathway. AMPK is highly expressed within 
the myocardium (Stapleton et al. 1996), the activation of AMPK signalling is 
associated with protecting against cytotoxic effects in non-cancerous cells such as 
cardiac myocytes, inhibiting the release of EEF-2 (Terai et al. 2005). It was 
mentioned in the study by Kerkela et al. (2009) that in the presence of Sunitinib, 
ATP is unable to bind to AMPK, therefore AMPK is unable to transfer phosphate 
from ATP to the required substrates and therefore the energy conservation 
mechanism is not recruited, and energy depletion is exacerbated. Studies involving 
Sunitinib-direct inaction of AMPK signalling is limited, the review by Force et al. 
(2007) suggested the hypothetical inhibition of AMPK signalling. The study by 
Kerkela et al. (2009) demonstrated the potential for Sunitinib to inhibit AMPK 
signalling, whilst over-expression of a constitutively active mutant AMPK was able 
to ameliorate Sunitinib-induced cardiac myocyte cytotoxicity. If this is correct, the 
inactivation of AMPK could result in the release EEF-2, mTOR and ACC from 
inhibition and potentially contribute towards exacerbating ATP depletion as 
mentioned (McLeod and Proud 2002, Moore and Brophy 1994, Terai et al. 2005, 
Dennis et al. 2001). Moreover, the study by Laderoute et al. (2010) demonstrated 
that Sunitinib competitively binds to AMPK, as potent as the AMPK-inhibitor 
Compound C. As reported, the resulting depletion of ATP would result in the 
activation of apoptosis and necrosis and cardiac myocyte loss, contractile and 
ventricular dysfunction (Fliss and Gattinger 1996, Webster et al. 1999, Doenst et al. 
2013, Gupta et al. 2009, Weiss et al. 2005, Ingwall 1993, Bolling et al. 1991). This 
highlights the complexity and importance of investigating the role of AMPK 
signalling in both drug-induced cardiotoxicity and cancer cell death.  
In contrast, Metformin hydrochloride, used to treat type-2 diabetes and insulin 
resistance, is associated with cardioprotective properties within ischaemic settings 
(Paiva et al. 2009, Paiva et al. 2010, Bhamra et al. 2008, and Barreto-Torres et al. 
2012). The exact mechanism of Metformin-induced cardioprotection is still 
unknown, however Metformin is postulated to be involved in a number of anti-
apoptotic activating pathways. Several suggested routes of cardioprotection by 
Metformin involves the inhibition of mTOR (Melnik and Schmitz 2014), the 
phosphorylation of the Akt signalling pathway (Bhamra et al. 2008), PPAR (Barreto-
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Torres et al. 2012). Metformin’s anti-hyperglycaemic ability is dependent on the 
activation of AMPK (Rena et al. 2013); the phosphorylation of AMPK was shown to 
be mediated by the increase in the cytosolic AMP concentration (Zhang et al. 2007). 
The stimulation of the adenosine receptor was shown to be an important mechanism 
in infarct size-limiting effects of ischaemic pre- and post-conditioning (Yellon and 
Downey 2003), whilst adenosine receptor stimulation was shown to activate Akt 
(Yang et al. 2004) and inhibit the opening of mPTP (Hausenloy et al. 2002). In 
particular the AMPK pathway is vital in response of cells to hypoxic conditions and 
ischaemia in the heart (Hardie and Hawley 2001, Frederich et al. 2005), therefore 
cardiac myocyte survival may be affected in events of hypoxia and ischaemia. 
Activation of AMPK protects against hypoxia-induced cardiac myocyte death via 
intracellular ATP conservation (Terai et al. 2005). It must be critically noted that the 
inhibition of AMPK signalling is a crucial pathway for tumour cell death, therefore 
re-designing Sunitinib to avoid AMPK inhibition is unavoidable as described by 
Kerkela et al. (2009) and a compromise must be drawn when applying extracellular 
stimuli leading to AMPK activation or when attempting to initiate a form of potential 
cardioprotection via AMPK activation to counter Sunitinib-induced heart damage. 
However, as discussed Metformin has anti-cancer properties via the activation of 
AMPK, therefore it is crucial to investigate the role of AMPK in both cardioprotection 
and cancer treatment. This further reinforces the importance of investigating the 
direct role of AMPK involvement, with the possibility of designing adjunctive therapy 
in order to maintain the activation of AMPK. Metformin has currently been trialled in 
studies involving patients undergoing Sunitinib treatment (Keizman et al. 2016, 
Hamieh et al. 2017), demonstrating a potential to improve overall survival in diabetic 
patients with metastatic renal cell carcinoma whilst also demonstrating an 
improvement in cardiovascular prognosis and reducing incidences of MI within 
patients (UKPDS 1998). 
Metformin demonstrated a cardioprotective effect in ischaemia-reperfusion in rats 
via the activation of PPAR, in particular PPARα (Barreto-Torres et al. 2012, Oidor-
Chan et al. 2016, Wayman et al. 2002). PPARα is highly expressed in the heart and 
plays a role in maintaining cardiac metabolic homeostasis (Yue et al. 2003). 
Moreover, it was highlighted by Oidor-Chan et al. (2016) that PPARα ligands were 
shown to reduce myocardial ischaemia-reperfusion injury in diabetic and non-
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diabetic animal models, involving the anti-inflammatory mechanism of PI3K, the Akt 
and nitric oxide pathways (Dumitrescu et al. 2007, Yue et al. 2003, Wayman et al. 
2002). From this, Metformin’s ability to activate PPARα could result in the activation 
of fatty acid oxidation enzyme activity and fat metabolism, previously reported to be 
decreased following ischaemia-reperfusion (Yue et al. 2003). The activation of fatty 
acid oxidation enzyme by PPARα is suggested to improve the ability of the heart to 
use fatty acid as an energy source and maintain adequate energy production in the 
heart (Yue et al. 2003). Furthermore, activation of PPARα was shown to potentially 
attenuate the accumulation of neutrophils and proinflammatory cytokines, 
associated with the reperfusion cardiac injury (Yue et al. 2003). 
Using this knowledge, we aim to investigate the potential for Metformin to 
demonstrate cardioprotective properties during Sunitinib administration in order to 
potentially attenuate Sunitinib-induced cardiotoxicity in Langendorff heart 
experiments. The haemodynamic measurements of LVDP, HR and CF will be 
measured to investigate heart function during adjunctive administration. Moreover, 
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3.2. Methodology  
3.2.1. Chemicals  
Metformin hydrochloride (500 mg, MW 165.62 mg/mM) was purchased from Sigma 
Aldrich. Metformin was dissolved in ultra-pure RO water; the stock solution was 
stored at -20 oC. Sunitinib Malate (25 mg, MW 532.56 mg/mM) was purchased from 
Sigma Aldrich. Sunitinib was dissolved DMSO; the stock solution was stored at -20 
oC and care was taken to avoid exposure to light and UV radiation during use and 
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3.2.2. Isolated perfused heart preparation and Langendorff protocol. 
SD rats (2-3 month old male, 345–375 g b/w, Charles River research laboratories, 
Margate, UK) were sacrificed and hearts were immediately mounted onto the 
langendorff system and retrogradely perfused with KH buffer as described in 
Section 2.3.1. Functional parameters of LVDP, HR and CF were measured and 
recorded at regular intervals 5 minutes for 55 minutes, followed by intervals of 15 
minutes for 120 minutes. At the end of the experiment hearts were weighed and 
frozen at -20 oC. Frozen hearts were sliced into 2 mm thick transverse sections 
before being incubated in TTC solution (1 % in phosphate buffer) at 37 oC for 10–
12 minutes and fixed in 10 % formalin for a minimum of 4 hours. Infarct area was 
traced onto acetate sheets and infarct percentage (%) was calculated. 
Computerised ImagetoolTM software was used to analyse the percentage of infarct 
tissue. Infarct size was normalised to the total area of each heart slice. 
All hearts were allowed to stabilise for 20 minutes prior to being subjected to drug 
treatment for 155 minutes (Figure 11, Section 2.3.1.-2.3.2.). Hearts were randomly 
assigned to the following groups; (i) vehicle control hearts perfused with KH buffer 
and DMSO final concentration <0.1 %; (ii) hearts perfused with KH buffer and 
Metformin hydrochloride (50 µM) for 155 minutes; (iii) hearts perfused with KH buffer 
and Sunitinib malate (1 µM) for 155 minutes; (iv) hearts perfused with KH buffer and 
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3.2.3. Statistical Analysis. 
The data were expressed as mean ± SEM. Haemodynamics LVDP, HR and CF 
were assessed for the statistical difference (p<0.05) using ANOVA with LSD post 
hoc tests for each specific time point. The use of the two-way repeated measures 
ANOVA was used to assess the statistical significance (p<0.05) between time and 
time against treatment group for HR, LVDP and CF. The infarct size percentage 
data was tested for group significant differences (p<0.05) using one-way ANOVA 
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3.3.1. Results.  
Results from 24 successful experiments were included for the Langendorff study to 
assess the effect on HR (Figure 12a), LVDP (Figure 12b) and CF (Figure 12c) 
during Metformin co-administration with Sunitinib in SD rat hearts. Experiments 
were carried out for vehicle control, Metformin (50 µM), Sunitinib (1 µM) and the 
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3.3.2. The effects of Sunitinib in the absence and presence of Metformin on 
haemodynamic parameters in SD rat hearts.    










Figure 12a: The effects of drug treatment on HR as a percentage of mean 
stabilisation value: vehicle control (blue), Metformin (50 µM) (green), Sunitinib (1 
µM) (red) and the combination of Metformin (50 µM) and Sunitinib (1 µM) (co-
treatment, purple). Data is presented as mean ± SEM of 6 experiments (n=6).   
From Figure 12a, Sunitinib treatment showed no significant changes to HR during 
the treatment period when compared to the vehicle control. Moreover, co-treatment 
showed no significant change to HR when compared to the Sunitinib treatment.  
Single factor ANOVA, and post-hoc LSD during one-way ANOVA, determined no 
statistical significance between the co-treatment and 1 µM Sunitinib treatment group 
at selected time points (p>0.05) and no statistical significance between the 1 µM 
Sunitinib treatment group and the vehicle control group at selected time points 
(p>0.05). Single factor ANOVA and post-hoc LSD during one-way ANOVA 
determined no statistical significance for HR between treatment groups against 
vehicle control at selected time points (p>0.05).  
Stabillisation 
// 
Drug added  
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Two-way repeated measures ANOVA, with post-hoc Tukey HSD during repeated 
measures ANOVA, demonstrated statistical significance for time on HR (p<0.001) 
for the Wilks’ Lambda score but no statistical significance for time against treatment 
(p>0.05). As Mauchly’s Test of Sphericity® was violated (p<0.001), from this 
Greenhouse-Geisser determined statistical significance for time on HR (p<0.001) 
and time against Treatment on HR (p<0.05). However, use of Tukey HSD post-hoc 
test for multiple comparisons determined no statistical significance between all 
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Figure 12b: The effects of drug treatment on LVDP as a percentage of mean 
stabilisation value: vehicle control (blue), Metformin (50 µM) (green), Sunitinib (1 
µM) (red) and the combination of Metformin (50 µM) and Sunitinib (1 µM) (co-
treatment, purple). Data is presented as mean ± SEM of 6 experiments (n=6). Key 
statistical significance: *=p<0.05 1 µM Sunitinib vs vehicle control.  *=p<0.05 1 µM 
Sunitinib vs Co-treatment. 
From Figure 12b, Sunitinib treatment showed a significant reduction in LVDP during 
the treatment period when compared to vehicle control. Co-treatment of Sunitinib 
with Metformin was demonstrated to attenuate this decrease in the mean LVDP 
when compared to time-matched Sunitinib treatment.  
Single factor ANOVA and post-hoc LSD during one-way ANOVA determined 
statistical significance for LVDP for the 1 µM Sunitinib treatment group against the 
vehicle control group at selected time points 145, 160, 175 minutes (p<0.05. 145 
minute; 64 ± 5 % vs. 80 ± 3 %, 165 minute; 57 ± 6 % vs. 79 ± 4 %, 175 minute; 58 
± 6 % vs. 77 ± 3 %).  
Single factor ANOVA and post-hoc LSD during one-way ANOVA determined 
statistical significance for the 1 µM Sunitinib treatment group against the co-
treatment group at selected time points 145, 160, 175 minutes (p<0.05, 145 minute; 
// 
* 
* * * 
* * 
Stabillisation 
Drug added  
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64 ± 5 % vs. 80 ± 6 %, 160 minute; 57 ± 6 % vs. 75 ± 3 %, 175 minute; 58 ± 6% vs. 
74 ± 3%).   
Two-way repeated measures ANOVA, with post-hoc Tukey HSD during repeated 
measures ANOVA, determined statistical significance for time on LVDP (p<0.001) 
for the Wilks’ Lambda score but no statistical significance for time against treatment 
on LVDP (p>0.05). 
Moreover, Mauchly’s Test of Sphericity® was violated (p<0.001), from this 
Greenhouse-Geisser determined statistical significance for time on LVDP (p<0.001) 
and significance for time against treatment on LVDP (p<0.05). Moreover, use of 
Tukey HSD post-hoc test for multiple comparisons determined no statistical 
significance between the Sunitinib treatment group against the vehicle control 
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Figure 12c: The effects of drug treatment on CF as a percentage of mean 
stabilisation value: vehicle control (blue), Metformin (50 µM) (green), Sunitinib (1 
µM) (red) and the combination of Metformin (50 µM) and Sunitinib (1 µM) (co-
treatment, purple). Data is presented as mean ± SEM of 6 experiments (n=6). Key 
statistical significance: *=p<0.05 1 µM Sunitinib vs. Co-treatment. 
CF was recorded by collecting the effluent for 1 minute at regular intervals; data 
was corrected for heart weight at the end of the Langendorff experiment and is 
presented as a percentage of mean stabilisation ± SEM in Figure 12c.  
From Figure 12c, Sunitinib demonstrated no changes to CF when compared to 
vehicle control. Single factor ANOVA and post-hoc LSD during one-way ANOVA 
determined statistical significance for CF for the co-treatment group against the 1 
µM Sunitinib treatment group at the 160 and 175 minute time points (p<0.05, 160 
minutes; 65 ± 3 % vs. 83 ± 6 %, 175 minutes; 59 ± 3 % vs. 80 ± 6 %). 
Furthermore, single factor ANOVA and post-hoc LSD during one-way ANOVA 




Drug added  
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vehicle control treatment group at the 160 and 175 minute time points (p<0.05, 160 
minutes 65 ± 3 % vs. 80 ± 4 %, 175 minutes 59 ± 3 % vs. 78 ± 3 %, p<0.05). 
Two-way repeated measures ANOVA, with post-hoc Tukey HSD during repeated 
measures ANOVA, determined statistical significance for time on CF (p<0.001) for 
the Wilks’ Lambda score and statistical significance for time against treatment on 
CF (p<0.05). 
Moreover, Mauchly’s Test of Sphericity® was violated (p<0.001), from this 
Greenhouse-Geisser determined statistical significance for time on CF (p<0.001) 
and determined significance for time against treatment on CF (p<0.001). Moreover, 
use of Tukey HSD post-hoc test for multiple comparisons determined no statistical 
significance between the Sunitinib treatment group against the vehicle control 
(p>0.05) or against the co-treatment group (p>0.05). Tukey HSD post-hoc test 
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3.3.3. The effects of Sunitinib in the absence and presence of Metformin on 
infarct percentage in SD rat hearts.  
Results from 24 successful experiments were included for the Langendorff study to 
assess the effect on infarct size percentage (Figure 13) during co-treatment of 
Metformin and Sunitinib in SD rat hearts (n=6). Experiments were carried out for 
vehicle control, Metformin concentration 50 µM, Sunitinib 1 µM and the combination 
(co-treatment) of Metformin (50 μM) and Sunitinib (1 μM). 
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Figure 13: The effects of vehicle control, Metformin (50 µM), Sunitinib (1 µM) and 
the combination of Metformin (50 µM) and Sunitinib (1 µM) (Co-treatment) on infarct 
percentage (%). Data is presented as mean ± SEM of 6 experiments (n=6). Key 
statistical significance: ***=p<0.001 1 µM Sunitinib vs. vehicle control. #=p<0.05 Co-
treatment vs Sunitinib.  
Infarct size was determined as a percentage of the total area of the heart and 
presented in Figure 13.  
From Figure 13, an increase in infarct percentage was demonstrated for the 1 µM 
Sunitinib treatment group in comparison to the vehicle control group (p<0.001, 31 ± 
2 % vs. 11 ± 1 %). The co-treatment group demonstrated a significant reduction in 
infarct percentage compared to the 1 µM Sunitinib treatment group (p<0.05, 20 ± 2 
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3.4. Discussion 
We demonstrated that the multi-TKI Sunitinib (1 µM) was able to result in a 
significant decrease in LVDP at certain time points in SD rat hearts, compared to 
vehicle control using the Langendorff system (Figure 12b). It can be suggested that 
the resulting decrease in LVDP compared to vehicle control may be attributed to 
Sunitinib-induced energy impairment of cardiac function. The potential for Sunitinib 
inhibition of AMPK signalling and receptors PDGF and VEGF are said to result in 
and contribute towards energy impairment of cardiac function (Greineder et al. 
2011, Gorini et al. (2018). In particular, VEGF was shown to be expressed in the 
heart and expression of VEGF is significantly increased in the infarcted myocardium 
during the early stage of MI (Li et al. 1996). Moreover, following MI VEGFR and 
PDGF are involved in the angiogenic occurs in order to carry out cardiac repair and 
scar tissue formation, with newly formed vessels shown in the infarcted myocardium 
(Zhao et al. 2010, Liu et al. 2014). The proposed effects are known to result from 
Sunitinib’s targeting of PDGF, VEGF and AMPK in relation to Sunitinib’s TKI ability 
in cancer treatment, targeting tumour proliferation and tumour angiogenesis via the 
inhibiting of energy required for cancer cell neoangiogenesis and growth which can 
arise from mutant TKs (Kerkela et al. 2009, Krause and Van Etten 2005, Chen et 
al. 2008, Folkman 2007, Jain et al. 2005).  
The effects can also be attributed to Sunitinib’s lack of selectivity and a possible 
increased risk of off-target toxicities by inhibiting additional kinases (Kerkela et al. 
2009). Furthermore, the resulting inhibition of growth factor pathways by Sunitinib 
results in the impairment of cardiac energy homeostasis in cardiac myocytes (Chu 
et al. 2007, Chintalgattu et al. 2011). Sunitinib treatment at 1 µM was shown to result 
in energy deprivation and energy generation impairment in cardiac myocytes 
(Kerkela et al. 2009), the resulting effects of energy impairment in cardiac myocytes 
result in a decrease in heart function and therefore can contribute to a significant 
decrease in LV function as shown in Figure 12b (Jessen et al. 2010, Suematsu et 
al. 2003, Doenst et al. 2013, Ingwall 2008, Gorski et al. 2015, Harvey and Leinwand 
2011, Corrado et al. 1997). In concordance with the proposed hypothesis of energy 
deprivation following Sunitinib administration, patients with metastatic and 
gastrointestinal stromal tumours, following Imatinib–resistance, were demonstrated 
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to improve LV dysfunction and symptoms following Sunitinib interruption, however 
episodic LV ejection fraction reductions were shown in some patients following 
Sunitinib administration restarting (Chu et al. 2007). The authors indicated that the 
contractile dysfunction may have occurred due to impaired ATP generation 
secondary to mitochondrial dysfunction and not from irreversible damage (Chu et 
al. 2007).  
Results from Figure 13 demonstrated that Sunitinib at 1 µM significantly increased 
infarct percentage when compared to the vehicle control, highlighting the ability for 
Sunitinib to directly result in cardiac tissue damage using the Langendorff system, 
possibly acting via cardiac myocyte damage and activation of apoptosis. Sunitinib 
at 1 µM was selected in line with previous studies (Henderson et al. 2013) 
demonstrating the steady-state blood concentration of Sunitinib to be in the range 
of 0.1-1 µM (Goodman et al. 2007, Henderson et al., 2013). Results from Figure 13 
are supported by a study demonstrating Sunitinib at 1 µM administration resulted in 
the significant increase in pro-apoptotic caspase-9 signalling (Chu et al. 2007). 
Moreover, mice fed with Sunitinib to produce blood concentrations comparable to 
patients, demonstrated abnormalities in cardiac myocytes including mitochondrial 
swelling (Chu et al. 2007). Furthermore, in cultured cardiac myocytes Sunitinib 
demonstrated the release of pro-apoptotic cytochrome-c into the cytosol (Chu et al. 
2007), the release of cytochrome-c is known to activate the mitochondrial pathway 
for cellular death and apoptosis (Baines and Molkentin 2005). The same study by 
Chu et al. (2007) demonstrated Sunitinib to result in the activation of caspase-9 
involved in the mitochondrial apoptotic pathway. Furthermore, in mice administered 
with Sunitinib to achieve a blood-plasma concentration similar to human patients 
resulted in the release of pro-apoptotic markers of chromatin condensation and 
distortion of mitochondrial cristae (Chu et al. 2007). Moreover, a recent study 
highlighted phenotypic changes indicative of cellular death in cardiac fibroblasts, 
including intracellular vacuoles, incubated with Sunitinib 1 µM (McBride et al. 2018). 
Using this, it can be suggested that Sunitinib is associated with the activation in 
cellular apoptosis of cardiac myocytes, resulting in the possible heart tissue damage 
and an increase in infarct percentage of the heart (Figure 13) during administration 
throughout the Langendorff study, however to confirm this, clinical biomarkers of 
cardiac myocyte damage and apoptosis would need to be investigated. 
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Studies by Sandhu et al. 2017 and Cooper et al. 2018 involving Sunitinib at 1 µM 
were able to demonstrate an increase in infarct percentage similar to our results 
obtained in Figure 13. Similar to our results obtained in Figure 12c, Sunitinib at 1 
µM concentration did not demonstrate an alteration in CF when compared to vehicle 
control group (Sandhu et al. 2017). Sunitinib at 1 µM was demonstrated to result in 
an increase in infarct percentage similar to that obtained in Figure 13, when 
administered using the Langendorff technique (Sandhu et al. 2017, Cooper et al. 
2018). Moreover, Sunitinib at 1 µM was demonstrated to result in a significant 
decrease in LVDP at certain time points during Langendorff perfusion using SD rat 
hearts (Sandhu et al. 2017). However in contrast to our results obtained in Figure 
12a, Sunitinib was demonstrated to result in a significant decrease in HR (Sandhu 
et al. 2017), whilst our data demonstrated that Sunitinib did not result in an alteration 
of HR, the endpoint value of HR at 125 minutes obtained by Sandhu et al. (2017) is 
similar to the end point value of HR at 175 minutes shown in Figure 12a (83 ± 5 % 
vs. 80 ± 6 %). This highlights that, although the end-point value for Sunitinib from 
Figure 12a is similar to that from Sandhu et al. (2017), Sunitinib did result in a similar 
effect in our study but showed a greater degree of toxicity for the study by Sandhu 
et al. (2017) as shown by the significant decrease in HR compared to vehicle 
control. To explain this, although we tried to keep experimental conditions as similar 
as possible, the use of the Langendorff system requires attention to detail and two 
different Langendorff systems may result in a different set of results depending on 
the duration of time taken to hang the heart following cerebral dissection and the 
system itself. Moreover, the study by Sandhu et al. (2017), demonstrated an end-
point value of (insert) for the vehicle control group, whereas the end-point value of 
HR in Figure 12a was 88 ± 3 %  
Similar to the proposed mechanism of toxicity, the authors concluded that results 
obtained were in accordance to previous studies demonstrating Sunitinib’s ability to 
induce cardiotoxicity via apoptosis and reports of LV dysfunction and HR in patients 
(Chu et al. 2007, Henderson et al. 2013). The study by Sandhu et al. (2017) further 
demonstrated that Sunitinib resulted in the increase of PKCα in heart tissue. PKCα 
is demonstrated to be activated during cellular apoptosis (Shimizu et al. 1998), this 
can be used to suggest that Sunitinib demonstrated an activation of apoptosis and 
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was able to result in an increase in infarction percentage of the heart tissue as 
shown in Figure 13.  
Interestingly it was demonstrated from Figure 12c, co-administration of Metformin 
(50 µM) with Sunitinib (1 µM) resulted in a significant decrease in CF when 
compared to vehicle control at time points 160 and 175 minutes (p<0.05). This could 
suggest that the co-treatment of Metformin and Sunitinib resulted in a potential 
vasoconstrictive effect when administrated together. A possible explanation of this 
could be due to Metformin-associated and prolonged AMPK activation-associated 
with lactic acidosis (Vecchio and Protti 2011, Cerda-Kohler et al. 2018, Corremans 
et al. 2018). However, Metformin-induced lactic acidosis remains unclear among 
existing literature (Baradari et al. 2011, Misbin 2004). It is worth noting that the 
significant difference was shown only at the 160 and 175 minute time points and not 
during previous time points, highlighting that the effects are time-dependent and 
could be prevented with intervention or drug-discontinuation (Cezur et al. 2009, 
Yavari et al. 2016, Silvestre et al. 2007, Ashall and Dawes 2008). 
As we discussed in Section 3.1., Sunitinib can potentially target VEGFRs on the 
surface of cardiac myocytes, thereby resulting in a pro-apoptotic response on non-
cancerous cells. Results obtained in Figure 13 can be suggested to stem from the 
proposed activity, as the binding to and resulting apoptosis of cardiac myocytes 
would result in myocardial ischaemia, in particular the inhibition of the VEGF 
receptor by Sunitinib was shown to be associated with causing hypertension and 
myocardial ischaemia (Orphanos et al. 2009). Neo-angiogenesis is critical for 
metastasis and the formation of vessels for tumour growth but also for growth of 
cardiac myocytes and the angiogenic response to MI, VEGF is considered to play 
a vital role in the process, moreover VEGF inhibitors such as Sunitinib has become 
an established treatment for tumour types (Lankhorst et al. 2015, Ellis and Hicklin 
et al. 2008, Kamba and McDonald 2007). However, as the heart is highly dependent 
on energy, it is more susceptible to damage that can result from an altered blood 
supply, the cardiovascular system is said to exhibit a higher sensitivity to Sunitinib 
damage when compared to other organs (Lankhorst et al. 2015). To support the 
proposed binding to VEGFRs, toxicity via Sunitinib administration was indicated to 
occur in the kidneys with glomerular and thrombotic microangiopathy was said to 
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be frequently observed due to disruption of the VEGF signalling pathway (Eremina 
et al. 2008, Vigneau et al. 2014, Maynard et al. 2003). The resulting action by 
Sunitinib would interfere with cellular signal transduction, cell cycle regulation 
metabolism and transcription, all contributing to an increased risk of cardiac events 
in cancer patients, with coronary microvessels implicated as the primary target of 
toxicity (Chintalgattu et al. 2013). In accordance with this, the study by Lankhorst et 
al. (2015) demonstrated that the severity of hypertension and renal injury are dose-
dependent, it was highlighted that using a low dose of Sunitinib, equivalent to 50 
mg/kg in patients, the concentration of the active metabolite N-desethyl in Sunitinib 
was higher than that observed in patients, indicating an increased metabolism of 
the compound in rats (Yu et al. 2015, Speed et al. 2012). Glomerular capillaries 
were also shown to be obliterated when using a high dose of Sunitinib; glomerular 
endotheliosis is considered a hallmark in angiogenesis inhibition-induced renal 
injury (Eremina et al. 2008).   
As discussed, Metformin is associated with cardioprotective properties during 
ischaemia-reperfusion damage (Paiva et al. 2009, Paiva et al. 2010, Bhamra et al. 
2008). Metformin has been further associated with anti-neoplastic actions that has 
led to studies investigating the molecular actions (Evans et al. 2005, Giovannucci 
et al. 2010, Ben Sahra et al. 2008, Zakikhani et al. 2006, Andrzejewski et al. 2014). 
For this reason, we favoured the use of Metformin over other protective agents as 
there is potential for Metformin to be used as an adjunctive form of cancer treatment 
with Sunitinib. We investigated to determine if Metformin can exhibit a potential 
similar cardioprotective effect during Sunitinib co-administration within a normoxic 
study Langendorff perfused rat hearts (Figures 12a–12c, 13). We demonstrated that 
Metformin when co-administered at 50 µM was able to significantly reduce infarct 
percentage in SD rat hearts when compared to Sunitinib treatment alone in the 
Langendorff experiment (Figure 13). It was also demonstrated that the 
administration of Metformin in co-treatment with Sunitinib was able to attenuate 
Sunitinib’s induced significant decrease in LVDP as shown in Figure 12b.  
As proposed previously, the hypothesis that Sunitinib inactivates or down regulates 
certain signalling pathways such as AMPK and results in energy deprivation, it can 
be suggested from results in Figures 12b and 13 that Metformin co-administration 
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was able to prevent this. As discussed, the potential for Sunitinib to induce energy 
deprivation and ATP depletion resulted in the significant decrease in LVDP in Figure 
12b, the attenuation in LVDP decrease following Metformin co-administration may 
have resulted from Metformin’s proposed ability to activate AMPK signalling during 
events of ischaemic stress in order to counter the reduction in ATP, to restore 
energy levels (Paiva et al. 2009, Paiva et al. 2010, Bhamra et al. 2008).   
In support of our data obtained in Figures 12b and 13, similarities can be drawn to 
existing data. Paiva et al. (2010) demonstrated that Metformin (50 µM) 
administration was able to significantly reduce ischaemia-reperfusion-induced 
infarct percentage, suggesting that Metformin has cardioprotective properties. The 
concentration of 50 µM for Metformin was said to produce a higher peak plasma 
concentration within humans (Bhamra et al. 2008), however our data in Figure 13 
demonstrated that this concentration did not result in a significant increase in drug-
induced infarct percentage when compared to vehicle control. 
Moreover, Wang et al. (2017) demonstrated that Metformin (100 µM) was able to 
reduce infarct size percentage when compared to the ischaemia-reperfusion control 
via an AMPK-activation manner whilst Xu et al. (2014) demonstrated that Metformin 
protected against systolic overload-induced HR. Wang et al. (2017) further 
demonstrated that Metformin (100 µM) administration 15 minutes prior to ischaemia 
was able to attenuate the ischaemia-induced LVDP decrease improving LV function 
when compared to normoxic control. Using this knowledge, it can be suggested that 
results obtained in Figures 12b and 13 were as a result of Metformin attenuating 
Sunitinib-induced cardiotoxicity via AMPK activation, reversing the significant 
decrease in LVDP and the increase in infarct percentage. Moreover, it can be 
suggested that in order for Metformin to initiate a potential cardioprotective 
response via AMPK activation, Metformin administration will need to be 
continuously perfused during the period of cardiac damage, either via ischaemia or 
drug-induced, as demonstrated by the study by Hasinoff et al. (2008) of which 
cultured cardiac myocytes were incubated with Metformin prior to removal of 
Metformin and incubation with Sunitinib. The study showed that Metformin 
treatment, and removal, prior to Sunitinib administration did not demonstrate 
cardioprotective properties.  
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Hasinoff et al. (2008) demonstrated that Sunitinib was able to result in a dose-
dependent lactate-dehydrogenase (LDH) release in cardiac myocytes, at 
concentrations similar to peak plasma concentrations in a therapeutic single-day 
dose (Deeks and Keating 2006, Faivre et al. 2006). Sunitinib further inhibited the 
enzyme activity of AMPK and RSK1 at IC50 concentrations 0.32 µM and 0.36 µM, 
both concentrations were said to be within the therapeutic plasma concentration 
range and therefore may potentially contribute to cardiotoxicity induced by Sunitinib 
(Hasinoff et al. 2008, Deeks and Keating 2006, Faivre et al. 2006, Chu et al. 2007, 
Telli et al. 2008). However, the authors concluded that because the kinase inhibition 
assays used, measured 50 µM ATP which was said to be much less than the mM 
intracellular ATP concentration, the IC50 values would increase due to competition 
with ATP (Hasinoff et al. 2008).  
As AMPK is a known sensor of cellular energy status and activation controls ATP, 
it is worth mentioning that cardiac tissue, unlike other tissue, contains a reserve of 
ATP, therefore impaired ATP production could be a factor in Sunitinib-induced 
cardiotoxicity (Hasinoff et al. 2008, Hardie 2004). Hasinoff et al. (2008) attempted 
to demonstrate if inhibition of AMPK by Sunitinib could result in cardiotoxicity by 
measuring the effect on intracellular ATP levels in cardiac myocytes, however 
following the 4-hour treatment with Sunitinib the authors concluded that they were 
unable to demonstrate if Sunitinib did result in myocyte death by reducing ATP 
levels (Hasinoff et al. 2008). The dosages of 5 and 10 µM were able to decrease 
pACCα levels in cardiac myocytes, whilst doses of 0.5, 1, 5, and 10 µM 
demonstrated significance against non-treated vehicle control when investigating 
caspase–3/7 activity (Hasinoff et al. 2008). A Sunitinib concentration of 0.1 µM is 
said to be approximately equal to that of a therapeutic plasma concentration 
(Hasinoff et al. 2008, Deeks and Keating 2006, Faivre et al. 2006), as concluded by 
the authors, the previously mentioned concentrations were agreed to be much 
greater than the therapeutic Sunitinib plasma levels, with 5 µM said to be 
approximately 25-fold greater, it is difficult to conclude if therapeutic doses could 
significantly inhibit AMPK to determine Sunitinib-induced cardiotoxicity (Hasinoff et 
al. 2008, Deeks and Keating 2006, Faivre et al. 2006). However, it should be 
mentioned that the study by Hasinoff et al. (2008) only subjected cardiac myocytes 
to 2 hours of treatment with Sunitinib, whereas patients undergoing Sunitinib 
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treatment would be administered daily for an extended period of time, therefore 
continuous inhibition of AMPK by Sunitinib could occur as a result of long-term 
treatment and could potentially have more subtle effects in inducing cardiotoxicity 
(Hasinoff et al. 2008). Moreover, the cellular levels of Sunitinib in daily administered 
doses are unclear and could be potentially greater than the stated doses (Hasinoff 
et al. 2008).  
In contrast to the measured caspase-3 levels, levels of the pro-apoptotic Bax were 
shown to be not significant following Sunitinib treatment, suggesting that the 
involvement of this pathway was not present in the induction of apoptosis, whilst 
Sunitinib was found to have no significant effect on oxidative stress on cardiac 
myocytes (Hasinoff et al. 2008). Furthermore, the pre-treatment of cardiac myocytes 
with AMPK activators Metformin or Phenformin failed to protect against Sunitinib-
induced damage (Hasinoff et al. 2008, Bertrand et al. 2006). This adds to the 
continuing debate amongst existing literature in regards to the exact route of 
Sunitinib-induced cardiotoxicity.  
It has been mentioned that during an event of ischaemia, activation of AMPK within 
the myocardium is considered to enhance glucose uptake, utilise anaerobic glucose 
and produce sufficient ATP required for cardiac myocyte function (Paiva et al. 2010, 
Dyck and Lopashuk 2006). The resulting action prevents cardiac myocyte death 
and allow the heart to readjust from anaerobic glucose metabolism to aerobic 
oxidative metabolism of glucose (Paiva et al. 2010, Dyck and Lopashuk 2006).  
Using this knowledge, it can be suggested that Metformin’s potential mode of 
cardioprotection is associated with the activation of the AMPK signalling pathway 
(Gundewar et al. 2009). It has been said that upon activation, AMPK results in the 
inhibition of protein translation, protein synthesis and fatty acid synthesis, 
conserving ATP consumption, whilst activating AMP generating pathways via 
increasing fatty acid oxidation and glycolysis to counter the loss of ATP (Towler and 
Hardie 2007). Studies have shown AMPK to protect cardiac myocytes from anoxic 
damage, associated with anti-apoptotic activity (Igata et al. 2005, Capano et al. 
2003, Shibata et al. 2005, Russell et al. 2004, Arad et al. 2007). The proposed 
activation of AMPK signalling by Metformin following Sunitinib co-administration can 
be reinforced with a study demonstrating AMPK signalling to be restored following 
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the gene transferring of active AMPK in a study involving Sunitinib-administration in 
cardiac myocytes (Kerkela et al. 2009). Moreover, Metformin was able to attenuate 
pressure-overload-induced cardiac hypertrophy within non-diabetic mice via the 
activation of AMPK, preventing cardiac myocyte loss (Fu et al. 2011). Metformin 
was further demonstrated to inhibit cardiac myocyte apoptosis and improving 
cardiac function via AMPK activation (Gundewar et al. 2009, Sasaki et al. 2009). 
Using this knowledge, it can be suggested that Metformin was able to attenuate 
Sunitinib-induced LVDP decrease and infarct percentage increase via AMPK 
activation to counter the loss of ATP, energy re-balance and salvage cardiac 
myocyte cell death following Sunitinib-administration.   
Moreover, aside from AMPK several other non-direct mechanisms and signalling 
pathways may be contributing towards the associated effects shown in our results. 
The potential cardioprotective effects by Metformin in Figures 12a-13 can be 
hypothesised to stem from an AMPK-independent effect. It can be suggested 
Metformin is acting to inhibit Sunitinib-induced mPTP formation, Sunitinib has been 
said to result in mPTP formation following activation of apoptosis during 
administration (Gorini et al. 2018, Kerkela et al. 2009, Chu et al. 2007).  mPTP 
formation within cardiac myocytes and the myocardium is in correlation with an 
increase in infarct percentage and a decrease in heart function (Bhamra et al. 2008), 
as shown in Figures 12b and 13. To support this, studies have demonstrated the 
activation of the reperfusion injury salvation kinase (RISK) pathway kinase Akt 
following Metformin administration during ischaemia, the subsequent activation of 
RISK/Akt acts to inhibit mPTP and result in a decrease in infarct percentage 
(Hausenloy et al. 2007, Bhamra et al. 2008, Whittingham et al. 2013, Driver et al. 
2018, Sridharan et al. 2016). However to conclude this, the direct investigation of 
AMPK, RISK and/or Akt signalling following Metformin co-administration with 
Sunitinib would need to be investigated. 
From Figure 12a, use of the two-way repeated measures ANOVA, with post-hoc 
Tukey HSD during repeated measures ANOVA, demonstrated that there was 
significant difference for time on HR (p<0.001), moreover statistical significance was 
demonstrated for time against treatment on HR (p<0.05). From this, it can be 
observed in Figure 12a that there is a gradual decrease in HR for the Sunitinib and 
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co-treatment groups against the vehicle control, however when comparing each 
treatment group against individual time points no significance was shown for time 
on HR and time against treatment at individual time points using the repeated 
measures ANOVA with Tukey HSD (p>0.05). Moreover, to confirm this the single 
factor ANOVA used for Figure 12a also demonstrated that there was no significance 
between each treatment group at individual time points (p>0.05). From Figure 12a, 
it is shown that both time and time against treatment is having a significant effect 
on HR as shown by a gradual decrease in HR following all treatments, this is 
somewhat expected as the Langendorff technique itself is a system that does not 
prevent the isolated perfused heart form dying, it is expected that there will be a 
gradual decrease in haemodynamic parameters as the technique itself is described 
as a dying procedure (Bell et al. 2011). As mentioned by Bell et al. (2011), a 10 % 
deterioration of contractile strength was shown using the Langendorff system. 
However, when investigating the perfusion of a drug such as Sunitinib it was shown 
that the observed changes were more significant, when compared to vehicle control 
such as shown in Figure 12b.     
From Figure 12b, use of the two-way repeated measures ANOVA multiple factor 
demonstrated significant difference for time on LVDP, as well as time against 
treatment on LVDP (p<0.001). However in contrast, no significance was shown for 
the Sunitinib treatment group against the vehicle control, as well as for the Sunitinib 
treatment group against the co-treatment group using Tukey HSD (p>0.05). As the 
use of the repeated measures ANOVA determined significance for the effects of 
time and time against treatment on LVDP, this demonstrated that time and time 
against treatment had an effect on LVDP in Figure 12b. However, the use of the 
post-hoc Tukey HSD demonstrated no significance for time and time against 
treatment for Sunitinib against vehicle control overall and Sunitinib against co-
treatment overall (p>0.05). However, when investigating individual time points, the 
use of the single-factor ANOVA determined significance for Sunitinib against vehicle 
control and Sunitinib against co-treatment (p<0.05).   
From Figure 12c, significance was determined for time on CF and time against 
treatment on CF (p<0.001). However, no significance was determined for the 
Sunitinib treatment against vehicle control, as well as the Sunitinib treatment group 
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against co-treatment (p>0.05). Moreover, no significance was demonstrated for the 
co-administration treatment group against the vehicle control group for individual 
time points (p>0.05). In contrast, when investigating individual time points, it was 
determined using the single-factor ANOVA that significance was shown for the co-
treatment group against the vehicle control at the 160 and 175 minute time points 
(p<0.05).   
In contrast to our results obtained in Figures 12b and 13, the Carotid 
Atherosclerosis: Metformin for Insulin Resistance (CAMERA), and the 
Glycometabolic Intervention as Adjunct Primary Percutaneous Coronary 
Intervention in ST–Segment Elevation Myocardial Infarction (GIPS) III randomised 
trial studies failed to demonstrate protective properties of Metformin (Preiss et al. 
2014, Lexis et al. 2014). No significance among LVEF or markers of cardiovascular 
disease (carotid intima-media thickness) were found when administering 1g/day 
Metformin for 4 months vs placebo/control in patients who previously underwent 
primary percutaneous coronary intervention for ST-segment elevation myocardial 
infarction or patients taking statins who were not diagnosed with type 2 diabetes but 
did have coronary heart disease (Preiss et al. 2014, Lexis et al. 2014). However, as 
highlighted by many authors, the use of 1g/day of Metformin may not be enough to 
demonstrate an impact on endpoint of LVEF or any potential cardioprotective effect, 
whilst the use of carotid intima-media thickness as a potential marker for 
cardiovascular disease is in debate (Pauriah et al. 2008). However, the UK 
Prospective Diabetes Study from 1998 and Holman et al. (2008) were able to 
demonstrate that Metformin was able to significantly decrease the risk of diabetes-
related cardiovascular end points and all-cause death when compared to 
conventional therapies after accounting for blood glucose levels.  
The study by Kravchuk et al. (2011) demonstrated that Metformin did not 
significantly affect the HR, LVDP and CF amongst control and type-2 diabetes 
mellitus rats, pre-administered with Metformin 200mg/kg, during ischaemia-
reperfusion, suggesting that Metformin does not have a cardioprotective effect 
during pre-treatment and does not result in myocardial pre-conditioning. However, 
similar to the study by Hasinoff et al. (2008) of who carried out Metformin pre-
treatment prior to Sunitinib administration, Metformin was administered prior to a 
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form of ischaemia and therefore was not able to override ATP depletion that was 
caused by the ischaemia itself. The authors further mentioned that drug-washout 
may have occurred at the time of ischaemia-reperfusion (Kravchuk et al. 2011), it 
would be worth seeing if this effect can be reversed if Metformin was Langendorff-
perfused during ischaemia-reperfusion. Despite this study, many studies involving 
Metformin administration within the Langendorff model are modelled around 
preventing ischaemic injury at the time of, or following, reperfusion injury therefore 
it is difficult to draw a direct comparison with our data. We demonstrated that co-
administration of Metformin with Sunitinib in Figure 12c significantly lowered CF at 
the 160 and 175 minute time points when compared to vehicle control, however 
Metformin administration alone did not significantly lower CF when compared to 
vehicle control. Moreover, the co-treatment of Metformin and Sunitinib was shown 
to attenuate Sunitinib-induced decrease in LVDP (Figure 12b) and not have an 
effect on HR (Figure 12a) when compared to vehicle control. Following this, it is 
difficult to explain the reduction in CF at these time points and further work would 
be required to investigate the reduction in CF. If we choose to explore AMPK 
signalling it is worth noting that persistent activation of AMPK during reperfusion 
results in glycolysis being favoured ahead of pyruvate oxidation, increases acidosis 
and reduces cardiac efficiency during the period of recovery, adding one possible 
explanation for the reduction in CF at time points 160 and 175 minutes in Figure 
12c (Paiva et al. 2010). Moreover, the coadministration of Metformin and Sunitinib 
could potentially be resulting in a vasoconstrictive effect and thusly lowering CF at 
these time points shown in Figure 12c. Sunitinib has previously been shown to result 
in vasoconstriction and hypertension, affecting the endothelin without an increase 
in oxidative stress (Kappers et al. 2011). Using this information, it could be 
suggested that although Metformin is producing a cardioprotective effect in 
combination with Sunitinib, as shown by the restoration of LVDP and infarct 
percentage, Sunitinib is able to override some of the potential effects of Metformin 
and thusly can result in a vasoconstrictive effect. Interestingly, from Figure 12c 
Sunitinib administration alone did result in a decrease in CF when compared to 
vehicle control. The study by Sandhu et al. (2017) demonstrated that Sunitinib-
induced changes to LVDP and HR were able to be overcome with the addition of 
the protective agent IB-MECA, however the addition of IB-MECA was not able to 
attenuate Sunitinib-induced decrease in CF compared to Sunitinib treatment alone. 
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Using this, it can be suggested that Sunitinib may be able to override the protective 
effects of IB-MECA and carry out a vasoconstrictive effect, as suggested for the 
possible decrease in CF resulting from the coadministration of Sunitinib and 
Metformin from Figure 12c.  
However, the resulting decrease at the 160 and 175 minute time-points of CF for 
the coadministration of Sunitinib and Metformin may be due to certain properties of 
Metformin. As mentioned previously reports of Metformin-induced lactic acidosis 
exists, the statement by Page et al. (2016) further indicated Metformin as a possible 
contributor to exacerbating underlying myocardial dysfunction, moreover the 
author’s highlighted Metformin as a ‘major’ category for ‘Magnitude of HF Induction 
or Precipitation’. Page et al. (2016) further stated that the possible reason for this 
was due to Metformin-associated increase in anaerobic metabolism and elevated 
lactic acidosis, with an immediate or delayed onset of effects. Although information 
presented by Page et al. (2016) is contraindicated by information presented in the 
statement, the information presented highlights the importance of monitoring 
Metformin treatment, particularly in the context of HR, in multiple parameters of 
haemodynamics as well as infarct percentage. As well as this, Metformin was 
demonstrated to have inotropic effects, the study by Teng et al. (2015) 
demonstrated that Metformin was able to degrade phospholamban located in the 
sarcoplasmic reticulum membrane of mouse neonatal cardiac myocytes via an 
autophagic-associated response, phospholamban acts to regulate Ca2+ uptake in 
the sarcoplasmic reticulum in cardiac myocytes. This suggests that Metformin may 
have certain inotropic effects within the heart which could account for certain 
changes on haemodynamic parameters. However, more research would be 
required to investigate this effect within our experimental model as we reported no 
changes to HR and LVDP during Metformin treatment alone. The decrease in CF 
following cotreatment of Metformin and Sunitinib could be resulting from myocardial 
edema as Metformin is also reported to cause edema in certain parts of the body, 
mainly legs and feet. However, the effects of edema on the heart are reported with 
Thiazolidinedione treatment (Kermani and Garg 2003), with very few sources 
indicating Metformin-induced pulmonary edema and has not been reported by either 
the National Institute for Health and Care Excellence (National Institute for Health 
and Care Excellence 2019) or by manufacturers (Bristol-Myers Squibb 2018).  
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Taking this into consideration, Metformin combination therapy has previously been 
demonstrated in studies. The study by Olsson et al. (2000) demonstrated the 
increase in cardiovascular mortality in patients with T2DM taking Sulfonylurea and 
Metformin in comparison to Sulfonylurea monotherapy. The author’s concluded that 
this combination of therapy cannot exclude for the possibility of increasing 
cardiovascular mortality (Olsson et al. 2000). However, it is worth mentioning the 
study by Olsson et al. (2000) carried out a comparison of 741 patients undergoing 
Sulfonylurea therapy alone and 169 patients undergoing Sulfonylurea and 
Metformin combination therapy, whilst the authors mentioned that the increase in 
mortality was secondary to a more aggressive form of diabetes present in the 
combination therapy group. However, our results indicated that Metformin 
administration alone throughout the Langendorff protocol following 20 minutes 
stabilisation, did not significantly reduce HR, LVDP or CF when compared to the 
normoxic control, whilst in coadministration with Sunitinib significantly attenuated 
the increase in infarct percentage caused by Sunitinib treatment alone and 
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3.5. Conclusion. 
To conclude, we observed an increase in infarct percentage in SD rat hearts when 
administered with the multi-TKI Sunitinib malate at the relevant dose of 1 µM, using 
the Langendorff technique. Moreover, Sunitinib was demonstrated to result in a 
significant decrease in LVDP when compared to vehicle control. Both HR and CF 
were demonstrated to not be altered during Sunitinib administration using the 
Langendorff technique compared to the vehicle control. The decrease in LVDP and 
increase in infarct percentage were both attenuated when co-administered with the 
type-2 diabetes agent Metformin hydrochloride at 50 µM concentration. Moreover, 
Metformin administration alone was demonstrated to not alter haemodynamics and 
infarct percentage compared to vehicle control, however the coadministration of 
Metformin and Sunitinib resulted in a significant decrease in CF at the 160 and 175 
minute time points, when compared to the vehicle control. The proposed 
mechanism of Sunitinib-induced cardiotoxicity was discussed in Section 3.4., whilst 
the proposed mechanism of Metformin-induced cardioprotection was touched upon 
in the same chapter. The direct role of Metformin-induced cardioprotection in 
Sunitinib-induced cardiotoxicity will explored and discussed further in Chapters 4 
and 5, whilst the proposed mechanism of AMPK-signalling involvement will be 
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Chapter Four: Inhibition of the human equilibrative nucleoside transporter 
prevents Metformin-induced cardioprotection in Sunitinib-induced 
cardiotoxicity, the role of AMPK activation. 
 
Disclaimer: Results presented in Sections 4.3.1 and 4.3.2. were previously 
presented in Sections 3.3.1., 3.3.2 and 3.3.3. Sections 4.3.1. and 4.3.2. builds on 
this study and incorporates the use of NBTI and the combination of Metformin, 
Sunitinib and NBTI.    
Data and contents in this chapter were published / presented as following: 
Conferences 
• British Pharmacological Society Annual Conference (2018) London, 
England. 
• 2nd MCRN meeting at Aston University, (2018), Birmingham, England.  
• British Society of Cardiovascular Research Autumn Meeting (2017), Oxford, 
England. 
• Safety Pharmacology Society and National Centre for the Replacement, 
Refinement and Reduction of Animals in Research: The use of human 
tissues for safety assessment, Regional meeting (2017), Coventry, England.  
Abstract and poster presentation 
• The Role of AMPK Signalling During Metformin Co-administration with 
Sunitinib, British Pharmacological Society Annual Conference (2018), 
London, England.  
• The Role of AMPK Signalling During Metformin Co-administration with 
Sunitinib, 2nd MCRN meeting at Aston University, (2018), Birmingham, 
England.  
• The Assessment of the Cardioprotective Properties of Metformin during 
Sunitinib-Induced Cytotoxicity, British Society of Cardiovascular Research 
Autumn Conference (2017), Oxford, England. 
• The Cardioprotective Properties of Metformin during Sunitinib-Induced 
Cytotoxicity, Safety Pharmacology Society and National Centre for the 
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4.1. Introduction 
As discussed in Chapter 1, cardiotoxicity is described as a broad range of adverse 
effects on heart function that can ultimately lead to HF and death. Cardiac muscle 
tissue relies heavily on aerobic metabolism as a source of ATP due to the tissue 
being highly energetic (Mellor et al. 2011). The use of chemotherapeutic agents for 
the treatment of cancer has been associated with an increased risk of 
cardiovascular complications. During cancer treatment, when the cancer is said to 
be incurable the improvement in overall survival via treatment with a potentially 
cardiotoxic agent will outweigh the associated safety risk (Mellor et al. 2010). 
Moreover, if the drug treatment can be used as an adjunctive form, the balance 
between risk and benefit will need to be examined carefully. To date, the TKI 
Sunitinib is administered, despite reports of adverse cardiac events, due to the drug 
being highly effective within settings where treatment is limited especially during 
oncology drug development where there is an issue in achieving anticancer 
efficiency is great, the risk of cardiotoxicity is considered on balance (Mellor et al. 
2010). New concerns exist regarding targeted drugs where cardiac effects are either 
unknown, not anticipated or detected in pre-clinical studies such as that with TKI 
Sunitinib (Orphanos et al. 2009, Henderson et al. 2013).  
We were able to demonstrate that Sunitinib when administered at 1µM significantly 
increased infarct percentage compared to the vehicle control, in Sections 3.1.-3.5., 
and the combination with Metformin at 50 µM was shown to attenuate this increase. 
From this, we aimed to investigate the signalling pathway associated with 
Metformin-induced cardioprotective properties in combination with Sunitinib. AMPK 
has previously been proposed as a protein of interest during Sunitinib-induced 
cardiotoxicity as well as Metformin-induced cardioprotection (Laderoute et al. 2010, 
Force et al. 2007, Paiva et al. 2009, Paiva et al. 2010, Bhamra et al. 2008).  
AMPK, both protein and messenger RNA (mRNA), is highly expressed in cardiac 
and skeletal tissue compared to liver in both rat studies and human studies 
(Verhoeven et al. 1995, Gao et al. 1995, Beri et al. 1994, Aguan et al. 1994). 
However, as mentioned by Kudo et al. (1996), it is unlikely that cardiac AMPK acts 
to regulate lipid biosynthesis, due to fatty acid and cholesterol biosynthesis being 
not important pathways in the heart, moreover the role of AMPK in cardiac tissue 
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may be to regulate fatty acid oxidation. Within the liver, AMPK phosphorylates and 
inactivates ACC, however ACC is also expressed in the heart and has a role in fatty 
acid oxidation and malonyl-CoA production for CPT-1 inhibition, CPT1 acts to 
uptake fatty acid in the mitochondria (Hardie 1992, Thampy 1989, Bianchi et al. 
1990, McGarry et al. 1978). Fatty acids provide 60-70 % of the energy requirement 
for the heart, during reperfusion following ischaemia, fatty acid oxidation was shown 
to recover and provide 90–100% of the energy requirement for the heart (Neely and 
Morgan 1974, Liedtke et al. 1988, Lopaschuk et al. 1990).  
The study by Kudo et al. (1995) demonstrated that the decrease in ACC activity and 
malonyl-CoA levels following ischaemia-reperfusion result in an accelerated rate of 
fatty acid oxidation, whilst the decrease in ACC activity resulted in an increase in 
AMPK activity. Following this, AMPK activation was shown to be present following 
ischaemic stress using post-mitochondrial extracts from rat heart tissue (Kudo et al. 
1996). The resulting activation of AMPK phosphorylates and inactivates ACC (Kudo 
et al. 1996), in accordance with previous studies highlighting ACC’s role in 
regulating cardiac fatty acid oxidation. Using this, it can be suggested that AMPK 
acts to regulate myocardial fatty acid oxidation (Kudo et al. 1996).  
Within cardiac tissue, AMPK acts to protect cardiac myocytes following ischaemic 
stress via intracellular ATP conservation, a potential form of cardioprotection (Paiva 
et al. 2010, Hardie and Hawley 2001, Frederich et al. 2005, Terai et al. 2005). During 
ischemia, cardiac AMPK is active following reduced oxygen levels, an increase in 
5’AMP levels and nutrient supply with oxidative phosphorylation resulting in the 
reduction of ATP production (Lopaschuk 2008, Kudo et al. 1995, Kudo et al. 1996, 
Weekes et al. 1994). Mitochondria are known to play an important role in events 
such as cardiac ischaemia-reperfusion, it was mentioned by Murphy and 
Steenbergen (2011) that defects in the electron transport chain contributes towards 
energy deprivation of the myocardium and result in increased mitochondrial 
generation of ROS and extensive oxidative damage. Therefore, preventing 
mitochondrial stress, mPTP formation and preserving mitochondria are vital for 
cardiac myocyte survival. Continuing from this, acute Metformin treatment was 
shown to improve myocardial energy metabolism during sustained ischaemic insult 
via upregulating NO production as a cardioprotective effect (Kawabata and Ishikawa 
2003), the same effects were demonstrated among diabetic murine hearts (Calvert 
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et al. 2008) and delay the opening of mitochondrial transition pores in cardiac 
myocytes, a PI3K-dependent manner (Bhamra et al. 2008).  
Continuing from results shown in Sections 3.1.-3.5., the role of AMPK signalling in 
Metformin-induced cardioprotection was a key focus. As mentioned in Section 1.14., 
the use of NBTI was demonstrated to inhibit Metformin-induced AMPK activation is 
settings of ischaemia-reperfusion (Paiva et al. 2010). NBTI is described as a high 
affinity binding and tight-binding specific inhibitor of ENT1, whilst also previously 
used to indicate ENT1 protein expression on the plasma membrane of cardiac 
myocytes (Cass et al. 1974, Chaudary et al. 2002, Rose et al. 2010). Within 
cardiovascular physiology, the purine nucleoside adenosine signalling molecule 
acts to reduce stress and regulate energy use within the cell (Mubagwa and Fleming 
2001, Rose et al. 2009). Adenosine is required for ATP synthesis, nucleic acid 
formation whilst further initiating a cardioprotective response during an imbalance 
in oxygen demand and availability (Rose et al. 2010, Headrick et al. 2003, Mubagwa 
and Fleming 2001, Pelleg et al. 2002). Cardioprotection involving purines in the 
cardiovascular system are widely investigated and accepted to involve murine 
nucleoside, adenosine, adenosine receptors and their associated signalling 
pathways, metabolic enzymes and purine nucleoside transporters (Rose et al. 
2010). However, few studies exist demonstrating the nucleoside transporters in 
cardiovascular physiology (Rose et al. 2010).  
Although the use of Metformin as a cardioprotective agent in co-treatment is nothing 
new, few studies exist involving the co-treatment of Metformin and Sunitinib, 
moreover Metformin’s potential ability to demonstrate cardioprotective properties 
during Sunitinib-induced cardiotoxicity is limited. The study by Hasinoff et al. (2008) 
demonstrated that cardiac myocytes were not protected from Sunitinib-induced cell 
death following Metformin pre-treatment. The authors aimed to demonstrate if 
activation of AMPK was able to prevent Sunitinib-induced myocyte damage, the 
authors further demonstrated that the clinically approved Doxorubicin-
cardioprotective agent Dexrazoxane was also unable to prevent Sunitinib-induced 
myocyte damage (Hasinoff et al. 2008). However, it was suggested that Sunitinib 
did not induce oxidative damage within cultured cardiac myocytes (Hasinoff et al. 
2008). It must be noted that the study involved the pre-treatment of cardiac 
myocytes with Metformin; this was followed by Metformin removal and replaced with 
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Sunitinib. From this, it is difficult to conclude if AMPK was still active following 
incubation with Sunitinib.  
From this, we previously demonstrated in Chapter 3, that Sunitinib at 1 µM was able 
to significantly increase infarct percentage of SD rat hearts during Langendorff 
perfusion. We aim to follow this up by investigating the effects of Sunitinib-induced 
cardiotoxicity directly in isolated cardiac myocytes. Using the information presented 
in Section 3.1.-3.5., as well as the aforementioned studies, it can be hypothesised 
that Sunitinib has a direct cardiotoxic role on cardiac myocytes, potentially resulting 
in the activation of pro-apoptotic pathways or acting on the mitochondria directly. 
Moreover, as presented using the Langendorff system involving SD rat hearts, 
Metformin was able to attenuate the increase in infarct percentage when co-
administered together with Sunitinib. We aim to demonstrate the similar effect on 
isolated cardiac myocytes.   
Using this knowledge, we aim to investigate the role of AMPK signalling in 
Metformin-induced cardioprotection and Sunitinib-induced cardiotoxicity. We have 
previously reported in Section 3.1.–3.5., that Sunitinib demonstrated cardiotoxic 
properties, resulting in an increase in infarct percentage of rat hearts during 
Langendorff perfusion. It was suggested that this may have resulted in Sunitinib 
activating apoptotic pathways as well as acting to limit ATP and energy to the 
myocardium, possibly via inhibiting AMPK signalling. We were able to attenuate this 
via the co-administration of Metformin.  
As discussed in Section 3.4., we used existing studies and literature to suggest that 
this may have resulted from Metformin’s ability to activate AMPK signalling in co-
administration with Sunitinib. We aim to demonstrate the ability for Metformin to 
activate AMPK signalling during co-administration with Sunitinib in the Langendorff 
system, in doing so aim to inhibit the proposed activity of AMPK via the use of the 
ENT1 signalling antagonist NBTI, as demonstrated in studies by Paiva et al. (2010) 
and Aymerich et al. (2006). We aim to demonstrate this using Western blot analysis 
involving isolated rat myocardial tissue following Langendorff perfusion.  
The information presented contributes to the debate surrounding the use of 
Metformin in cardioprotection in existing studies; nevertheless we aim to use this 
information to propose the potential for Metformin to activate AMPK signalling 
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during the course of Sunitinib administration using the Langendorff study. In doing 
so, we aim to potentially inhibit the route of Metformin-induced AMPK activation by 
using NBTI to potentially inhibit the recruitment of extracellular adenosine needed 
for AMPK activation. We further aim to demonstrate the direct phosphorylation of 
AMPK during all mentioned treatments, by investigating the phosphorylation of 




















Metformin hydrochloride (500 mg, MW 165.62 mg/mM) was purchased from Sigma 
Aldrich and dissolved in ultra-pure RO water. The Metformin stock solution was 
stored at -20oC.  
Sunitinib malate (25 mg, MW 532.56 mg/mM) was purchased from Sigma Aldrich 
and dissolved in DMSO. The Sunitinib stock solution was stored at -20oC and care 
was taken to avoid exposure to light and UV radiation.  
S-(4-Nitrobenzyl)-6-thioinosine (NBTI, 100 mg, MW 419.41 mg/mM) was purchased 
from Sigma Aldrich and was dissolved in DMSO. The NBTI stock solution was 
stored at -20oC.  
AMPKα, Phospho-AMPKα (pAMPK, Thr172) and GAPDH antibodies were 
purchased Cell Signalling Technology® (New England BioLabs), and stored at -20 
oC.  
Remaining reagents were standard laboratory reagents from Sigma Aldrich and 
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4.2.2. Isolated perfused heart preparation. 
As described in Section 2.3.1., SD rats (2-3-month-old male, 345–375 g b/w, 
Charles River research laboratories, Margate, UK) were sacrificed and hearts were 
immediately mounted onto the langendorff system and retrogradely perused with 
KH buffer. Functional parameters of LVDP, HR and CF were measured and 
recorded at regular intervals 5 minutes for 55 minutes, followed by intervals of 15 
minutes for 120 minutes. At the end of the experiment hearts were randomly 
selected to be used for (i) TTC staining or (ii) Western blotting. Hearts selected for 
(i) TTC staining were weighed and frozen at -20oC. Frozen hearts were sliced into 
2 mm thick transverse sections before being incubated in TTC solution (1 % in 
phosphate buffer) at 37oC for 10–12 minutes and fixed in 10 % formalin for a 
minimum of 4 hours. Total area and infarct area were traced onto acetate sheets 
and infarct percentage (%) was calculated. Computerised ImagetoolTM software 
was used to analyse the percentage of infarct tissue. Infarct size was normalised to 
the total area of each heart slice. Hearts selected for (ii) Western blot analysis had 
the left atrium removed and snap frozen in liquid nitrogen. Samples were stored in 
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4.2.3. Langendorff protocol. 
As described in Section 2.3.1., all hearts were allowed to stabilise for 20 minutes 
prior to being subjected to drug treatment for 155 minutes (Figure 11). Hearts were 
randomly assigned to the following group; (i) vehicle control hearts perfused with 
KH buffer and DMSO final concentration <0.1%; (ii) hearts perfused with KH buffer 
and Metformin hydrochloride (50 µM) for 155 minutes; (iii) hearts perfused with KH 
buffer and Sunitinib malate (1 µM) for 155 minutes; (iv) hearts perfused with KH 
buffer and Metformin (50 µM) and Sunitinib (1 µM) for 155 minutes, (v) hearts 
perfused with KH buffer and NBTI (1 µM) for 155 minutes, (vi) hearts perfused with 
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4.2.4. Isolated cardiac myocyte protocol. 
SD rat left ventricular cardiac myocytes were isolated by conventional enzymatic 
dissociation (Maddock et al. 2002). Hearts were immediately isolated and mounted 
onto a modified langendorff apparatus. Hearts were perfused with modified KH 
bicarbonate buffer for 5 minutes followed by 8 minutes of perfusion with collagenase 
buffer, as described in Section 2.6.1.  
After perfusion with collagenase the heart was removed, and the atrium was cut 
away before undergoing manual dissociation with collagenase buffer as described 
in Section 2.6.1. Samples were centrifuged and supernatant was removed before 
remaining pallet of viable tissue was resuspended in restoration buffer and calcium 
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4.2.5. Trypan Blue staining for percentage live cell population of cardiac 
myocytes. 
Sunitinib 1 µM, Metformin 50 µM and/or NBTI 1 µM was added to each appropriate 
well at concentrations with vehicle control. Cardiac myocyte cell suspension was 
added to each appropriate well, making each well final volume 1 ml. Cells were 
incubated for 4 hours in the normoxic incubator (37oC, 95 % O2, 5 % CO2) before 
undergoing trypan blue (1:1 dilution, 2x concentration) staining for live cell 
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4.2.6. Western blot detection of phosphorylated-AMPK (Thr172), AMPKα and 
GAPDH. 
As described in Section 2.4., a total of approximately 45-50 mg of frozen left 
ventricular tissue from the left atrium was lysed in lysis buffer before undergoing 
protein calculation for 60 µg, using PierceTM BCA protein assay kit (ThermoFisher 
Scientific). Protein was diluted with sample buffer as described in Section 2.4., 
before loading on Mini-PROTEAN TGX stain-free gel (BioRad, USA) and 
transferred onto membrane electrophoresis with Tran-Blot Turbo (BioRad, USA). 
Immunoblots are analysed using primary antibodies phosphorylated AMPK (p-
AMPK, Thr172), total AMPKα and GAPDH. Computerised ImagetoolTM software was 
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4.2.7. Statistical Analysis. 
All data was expressed as mean ± SEM. Haemodynamics LVDP, HR and CF were 
assessed for the statistical difference (p<0.05) using one-way ANOVA with LSD 
post hoc tests for each time point value. The use of the two-way repeated measures 
ANOVA was used to assess the statistical significance (p<0.05) between time and 
time against treatment group for HR, LVDP and CF with post hoc Tukey HSD. The 
infarct size percentage data was tested for group significant differences (p<0.05) 
using one-way ANOVA with LSD post hoc tests. Cardiac myocytes for live-cell 
population were assessed for the statistical difference (p<0.05) using one-way 
ANOVA with LSD post hoc tests. Western blot analysis for p-AMPK, AMPKα and 
GAPDH were assessed for the statistical difference (p<0.05) using one-way ANOVA 
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4.3. Results. 
Continuing from Section 3.3.1., results from 36 successful SD rat heart experiments 
were included in the Langendorff study to assess the effect on HR (Figure 14a), 
LVDP (Figure 14b) and CF (Figure 14c) during Metformin (50 μM) co-administration 
with Sunitinib (1 μM), and Metformin co-administration with Sunitinib and AMPK 
inhibitor NBTI (1 μM).  
Experiments were carried out for vehicle control, Metformin 50 µM, Sunitinib 1 µM, 
the combination (co-treatment) of Metformin (50 μM) and Sunitinib (1 μM), NBTI 1 
µM and the combination (co-treatment and NBTI) of Metformin (50 μM), Sunitinib (1 
μM) and NBTI (1 µM). As mentioned, data expressed for vehicle control, Metformin, 
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4.3.1. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI on haemodynamic parameters in SD rat hearts.    
 















Figure 14a: The effects of drug treatment on HR as a percentage of mean 
stabilisation: vehicle control (blue), Metformin (50 µM) (green), Sunitinib (1 µM) 
(red), the combination of Metformin (50 µM) and Sunitinib (1 µM) (co-treatment, 
purple), NBTI (1 µM) (turquoise), and the combination of Metformin (50 µM), 
Sunitinib (1 µM) and NBTI (1 µM) (co-treatment and NBTI, orange). Data is 
presented as mean ± SEM of 6 experiments (n=6).   
From Figure 14a, Sunitinib treatment demonstrated no statistical significant 
changes to HR during the treatment period when compared to the vehicle control, 
whilst co-treatment showed no significant change to HR when compared to the 
Sunitinib treatment, as previously highlighted in Figure 12a. The combination of 
Metformin, Sunitinib and NBTI (co-treatment and NBTI) demonstrated no significant 
change compared to the combination of Metformin and Sunitinib (co-treatment). The 
use of NBTI alone demonstrated no significant change to HR when compared to 
vehicle control.  
// 
Stabillisation 
Drug added  
155 | P a g e  
 
Single factor ANOVA and post-hoc LSD during one-way ANOVA determined no 
statistical significance between the co-treatment group and co-treatment and NBTI 
treatment group at selected time points (p>0.05).  
Two-way repeated measures ANOVA, with post-hoc Tukey HSD during repeated 
measures ANOVA, determined statistical significance for time on HR (p<0.001) for 
the but no statistical significance for time against Treatment on HR (p>0.05) for the 
Wilks’ Lambda score. Moreover, Mauchly’s Test of Sphericity® was violated 
(p<0.001), from this Greenhouse-Geisser determined statistical significance for time 
on HR (p<0.001) and time against treatment on HR (p<0.05). However, use of 
Tukey HSD post-hoc test for multiple comparisons determined no statistical 
significance between all treatment groups against the vehicle control on CF 
(p>0.05), moreover Tukey HSD determined no statistical significance for Sunitinib 
against co-treatment (p>0.05), and no significance for co-treatment against co-
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Figure 14b: The effects of drug treatment on LVDP as a percentage of mean 
stabilisation: vehicle control (blue), Metformin (50 µM) (green), Sunitinib (1 µM) 
(red), the combination of Metformin (50 µM) and Sunitinib (1 µM) (co-treatment, 
purple), NBTI (1 µM) (turquoise), and the combination of Metformin (50 µM), 
Sunitinib (1 µM) and NBTI (1 µM) (co-treatment and NBTI, orange). Data is 
presented as mean ± SEM of 6 experiments (n=6). Key statistical significance: 
*=p<0.05 1µM Sunitinib vs vehicle control. *=p<0.05 1µM Sunitinib vs Co-treatment. 
*=p<0.05 Co-treatment vs Co-treatment and NBTI.  
From Figure 14b, as previously highlighted in Figure 12b Sunitinib treatment 
resulted in a significant reduction in LVDP during the treatment period when 
compared to vehicle control, the co-treatment of Sunitinib with Metformin was 
demonstrated to attenuate this decrease in LVDP when compared to time-matched 
Sunitinib treatment. From Figure 14b, the co-treatment and NBTI group 
demonstrated an overall decrease in LVDP compared to the co-treatment group, 
similar to that of Sunitinib treatment. NBTI alone demonstrated no significant 
changes in LVDP compared to vehicle control. 
* * * 
Drug added  
Stabillisation 
// 
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Single factor ANOVA and post-hoc LSD during one-way ANOVA determined 
statistical significance for the co-treatment group against the co-treatment and NBTI 
group at selected time points 145, 160, 175 minutes (p<0.05, 145 minute; 80 ± 6 % 
vs. 65 ± 3 %, 160 minute; 75 ± 3 % vs. 64 ± 2 %, 175 minute; 74 ± 3 % vs. 64 ± 2 
%).  
Two-way repeated measures ANOVA, with post-hoc Tukey HSD during repeated 
measures ANOVA, determined statistical significance for time on LVDP (p<0.001) 
but no statistical significance for time against treatment on LVDP (p>0.05), for the 
Wilks’ Lambda score. Moreover, Mauchly’s Test of Sphericity® was violated 
(p<0.001), from this Greenhouse-Geisser determined statistical significance for time 
on LVDP (p<0.001) and significance for time against treatment on LVDP (p<0.05). 
Moreover, use of Tukey HSD post-hoc test for multiple comparisons determined 
statistical significance for the co-treatment and NBTI group against vehicle control 
(p<0.05), and for the co-treatment and NBTI group against the co-treatment group 
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Figure 14c: The effects of drug treatment on CF as a percentage of mean 
stabilisation: vehicle control (blue), Metformin (50 µM) (green), Sunitinib (1 µM) 
(red), the combination of Metformin (50 µM) and Sunitinib (1 µM) (co-treatment, 
purple), NBTI (1 µM) (turquoise), and the combination of Metformin (50 µM), 
Sunitinib (1 µM) and NBTI (1 µM) (co-treatment and NBTI, orange). Data is 
presented as mean ± SEM of 6 experiments (n=6). Key statistical significance: 
*=p<0.05 1µM Sunitinib vs Co-treatment. *=p<0.05 Co-treatment vs Co-treatment 
and NBTI.  
CF was recorded by collecting the effluent for 1 minute at regular intervals; data 
was corrected for heart weight and is presented as a percentage of mean 
stabilisation ± SEM in Figure 14c.  
It was demonstrated in Figure 14c that the co-treatment and NBTI group resulted in 
an overall decrease in CF compared to the co-treatment group alone. Single factor 
ANOVA and post-hoc LSD during one-way ANOVA determined statistical 
significance for CF for the co-treatment and NBTI group against the co-treatment 
group at selected time points 100, 115, 130, 145, 160 and 175 minutes (p<0.05, 
* * * * * * 
// 
Stabillisation 
Drug added  
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100 minute; 59 ± 7 % vs. 80 ± 3 %, 115 minute; 57 ± 6 % vs. 76 ± 5 %, 130 minute; 
55 ± 5 % vs. 75 ± 4 %, 145 minute; 52 ± 7 % vs. 70 ± 4 %, 160 minute; 48 ± 6 % vs. 
65 ± 3 %, 175 minute; 39 ± 5 % vs. 59 ± 3 %).  
Two-way repeated measures ANOVA, with post-hoc Tukey HSD during repeated 
measures ANOVA, determined statistical significance for time on CF (p<0.001) and 
statistical significance for time against treatment on CF (p<0.05) for the Wilks’ 
Lambda score. Moreover, Mauchly’s Test of Sphericity® was violated (p<0.001), 
from this Greenhouse-Geisser determined statistical significance for time on CF 
(p<0.001) and determined significance for time against treatment on CF (p<0.001). 
Moreover, use of Tukey HSD post-hoc test for multiple comparisons determined 
statistical significance for the co-treatment and NBTI group against the co-treatment 
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4.3.2. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI on infarct percentage in SD rat hearts.    
Results from 36 successful experiments were included for the Langendorff study to 
assess the effect on infarct size percentage (Figure 15) during co-treatment of 
Metformin, Sunitinib and NBTI in SD rat hearts (n=6). Experiments were carried out 
for vehicle control, Metformin concentration 50 µM, Sunitinib 1 µM, the combination 
(co-treatment) of Metformin (50 μM) and Sunitinib (1 μM), NBTI 1 µM and the 
combination (co-treatment and NBTI) of Metformin (50 µM), Sunitinib (1 µM) and 
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Figure 15: The effects of vehicle control, Metformin (50 µM), Sunitinib (1 µM), the 
combination of Metformin and Sunitinib (Co-treatment), NBTI (1 µM) and the 
combination of Metformin, Sunitinib and NBTI on infarct percentage (%). Data is 
presented as mean ± SEM of 6 experiments (n=6). Key statistical significance: 
***=p<0.001 1 µM Sunitinib vs vehicle control. #=p<0.05 Co-treatment vs Sunitinib, 
$=p<0.05 Co-treatment and NBTI vs Co-treatment.  
Infarct size was determined as a percentage of the total area of the heart and 
presented in Figure 15.  
From Figure 15, it was demonstrated that the combination of Metformin, Sunitinib 
and NBTI (Co-treatment and NBTI) was able to attenuate the decrease in infarct 
percentage when compared to the co-treatment group alone (30 ± 2 % vs. 20 ± 2 
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4.4. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI on live cell population of isolated cardiac myocytes using trypan blue 
staining. 
Results from 7 successful experiments were included for the cardiac myocyte 
isolation study to assess the effect on live cell population of isolated cardiac 
myocytes (Figure 16) during co-administration of Metformin, Sunitinib and NBTI in 
isolated cardiac myocytes from SD rat hearts (n=7). Experiments were carried out 
for vehicle control, Metformin concentration 50 µM, Sunitinib 1 µM, the combination 
(co-treatment) of Metformin (50 μM) and Sunitinib (1 μM), NBTI 1 µM and the 
combination (co-treatment and NBTI) of Metformin (50 µM), Sunitinib (1 µM) and 
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Figure 16: The effects of vehicle control, Metformin (50 µM), Sunitinib (1 µM), the 
combination of Metformin (50 µM) and Sunitinib (1 µM) (Co-treatment), NBTI (1 µM) 
and the combination of Metformin (50 µM), Sunitinib (1 µM) and NBTI (1 µM) (co-
treatment and NBTI) on live cell population of isolated cardiac myocytes (%) 
following trypan blue staining. Data is presented as mean ± SEM of 7 experiments 
(n=7). Key statistical significance: ***=p<0.001 1 µM Sunitinib vs vehicle control. 
#=p<0.05 Co-treatment vs Sunitinib, $=p<0.05 Co-treatment and NBTI vs Co-
treatment.  
Using Figure 16, live cell population was significantly decreased following Sunitinib 
(1 µM) administration when compared to vehicle control (12 ± 2 % vs. 40 ± 4 %, 
p<0.05). Moreover, the combination of Metformin (50 µM) and Sunitinib (co-
treatment) was shown to attenuate the decrease in live cell population when 
compared to Sunitinib alone (41 ± 3 % vs. 12 ± 2 %, p<0.05). The resulting 
attenuation was shown to be inhibited following the introduction of NBTI in 
combination with Metformin and Sunitinib (co-treatment and NBTI) as demonstrated 
by a significant decrease in live cell population compared to the co-treatment alone 
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4.5. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI in SD rat hearts using Western blot analysis for phosphorylated-AMPKα, 
AMPKα and GAPDH.   
Results from 47 successful experiments were included for the Western blot analysis 
study to assess the effect for phosphorylated-AMPKα (p-AMPKα, Thr172), total 
AMPKα and GAPDH levels during Metformin (50 μM) co-administration with 
Sunitinib (1 μM), and Metformin (50 μM) co-administration with Sunitinib (1 μM) and 
AMPK inhibitor NBTI (1 μM) during the Langendorff study. Western blot analysis 
was carried out to assess p-AMPKα (Thr172, 62 kDa, New England BioLabs #2531), 
AMPKα (Total AMPKα, 62 kDa, New England BioLabs #2532) and GAPDH 
(D16H11, XP-(R), New England BioLabs #5174) protein levels. Samples were run 
alongside positive and negative controls for AMPK (AMPK Control Cell Extract, New 
England BioLabs #9158).    
 
Expressed levels of p-AMPKα (Thr172) were standardised to Total-AMPKα for each 
respective sample and presented in Figure 18. Expressed levels of p-AMPKα were 
standardised to house-keeping protein GAPDH for each respective sample and 
presented in Figure 19. Probing for p-AMPKα (Thr172), Total-AMPKα and GAPDH 
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Figure 17 observed Western blot image for the effect of drug treatment on p-
AMPKα, Total-AMPKα and GAPDH signalling 
 
                       1          2            3           4          5              6 














Figure 17: Western blot analysis image for phosphorylation of Thr172 for p-AMPKα, 
Total-AMPKα and GAPDH signalling for Sunitinib (1 μM) ± Metformin (50 μM) ± 
NBTI (1 μM) in SD rat hearts. Key: 1=vehicle control, 2=Metformin 50 µM, 
3=Sunitinib 1 µM, 4=Co-treatment (Metformin 50 µM+Sunitinib 1 µM), 5=NBTI 1 μM, 
6=Co-treatment and NBTI. 
From Figure 17, bands demonstrating phosphorylation levels of p-AMPKα (Thr172) 
for the Sunitinib treatment group (lane 3) was observed to be fainter than the vehicle 
control group (lane 1). In contrast, the co-treatment group (lane 4) was observed to 
have a darker or more intense band than the Sunitinib treatment group (lane 3). 
Moreover, the co-treatment and NBTI group (lane 6) was also observed to have a 
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Figure 18 Western blot analysis for the effect of drug treatment on p-AMPKα 















Figure 18: Western blot signalling for p-AMPKα standardised to Total-AMPKα 
signalling, taken for the duration of the normoxic study involving normoxic vehicle 
control, Metformin (50 µM), Sunitinib (1 µM), the combination (co-treatment) of 
Metformin (50 µM)+Sunitinib (1 µM), NBTI (1 μM) and the combination of 
Metformin+Sunitinib+NBTI (co-treatment and NBTI). Data is presented as mean ± 
SEM of 7–9 experiments (n=7–9). Key statistical significance: ***=p<0.001 Sunitinib 
vs vehicle control. #=p<0.05 Co-treatment vs Sunitinib, $=p<0.05 Co-treatment and 
NBTI vs Co-treatment. 
From Figure 18, the Sunitinib treatment group resulted in a significant decrease in 
p-AMPKα signalling when compared to the vehicle control (53 ± 7 %, p<0.001), 
moreover the co-treatment group was demonstrated to attenuate this decrease 
when compared to Sunitinib treatment alone (101 ± 15 %, p<0.001). Metformin was 
demonstrated to increase p-AMPKα signalling when compared to the normoxic 
control (136 ± 24 %, p<0.001). NBTI alone demonstrated no significant changes in 
p-AMPKα signalling against vehicle control (104 ± 18 %, p>0.05). However, the co-
treatment and NBTI group was shown to significantly decrease p-AMPKα signalling 
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Figure 19 Western blot analysis for the effect of drug treatment on p-AMPKα 














Figure 19: Western blot signalling of p-AMPKα standardised to GAPDH signalling, 
taken for the duration of the normoxic study involving normoxic vehicle control, 
Metformin 50 µM, Sunitinib 1 µM, the combination (co-treatment) of Metformin (50 
µM)+Sunitinib (1 µM), NBTI 1 μM and the combination of Metformin+Sunitinib+NBTI 
(co-treatment and NBTI). Data is presented as mean ± SEM of 7–9 experiments 
(n=7–9). Key statistical significance: ***=p<0.001 1µM Sunitinib vs vehicle control. 
#=p<0.05 Co-treatment vs Sunitinib, $=p<0.05 Co-treatment and NBTI vs Co-
treatment. 
From Figure 19, the Sunitinib treatment group resulted in a significant decrease in 
p-AMPKα signalling when compared to the vehicle control (56 ± 10 %, p<0.05), 
moreover the co-treatment group was demonstrated to attenuate this decrease 
when compared to Sunitinib treatment alone (118 ± 17 %, p<0.05). Metformin was 
demonstrated to increase p-AMPKα signalling when compared to the normoxic 
control (155 ± 27 %, p<0.05). NBTI alone demonstrated a statistically significant 
increase in p-AMPKα signalling against vehicle control (132 ± 22 %, p<0.05, not 
shown). However, the co-treatment and NBTI group was shown to significantly 
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4.6. Discussion. 
Sunitinib-induced cardiotoxicity is thought to be mediated via the inhibition of 
several anti-apoptotic pathways as well as the activation of apoptosis itself. It was 
postulated in Section 3.1.-3.5., that this may have arisen form Sunitinib’s ability to 
induce pro-apoptotic proteins and the activation of apoptosis. The exact mechanism 
of Sunitinib-induced cardiotoxicity is not fully understood; however to support our 
hypothesis the proposed activation of apoptosis may arise from the lack of 
selectivity of Sunitinib, reports have shown 57 of 317 kinases were shown to be 
competitively bound at the dose of 1 µM (Karaman et al. 2008, Cohen et al. 2011). 
Furthermore, RISK has been highlighted as an important off-target kinase mediating 
Sunitinib cardiotoxicity (Fabian et al. 2005, Anjum and Blenis 2008, Cohen et al. 
2011), whilst AMPK was said to be implicated in Sunitinib-induced cardiotoxicity in 
patients (Kerkela et al. 2006, Chu et al. 2007). Inhibition of several pathways is 
thought to result in the activation of cytochrome c release and therefore direct 
mitochondrial toxicity, whilst Sunitinib has been further hypothesised to cause 
toxicity via a direct interaction with the mitochondria (Fabian et al. 2005). To support 
the hypothesis, we carried out live cell counting for isolated cardiac myocytes 
following administration with Sunitinib. We were able to demonstrate that Sunitinib 
was able to significantly reduce the live cell population of cardiac myocytes when 
compared to the vehicle control. Studies were able to demonstrate similar results in 
neonatal rat ventricular cardiac myocytes however at a different concentration of 
150 ng/ml (equivalent to 0.28 µM), believed to be close to the average peak plasma 
concentration within patients (Harvey and Leinwand 2015, Chu et al. 2007, 
Lankheet et al. 2011). Moreover, to support the proposed mechanism of Sunitinib-
induced cardiotoxicity in Figures 13–14, the study by Harvey and Leinwand 2015 
noted that Sunitinib was able to initiate a cardiotoxic response via the upregulation 
of apoptotic proteins Fas, Fasl, FADD, TRAIL and cleaved caspase-3, known to be 
involved in a pro-apoptotic response. Interestingly, the study by Henderson et al. 
(2013) was not able to determine Sunitinib-induced contractility loss and that this 
may not be due to cardiac myocyte damage, and the effect is not related to 
ischaemia caused via a reduce oxygen supply, however the concentration used was 
0.1 µM, a tenth of the concentration we used. It was further indicated that 
investigations would be required for Sunitinib effects on ion channel, sarcoplasmic 
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reticulum Ca2+ stores and if mitochondrial function is necessary (Henderson et al. 
2013).  
Using Figure 14b, Metformin co-administration with Sunitinib was shown to 
significantly attenuate the reduction in LVDP caused by Sunitinib administration 
alone, the effects of Metformin were further inhibited when co-administered with 
Sunitinib and NBTI. Therefore, results from Figure 14b can suggest that the 
activation of the AMPK signalling pathway is occurring following Metformin 
administration. With this, AMPK activation was said to result in the activation of the 
catabolic pathway and suppress non-essential ATP-consuming processes (Kudo et 
al. 1995). The resulting activation of the catabolic pathway can contribute towards 
the re-distributing of energy for cardiac myocyte and myocardium function, 
potentially explaining the increase in LVDP following Metformin co-administration 
with Sunitinib (Tian et al. 2001, Allard et al. 2007, Li et al. 2007, Fu et al. 2011, Cha 
et al. 2010). As cardiac tissue requires a constant and stable source of energy, 
resulting in a limited reserve of ATP, by inhibiting AMPK this could disrupt the 
cardiac myocytes ability to meet the energy demand, possibly explaining the overall 
decrease in LVDP following Sunitinib administration (Kudo et al. 1995).  
 
To investigate the role of AMPK signalling in Sunitinib-induced cardiotoxicity, we 
carried out Western blot analysis as demonstrated in Figures 17–19. We were able 
to demonstrate that phosphorylated levels of AMPK, at the Thr172 residue, was 
significantly decreased following Sunitinib administration at 1 µM. In accordance 
with our findings, phosphorylation of the α and β isoforms of ACC, a target of AMPK, 
is said to be reduced following Sunitinib administration, in a dose-dependent 
manner, after a 2 hour exposure, by Hasinoff et al. (2008). However, as highlighted 
by Mellor et al. (2011) the dose used (5 µM, by Hasinoff et al. 2008) is 25-fold 
greater than the therapeutic plasma concentration level. Nevertheless, ACC is a 
target of AMPK signalling and is required for the signalling of p-AMPKα at the Thr172 
residue, ACC is said to be undetectable in association with the absence of Thr172 
(Crute et al. 1998, Stein et al. 2000, Willows et al. 2017). Using this information, it 
can be suggested that our results are similar with that demonstrated by Hasinoff et 
al. (2008), of which demonstrated reduced phosphorylation of ACC following 
Sunitinib administration, whilst we were able to demonstrate a significant reduction 
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in p-AMPKα signalling following Sunitinib administration. Our results from Figures 
17-19 are in agreement with results demonstrated by Laderoute et al. (2010), 
demonstrating Sunitinib-induced inhibition of p-AMPK. Moreover, Laderoute et al. 
(2010) further demonstrated Sunitinib-induced inhibition of p-ACC as well as p-
AMPK following incubation of human prostate cancer cells for 4 hours. However, 
similar to the study by Hasinoff et al. (2008), the study by Laderoute used a 
concentration greater than that used in the Langendorff system in this study, at 5 
µM and 25 µM respectively. However despite this, Western blot images and results 
of p-AMPK from Laderoute et al. (2010) are similar to results obtained in Figures 
17-19. Using this information with our results, it is concluded that Sunitinib acts to 
potently bind to and inhibit p-AMPK signalling (Laderoute et al. 2010). Sunitinib is 
said to the AMPKα kinase domain as a type-2 protein kinase inhibitor and stabilises 
the catalytically inactive DFG-out conformation of the protein (Laderoute et al. 
2010).  
 
It has been proposed that increased phosphorylation of AMPK, before reperfusion, 
as well as during events of ischaemia may protect cardiac muscle from infarction, 
providing energy for cell viability while the myocardium is readjusting the 
metabolism to oxygen (Paiva et al. 2010, Bhamra et al. 2008, Gundewar et al. 2009, 
Calvert et al. 2008). In support of this, studies have demonstrated the extracellular 
activation of AMPK, such as via Metformin administration, improved myocardial 
energy metabolism during acute sustained ischaemic injury in non-diabetic rat 
hearts (Kawabata and Ishikawa 2003). Metformin-induced activation of AMPK was 
shown to be abolished with the non-specific nitric oxide synthase inhibitor L-NAME 
(Kawabata and Ishikawa 2003). Using this, in accordance with results obtained in 
Figures 14-18 it can be suggested that the administration of Metformin resulted in 
an improvement in energy metabolism, as evidenced by the restoration of LVDP 
similar to the vehicle control in Figure 14b. Moreover, the inhibition of AMPK 
signalling resulted in an attenuation of the LVDP restoration in Figure 14b. To 
support this, acute ischaemia-reperfusion studies suggest AMPK may modulate 
PPAR-α directly or indirectly through PGC-1α, as PPAR-α was indicated to be 
attributed to a post-translational level (Barreto-Torres et al. 2012). In normal 
conditions the myocardium uses fatty acid synthesis of glucose oxidation as the 
main source of energy, fatty acid oxidation is transcriptionally regulated via 
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members of nuclear receptor superfamily such as PPAR and their coactivator PGC-
1α (Vega et al. 2010, Mu et al. 2001, Schreiber et al. 2003). Furthermore, it is said 
that AMPK inhibits biosynthetic pathways via inhibition of mTOR and Co-A 
carboxylase, whilst many studies have used pharmacological AMPK activators 
Metformin or AICAR to initiate AMPK activation.  
It is known that the primary mechanism responsible for AMPK activation involves 
phosphorylation at the Thr172 residue found within the activation loop of the α-
catalytic subunits (Stein et al. 2000, Baron et al. 2005, Carling et al. 2003). The 
phosphorylation of Thr172 is mediated by the upstream kinase, AMPK-activating 
protein kinase (AMPKK) (Hawley et al. 1995). Moreover, during ischaemic stress 
AMPKK was shown to be activated in the heart via AMP augmentation to 
phosphorylate and activate the AMPK α subunit and interacting with the 
heterotrimeric AMPK complex (Baron et al. 2005). Furthermore, the use of AICAR 
was able to demonstrate the interaction of nucleotides with heterotrimeric AMPK 
was sufficient to increase AMPK Thr172 phosphorylation in in-vivo, in the absence of 
AMPKK (Baron et al. 2005). For this, we aimed to demonstrate the potential for 
AMPK phosphorylation to be affected by Metformin and Sunitinib treatment by 
measuring the levels of phosphorylation at the Thr172 as shown in Figures 18-19. 
We demonstrated that Metformin administration at 50 µM was able to significantly 
increase phosphorylation of AMPK at the Thr172 residue against vehicle control, in 
Figures 18 and 19, when standardised to both total AMPK and GAPDH. The 
observed results were expected particularly as Metformin acts to increase AMPK 
signalling (Rena et al. 2013). In regards to Thr172 phosphorylation, our results are in 
accordance to existing studies demonstrating a decrease in p-AMPK signalling 
following Sunitinib treatment, whilst p-AMPK signalling is increased with Metformin 
administration (Laderoute et al. 2010, Cohen et al. 2011, Zarrouk et al. 2014, Chu 
et al. 2007, Kerkela et al. 2009).  
We previously suggested and proposed, in Section 3.1.-3.5., the potential for 
Sunitinib to inactivate or reduce phosphorylation of AMPK signalling as well as other 
signalling pathways. It was demonstrated in Figures 18 and 19 that Sunitinib 
administration at 1 µM was able to significantly decrease phosphorylation of AMPK 
against the vehicle control. Moreover, the co-administration of Metformin with 
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Sunitinib was able to attenuate this decrease in AMPK as demonstrated. The 
introduction of NBTI with the co-administration of Metformin and Sunitinib was able 
to attenuate the effects of the co-treatment. This was demonstrated following the 
significant decrease in AMPK phosphorylation at the Thr172 residue compared to the 
co-treatment group in Figures 18 and 19 following Western blot analysis. The 
observed results suggest that the use of NBTI was able to inhibit or prevent the 
activation of AMPK by Metformin, following Sunitinib-induced cardiotoxicity. The 
results demonstrated can be said to be similar to that proposed by Paiva et al. 
(2010) and the results demonstrated by Aymerich et al. (2006).  
The use of NBTI at 1 µM was able to inhibit ENT-related transport, in support of this 
the study by Aymerich et al. (2006) demonstrated an approximate 80% decrease in 
ENT-transport activity and adenosine transport following incubation with NBTI in 
cultured cells. The authors concluded that extracellular adenosine was able to 
activate AMPK via a mechanism requiring adenosine transport, resulting in an 
increase in the AMP intracellular pool (Aymerich et al. 2006). Moreover, the same 
effect was demonstrated when blocking adenosine transport via CNT2, resulting in 
the inhibition of the AMPK signalling pathway, whilst the addition of adenosine 
demonstrated a significant increase in AMPK signalling (Aymerich et al. 2006). AMP 
generation was shown to be required for AMPK activation, with a marked decrease 
in ADP concentration, following the addition of adenosine (Aymerich et al. 2006). 
The study further demonstrated the inhibition of increased intracellular AMP 
concentrations after adenosine addition, and a marked decrease in ADP 
concentration, the authors concluded that the generation of AMP from extracellular 
adenosine was required for AMPK activation (Aymerich et al. 2006). To support this, 
Aymerich et al. (2006) demonstrated the addition of extracellular adenosine was 
said to enhance ACC phosphorylation, which was otherwise abolished following 
CNT2 inhibition. The mechanism of AMPK inhibition via NBTI was summarised 
using Figure 10. Using this information, extracellular adenosine, via administration 
with Metformin, was required for the activation and phosphorylation of AMPK 
Figures 18-19, therefore inhibition of AMPK signalling via this route resulted in the 
inhibition of Metformin-induced AMPK activation, hence the results obtained 
following administration of NBTI with the combination of Metformin and Sunitinib. 
As we discussed that AMPK signalling may be a primary route of Metformin-induced 
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cardioprotection, the inhibition of AMPK resulted in the loss of the cardioprotective 
properties in Figures 14b, 15, 16, 18 and 19. This was evidenced by the increase in 
infarct percentage as demonstrated in Figure 15 for the co-treatment and NBTI 
group compared to the co-treatment group alone.  
However, it must be noted that several non-specific or off-target mechanisms of 
cardioprotection could be taking place during Metformin administration. As 
explained, Metformin is proposed to inhibit mitochondrial complex I and AMP 
deaminase thereby increasing the AMP:ATP ratio and activating AMPK, this results 
in the phosphorylation of eNOS involved in the RISK pathway as explained by 
Bromage and Yellon 2015. The RISK pathway is known to inhibit the opening of 
mPTP which initiates the effects of calcium influx and ROS generation during 
reperfusion following the initiation of ischaemia (Bromage and Yellon 2015). 
Metformin has been noted to also exert pleiotropic effects such as changes in blood 
rheology, serum lipid profile as well as anti-ischaemic effects (Anfossi et al. 2010). 
However, the exact mode of cardioprotection by Metformin is still not fully 
understood. Metformin is suggested to increase activity of NO-synthase, resulting 
in a vasoprotective response (Sartoretto et al. 2005, Bhalla et al. 1996), furthermore 
Metformin was shown to attenuate LV post-ischaemic dysfunction (Legtenberg et 
al. 2002). Using this in regards to our results obtained in Figure 14b, it was 
demonstrated that Metformin was able to attenuate the Sunitinib-induced decrease 
in LVDP, an effect that was attenuated following the introduction of NBTI, supporting 
our evidence that Metformin administration resulted in an improvement in LV 
activity, associated with the activation of the AMPK signalling pathway.  
 
In accordance with our evidence of AMPK activation following Metformin co-
administration, Metformin is indicated to achieve a plasma concentration of 10-20 
μM/l in patient studies and was able to demonstrate a significant activation of AMPK 
in H4IIE cells at a Metformin concentration 50 μM/l, whilst activation was said to be 
two-fold greater following 72 hours of incubation (Hawley et al. 2002). Moreover, 
the authors concluded that higher doses of Metformin are not required for maximal 
AMPK activation to achieve a beneficial therapeutic effect (Hawley et al. 2002). 
Furthermore, patient studies involving greater doses of Metformin were said to 
result in gastrointestinal side effects, whilst also posing a risk for lactic acidosis, 
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possibly resulting from the compound acting as an inhibitor of the respiratory chain 
at higher concentrations (Hawley et al. 2002, Owen et al. 2000). Taking these 
factors into consideration the relevant dose of 50 µM was agreed to be used in the 
adjunctive treatment. Following this, we demonstrated that Metformin at 50 µM was 
able to significantly increase p-AMPKα signalling compared to the vehicle control, 
and a similar result was observed when administered together with Sunitinib when 
compared to Sunitinib treatment alone.  
Our results showed that Metformin induced s a cardioprotective response. To 
support this, Spector et al. (2007) demonstrated that AMPK activation leads to the 
protection against TNFα-induced cell death and activation of AMPK is able to 
reduce associated cardiotoxicity. HER2 small molecule tyrosine inhibitors 
demonstrated that inhibition of HER2 and EGFR kinase activity via GW2974 
prevention of HER3 transactivation, leading to increased intracellular Ca2+ (Spector 
et al. 2007). The increase in intracellular Ca2+ is said to lead to activation of CAMKK, 
CAMKK in turn activates AMPK and the activation of AMPK inhibits mTOR, eEF2, 
ACC blocking protein and fatty acid synthesis, whilst AMPK activation induces fatty 
acid oxidation via activation of mitochondrial ERRα and PGC-1α (Spector et al. 
2007).  
In accordance with our results in Figure 16 demonstrating that Metformin was able 
to attenuate Sunitinib-induced cardiac myocyte cell loss, Wang et al. (2017) 
demonstrated that Metformin was able to prevent ischaemia-reperfusion-induced 
apoptosis of cardiac myocytes; consequent AMPK activation was demonstrated 
with the Metformin treated group when compared to the normoxic control. Moreover 
within in-vitro AICAR was used to demonstrate the same AMPK activation whilst 
this was abolished using Compound C, highlighting the role of AMPK in Metformin-
induced cardioprotection (Wang et al. 2017). AMPK activation is known to occur 
following phosphorylation at the Thr172 and the α subunit via upstream AMPK 
kinases such as the calcium-activated protein kinases CAMKKβ and LKB1 (Mercy 
et al. 2005, Lizcano et al. 2004, Shaw et al. 2004, Inoki et al. 2003, Spector et al. 
2003). Within the heart, as well as skeletal muscle, AMPK activation results in the 
phosphorylation and inhibition of ACC, this acts to reduce malonyl-CoA levels which 
reduces the inhibition of CPT-1, the depression of CPT-1 results in the increase in 
β-oxidation of fatty acid and results in the increased mitochondrial production of 
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ATP (Spector et al. 2007, Kudo et al. 1995, Kudo et al. 1996, Lehman et al. 2000). 
Furthermore, upon stress-activation of AMPK, the resulting cascade is known to 
inhibit protein synthesis of mTOR and directly modulating elongation factor (EFF) 2, 
this translation elongation factor is considered to be associated with 
cardioprotective properties (Spector et al. 2007, Bolster et al. 2002, Horman et al. 
2002, Terai et al. 2005). Moreover AMPK-mediated TSC2 phosphorylation inhibition 
of cap-dependent translation is considered to be critical in cell survival in response 
to ATP depletion (Spector et al. 2003, Inoki et al. 2005).  
The use of the Langendorff system has been used to monitor LV contractility whilst 
also measuring ECG changes and the use of the isolated heart allows for the 
measuring of multiple indices of cardiac function, such as measuring biopsied tissue 
for protein or genomic biomarkers for cardiac injury and stress in a single assay 
allows for the reduction in animal use and experimental costs (Henderson et al. 
2013). In our study, we found that hearts perfused with KH buffer and vehicle 
remained stable with very slight changes over the 155 minute protocol. Reductions 
in HR, and possibly CF, within the control groups can be attributed to run down 
during KH buffer perfusion, an effect described to occur due to inefficient energy 
production (Henderson et al. 2013). It is said that for energy production pyruvate 
and glucose, provided via KH buffer, is less favoured than fatty acid use or insulin 
perfusion by the heart which may contribute towards a better stability and longevity 
within the Langendorff system (Henderson et al. 2013, Goodwin et al. 1998, 
Lopaschuk and Saddik 1992, Watanabe et al. 1984).    
To date, current studies involving AMPK activation in Sunitinib-induced 
cardiotoxicity studies have focused on the pre-treatment of cardiac tissue with either 
Metformin or AICAR and have thus far failed to demonstrate potential 
cardioprotection via pre-treatment (Hasinoff et al. 2008, Kerkela et al. 2009, Cohen 
et al. 2011). However, it must be noted that the study by Hasinoff et al. (2008) 
involved a pre-treatment period with Metformin, less that of the incubation period 
with Sunitinib. Moreover, the authors failed to demonstrate if Sunitinib-inactivation 
of AMPK can be overcome during adjunctive treatment with Metformin. Likewise the 
study by Cohen et al. (2011) involved pre-treating stem cell-derived cardiac 
myocytes with either Metformin or AICAR for a period of 3 hours, compared to the 
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24 hour incubation with Sunitinib to measure LDH levels. This could indicate the 
potential for Sunitinib to inactivate AMPK signalling following the removal of 
Metformin or AICAR, highlighting the importance of investigating AMPK-activation 
via adjunctive treatment rather than a means of prior activation of AMPK, as 
evidenced by the study by Laderoute et al. (2010) demonstrating Sunitinib potently 
binding to AMPK. Moreover, it was noted that LDH release as an indicator of cell 
death may not be suitable to indicate ATP content in cardiac myocytes for Sunitinib-
induced cardiotoxicity (Cohen et al. 2011). To date, no study has investigated the 
re-activation of AMPK after Sunitinib treatment, in order to investigate the potential 
for Metformin to activate AMPK signalling to counter Sunitinib’s ability to inhibit 
AMPK signalling. In contrast to many existing studies, our study aimed at 
investigating potential AMPK activation via adjunctive administration with the 
indirect AMPK-activator Metformin rather than pre-treatment. An overexpression of 
a constitutively active mutant form of AMPK was shown to be able to reduce 
Sunitinib-mediated apoptosis, whilst AMPK activation in the heart was shown to 
demonstrate anti-apoptotic properties, highlighting the potential need for AMPK 
activation to be present during Sunitinib administration and not via pre-treatment 
(Kerkela et al. 2009, Hickson-Bick et al. 2000, Russell et al. 2004, Shibata et al. 
2005, Terai et al. 2005, Dyck and Lopaschuk 2006, Spector et al. 2007).   
In our study we used the inhibition of AMPK via the use of NBTI. To date the most 
widely accepted cell permeable AMPK-inhibitor for inhibiting Metformin-induced 
AMPK activation is Dorsomorphin Dihydrochloride (Compound C, 6-[4-(2-Piperidin-
1-ylethoxy) phenyl]-3-pyridin-4-ylpyrzolo [1, 5-a] pyrimidine) (Zhou et al. 2001, 
Isakovic et al. 2007, Tang et al. 2011). Dorsomorphin was demonstrated to be a 
potent and reversible AMPK inhibitor that is competitive with ATP with Ki=109 ± 16 
nM in the absence of AMP (Zhou et al. 2001). Moreover, Dorsomorphin, structurally 
related to TK receptor inhibitors (Fraley et al. 2002), did not significantly inhibit 
structurally related kinases ZAPK, SYK, PKC, PKA and JAK3 (Zhou et al. 2001) 
however was demonstrated to inhibit bone morphogenic protein (BMP) signalling 
via an AMPK-independent manner (Paul et al. 2008). Furthermore, Dorsomorphin 
was also shown to reduce cell proliferation and growth of astrocytic tumours in in-
vitro and in-vivo (Rios et al. 2013) and was able to inhibit AMPK activity and kill 
glioma cells (Liu et al. 2014). It was suggested that Dorsomorphin not be used to 
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investigate AMPK functions due to the compound alone being significantly cytotoxic 
via an AMPK-independent route, whilst also reported to inhibit kinases with a lower 
Km that that of AMPK, the study by Bain et al. (2007) identified that a concentration 
of above 40 µM (EC50=0.1–0.2 µM) is required to inhibit AMPK completely in culture 
media, thereby the authors have advised against using the compound to inhibit 
AMPK (Bain et al. 2007, Vogt et al. 2011, Jin et al. 2009). Following this information, 
we favoured the use of the ENT-inhibitor NBTI in order to potentially prevent the 
activation of AMPK, over the use of Dorsomorphin. Moreover, in a study with glioma 
cells, Dorsomorphin was demonstrated to induce caspase-3 mediated apoptosis 
(Liu et al. 2014), whilst in breast cancer cells Dorsomorphin resulted in ceramide 
production and redistribution of Bax from the cytoplasm to the mitochondria, both 
effects were said to be AMPK-independent (Jin et al. 209). Finally, it has been 
suggested that Dorsomorphin works by blocking total AMPK activity rather than 
phosphorylation of AMPK, indicating this to be difficult to assess when administered 
in the context of Metformin use in AMPK activation (Paiva et al. 2010, Leon et al. 
2014). As demonstrated by band intensity in Figure 16, total levels of AMPKα are 
not altered during treatment of Metformin, Sunitinib or both in co-administration, but 
rather phosphorylation of AMPK is altered between treatment groups, shown in 
Figure 18 and 19, indicating that the use of Dorsomorphin would not be relevant in 
this study.  
It has been suggested that Metformin’s cardioprotective properties could be 
independent of hypoglycaemic actions (Solskov et al. 2008). Within our study we 
have primarily focussed on the AMPK signalling pathway, it is worth noting that 
drugs activate different pathways when administered acutely compared to 
chronically (Mensah et al. 2005, Mocanu and Yellon 2007, Teresi et al. 2006). 
Knowing this, Metformin is said to have an effect on numerous endogenous factors 
associated with cell survival including peroxisome PGC-1α known to have a role in 
energy metabolism and is expressed on mitochondrial-rich tissue such as the heart 
(Suwa et al. 2006, Liang et al. 2006). An increase in AMPK and PGC-1α were shown 
to exert a beneficial effect on cardiac function within a HF model (Gundewar et al. 
2009). The study by Saeedi et al. (2008) demonstrated that Metformin induced 
metabolic changes in the heart in the absence of AMPK in H9c2 cells derived from 
rat embryonic cardiac myocytes. The authors demonstrated that the metabolic 
178 | P a g e  
 
effects of Metformin were abrogated during the pharmacological inhibition of p38 
MAPK and PKC. ACC is down-stream of AMPK and phosphorylation of ACC was 
shown to not differ between Metformin-treated and non-treated hearts and H9c2 
cells. With the knowledge that a reduction in cellular energy status following 
Metformin administration likely occurs via Metformin’s ability to inhibit complex I of 
the respiratory chain complex (Hardie 2006, El-Mir et al. 2000, Owen et al. 2000), 
Saeedi et al. (2008) failed to demonstrate an impairment in cellular energy status 
and suggested that this was an indicator of AMPK not being activated, hence the 
lack of reduction in cellular energy status. It was said that inhibition of PKC and p38 
MAPK resulted in the reduction in Metformin acceleration of glycolysis in H9c2 cells, 
highlighting the importance of the two pathways. However, it is worth noting that 
H9c2 cells are rat embryonic ventricle derived and although morphological 
characteristically similar to immature embryonic cardiac myocytes and 
biochemically and electrophysiologically similar to adult cardiac cells, such cells are 
not completely representative of cardiac myocytes. For this, we favoured the use of 
isolated cardiac myocytes.  
Similar to our results, the study by Cohen et al. (2011) demonstrated that Sunitinib 
treatment resulted in cardiac myocyte death when treated for 2 hours. However, the 
concentration of Sunitinib used by Cohen et al. (2011) was 15 times greater than 
the concentration we used for the Langendorff, Western blot analysis and isolated 
cardiac myocyte studies. Cohen et al. (2011) also investigated levels of LDH 
release, whereas we measured live cell populations of isolated cardiac myocytes. 
Moreover, similar to our results, phosphorylation of AMPK at the Thr172 residue was 
almost absent for Sunitinib, when compared to vehicle control (Cohen et al. 2011). 
In contrast this study, we demonstrated similar results using Sunitinib at 1 µM but 
during a 4 hour treatment period. For this, we aimed to demonstrate the effect of 
Sunitinib directly on isolated cardiac myocytes using the same concentration of 
Sunitinib that we used in the Langendorff experiment. A concentration of 15 µM for 
Sunitinib would not be suitable in the Langendorff study as this could result in a 
complete death of the isolated rat heart.    
Moreover, treatment with Metformin alone was able to significantly increase levels 
of p-AMPK, compared to vehicle control (Cohen et al. 2011). However, Cohen et al. 
(2011) failed to demonstrate any cardioprotection of Metformin. It must be said that 
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the study involved pre-treating cardiac myocytes with Metformin, in comparison to 
our study that involved the co-administration of Metformin with Sunitinib. Moreover 
Cohen et al. (2011) measured LDH release in comparison to the live cell count for 
our study. LDH release may not be a predictive measure for ATP content, upon 
activation via metabolic stress AMPK acts to maintain ATP levels (Dyck and 
Lopaschuk 2006, Cohen et al. 2011), therefore the results obtained by Cohen et al. 
(2011) may not be the same when used in an in-vivo or ex-vivo experimentation. 
Moreover Cohen et al. (2011) indicated that ATP depletion was recorded as 80%, 
as well as a significant increase in apoptosis with 31 μM Sunitinib, whilst pre-
treatment with Metformin during 15 μM Sunitinib treatment was not able to attenuate 
cardiotoxicity or decrease phosphorylating levels of AMPK in Western blots. In 
contrast, we were able to demonstrate that the clinically relevant dose of 1 μM 
Sunitinib was able increase infarct percentage in SD rat hearts, whilst the non-toxic 
dose of Metformin 50 μM was able to attenuate Sunitinib-induced toxicity. It is 
difficult to foresee how the dose concentrations used by Cohen et al. (2011) were 
to be replicated in our ex-vivo experimentation due to the high concentrations of 
Sunitinib potentially causing a greater percentage of infarction and over-riding any 
potential cardioprotection offered by Metformin, however this would need to be 
investigated further. This is particularly important as the authors concluded that 
AMPK reactivation was not able to attenuate caspase-3/7 cleavage and did not 
result in a “rescue” of ATP, therefore it was said that AMPK alone was not a critical 
protein that contributed towards Sunitinib-induced cardiotoxicity (Cohen et al. 2011).  
It is also worth noting that Cohen et al. (2011) demonstrated that treatment of human 
iPSC-CM whole cell lysates with 15 μM Sunitinib and 31 μM Metformin inhibitor RO-
3857 did reduce the phosphorylation status of pACC-Ser79, a down-stream target 
of AMPK. Moreover, in a previous set of data Cohen et al. (2011) demonstrated that 
15 μM Sunitinib reduced the phosphorylation status of p-AMPKα (Thr172), the 
opposite was demonstrated with Metformin and AICAR treatment, and however as 
mentioned previously the cells used were pre-treated with either Metformin or 
AICAR but not used in coadministration with Sunitinib. In contrast, our study 
attempts to demonstrate that coadministration of Sunitinib and Metformin is able to 
prevent the reduction in the phosphorylated status of AMPK due to Sunitinib-
induced toxicity.  
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In contrast to the results obtained by Cohen et al. (2011) and Hasinoff et al. (2007), 
Metformin was able to reduce infarction percentage when administered at the first 
15 minutes of reperfusion (Paiva et al. 2010). The study by Paiva et al. (2010) 
demonstrated that the protective effect of Metformin, via AMPK activation, was not 
abolished following Compound C when administered 5 minutes after the 
administration of Metformin at the onset of reperfusion, this suggests that the 
phosphorylation of AMPK was not affected once Metformin-induced 
phosphorylation of AMPK was activated. However, as the study focussed on 
ischaemia-reperfusion it must be noted that other signalling pathways may be 
involved. If Sunitinib is able to reduce AMPK signalling, our data shows that 
Sunitinib was not able to inhibit or decrease phosphorylation of AMPK once 
Metformin was introduced and continuously perfused. Moreover, our data suggests 
that Metformin was able to activate AMPK during the state of Sunitinib-induced 
cardiotoxicity as evidenced by p-AMPK levels in Figures 18 and 19. This was similar 
to results obtained by Paiva et al. (2010) when investigating AMPK activation at the 
onset of reperfusion. Data regarding Metformin and ex-vivo animal experiments to 
demonstrate effects on HR, LVDP and CF are limited and sometimes difficult to 
conclude. It is worth noting that within settings of ischaemia-reperfusion, the study 
by Paiva et al. (2010) demonstrated that Metformin did not improve LVDP and did 
not have any significance when administered prior to and at the onset of reperfusion, 
despite demonstrating a reduction in infarct percentage (Paiva et al. 2010).  
Despite our data demonstrating Metformin has cardioprotective properties, 
considerations need to be taken when administering Metformin use in animal-based 
models. As we have previously stated, our selected dose of Metformin is higher than 
the suggested steady state plasma levels administered, the steady state plasma 
levels of Metformin are said to be approximately 10-40 µM (Cusi and DelFronzo 
1998, Wiernsperger 1999, Sum et al. 1992), whilst studies involving rats have 
demonstrated that levels in liver are considerably higher than plasma (Wilcock et al. 
1991). Moreover, membrane permeability is considered to be time-dependent whilst 
Metformin-activated AMPK signalling was indicated to be concentration and time-
dependent (Owen et al. 2000, Zhou et al. 2001). It was suggested that high 
concentrations or long-term exposure to Metformin is required to see the effects of 
AMPK (Zhou et al. 2001). The study by Yang and Holman (2006) indicated the 
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activation of AMPK via Metformin increases glucose uptake in cardiac myocytes at 
a concentration of 1 mM during an 18 hour course of treatment. However, in contrast 
the study by Bertrand et al. (2006) failed to demonstrate the same effects with the 
same concentration during a 4-hour treatment but still increased glucose uptake, 
however exposure to concentrations 5 and 10 mM for 4 hours did result in an 
activation of AMPK and the stimulation of glucose uptake.  
When investigating ischaemia, it has been highlighted that ischaemia-induced 
AMPK activation increases glucose uptake as well as anaerobic utilisation, this 
results in the heart producing sufficient ATP in order to maintain cardiac function 
(Paiva et al. 2010, Dyck and Lopaschuk 2006). This would suggest that during 
ischaemia, particularly Sunitinib-induced ischaemia via necrosis, the myocardium 
acts to activate AMPK to maintain cardiac function, this was particularly highlighted 
in Figures 17, 18 and 19, as we demonstrated some phosphorylation of AMPK 
occurred during Sunitinib administration rather than total inhibition of AMPK as 
suggested by Force et al. (2007). Moreover, our results are in accordance with 
results shown by Laderoute et al. (2010), of which Sunitinib resulted in an inhibition 
of p-AMPKα but did not result in a complete inhibition of AMPK signalling as 
evidenced on Western blot analysis. However, the activation of AMPK via the 
myocardium is suggested to not be enough to counter Sunitinib’s proposed other 
routes of cytotoxicity involving RSK and Akt, as well as pro-apoptotic proteins (Chu 
et al. 2007, Cohen et al. 2011).  
It is known that Metformin does not directly act on LKB1 or AMPK but rather 
indirectly via acting upon the respiratory chain complex 1 (El-Mir et al. 2000, Owen 
et al. 2000), something that is considerably misunderstood amongst many articles. 
It is understood that inhibition of ATP synthesis results in a rise in the ADP: ATP 
ratio, which is said to be amplified via adenylate kinase and results in a larger rise 
on AMP: ATP (El-Mir et al. 2000, Owen et al. 2000, Hardie 2006). The binding of 
AMP to AMPK allows for the better substrate binding for LKB1, whilst acting as a 
worse substrate for competing protein phosphatase, the resulting complex is said 
to be sensitive enough for a small increase in AMP: ATP to produce a large change 
in AMPK activity (Hardie et al. 1999, Scott et al. 2004). Metformin was demonstrated 
to not significantly phosphorylate AMPK via LKB1 in cell-free assays (Hawley et al. 
2002), however as LKB1 is required for Metformin to activate AMPK in cultured cells 
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and in vivo in skeletal muscle the activity of LKB1 is considered to not be altered 
during treatment of Metformin (Lizcano et al. 2004, Sakamoto et al. 2004, Hawley 
et al. 2003, Sakamoto et al. 2005). Furthermore, AMPK-related kinases 
downstream of LKB1 were demonstrated to not be activated during Phenformin 
cultured isolated rat muscle during conditions of AMPK activation via 
phosphorylation at the LKB1 site, although LKB1 is required for biguanides such as 
Metformin to activate AMPK it is said that LKB1 is not the direct target (Sakamoto 
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4.7. Conclusion. 
To conclude, data presented in this chapter demonstrated that the associated 
cardiotoxicity following Sunitinib administration using the Langendorff model and 
isolated cardiac myocytes including changes in haemodynamics, infarct percentage 
and live cell population, were attenuated when co-administered with Metformin. 
Moreover, the resulting cardioprotection was shown to be inhibited by the use of 
NBTI, resulting in the suggesting inhibition of adenosine binding to hENT1, thereby 
resulting in the attenuation of AMPK signalling. To confirm this, western blotting was 
carried and was able to successfully demonstrate that p-AMPK signalling was 
significantly decreased following Sunitinib administration. Furthermore, levels of p-
AMPK signalling were shown to be restored followed co-administration with 
Metformin, this was confirmed using NBTI, suggesting the involvement of AMPK 
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Chapter Five: The effect of Metformin co-administration during Sunitinib-
induced cytotoxicity in cancer cell lines. 
Data and contents in this chapter were published / presented as following: 
Conferences 
• British Pharmacological Society Annual Conference (2018) London, 
England. 
• 2nd MCRN meeting at Aston University, (2018), Birmingham, England.  
• British Society of Cardiovascular Research Autumn Meeting (2017), Oxford, 
England. 
• Safety Pharmacology Society and National Centre for the Replacement, 
Refinement and Reduction of Animals in Research: The use of human 
tissues for safety assessment, Regional meeting (2017), Coventry, England.  
Abstract and poster presentation 
• The Role of AMPK Signalling During Metformin Co-administration with 
Sunitinib, British Pharmacological Society Annual Conference (2018), 
London, England.  
• The Role of AMPK Signalling During Metformin Co-administration with 
Sunitinib, 2nd MCRN meeting at Aston University, (2018), Birmingham, 
England.  
• The Assessment of the Cardioprotective Properties of Metformin during 
Sunitinib-Induced Cytotoxicity, British Society of Cardiovascular Research 
Autumn Conference (2017), Oxford, England. 
• The Cardioprotective Properties of Metformin during Sunitinib-Induced 
Cytotoxicity, Safety Pharmacology Society and National Centre for the 
Replacement, Refinement and Reduction of Animals in Research: The use 
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5.1. Introduction. 
As discussed in Chapter 1, the multi- TKI Sunitinib is currently prescribed as a first-
line agent for the treatment against certain cancers such as renal-cell carcinoma in 
selected patients (Motzer et al. 2007, Powles et al. 2011). However, reports have 
highlighted co-morbidities associated with Sunitinib treatment. Chemotherapy itself 
and the release of cytokines have been associated with contributing towards 
developing co-morbidity in patients undergoing cancer treatment, including systolic 
dysfunction, reductions in ejection fraction and myocardial stunning contributing 
towards ischaemic heart disease (van Haelst et al. 2006, Yang et al. 2010, Goede 
et al. 2014). The concept that cancer is not only a potentially curable disease but 
also a manageable disease has been described, with small molecule TKIs playing 
a vital role treatment (Force et al. 2007). Co-morbid diseases are described to be 
aggressive and pose a greater risk to patients than the malignancy, therefore 
prevention and treatment are vital (Oeffinger et al. 2006, Force et al. 2007). 
However, complications exist regarding cancer treatment, cardiovascular disease 
in particular is said to be a greater risk in young cancer survivors of whom have 
been treated with chemotherapeutic agents (Oeffinger et al. 2006). Therefore, 
attention has focussed on TKIs, particularly humanised monoclonal antibodies and 
small-molecule inhibitors against tyrosine kinase receptors (Krause and Van Etten 
2005), as summarised in Table 1, Chapter 1 Section 1.9.  
It has been mentioned that clinical trials involving certain chemotherapeutic agents 
do not include predefined cardiac endpoints, therefore the measuring of LV function 
before and during treatment as well as the rate of cardiotoxicity associated with TKIs 
are not known (Force et al. 2007). The review by Force et al. (2007) mentioned that 
cardiotoxicity is not a TK class effect, and that toxicity is uncommon with TKIs such 
as those targeting EGFR, therefore toxicity needs to be determined on a case–by-
case basis (Force et al. 2007). Moreover, the same publication mentioned that it is 
difficult to diagnose coronary HF in cancer patients, particularly as many possible 
explanations exist regarding the development of dyspnoea, fatigue, and oedema 
other than LV dysfunction, all symptoms of coronary HF (Force et al. 2007). 
Furthermore, Force et al. (2007) highlighted that even when assessments of LV 
dysfunction have been included in clinical trials, rates of LV dysfunction are being 
186 | P a g e  
 
reported to make it difficult to examine the finding in a meaning context, rates of HF 
determined before drug approval are excluded and clinical trials are typically short 
of duration, whereas therapy with certain agents may be lifelong.  
Using this information, the management, treatment and prevention of co-morbidities 
such as cardiovascular side-effects are crucial for patients undergoing cancer 
treatment. We have previously demonstrated in Chapter 3 and 4 that Sunitinib, 
when administered at the relevant concentration of 1 µM in the Langendorff system 
with rat hearts, cardiotoxicity was observed such as increasing infarct percentage, 
changes in haemodynamics and the loss of a live cell population of isolated cardiac 
myocytes. We further demonstrated that the co-administration with the anti-diabetic 
agent Metformin was able to attenuate the associated cardiotoxic effects of 
Sunitinib. Following this, in Chapter 4 we investigated the route of the associated 
effects by investigating the role of the AMPK signalling pathway. We demonstrated 
that Sunitinib was able to decrease phosphorylated levels of AMPK signalling in 
Western blot analysis, an associated effect that is hypothesised as an anti-
neoplastic activity for Sunitinib treatment (Force et al. 2007, Laderoute et al. 2010), 
however the co-administration of Metformin was able to attenuate the decrease in 
p-AMPKα signalling. With this, it needs to be examined whether the effect of 
Metformin co-administration is preventing Sunitinib’s ability to carry out its mode of 
action in cancer treatment.  
The role of AMPK is implemented in Metformin’s ability to inhibit mTORC1, directly 
inactivating the Ragulator complex, thereby inhibiting RAG, GTPases and 
disassociating mTORC1 from the activator RHEB (Long et al. 2005, Mahoney et al. 
2018, Pernicova and Korbonits 2014). mTORC1 signalling was shown to be 
activated through RAG GTPases, recruiting mTORC1 to the lysosomal surface for 
the activating by RHEB (Kalender et al. 2010, Efeyan et al. 2013). Activation of the 
Ragulator mechanism is described to be responsive to perturbations in energy 
status in certain types of cancer (Kalender et al. 2010). A further independent AMPK 
effect is known to inhibit the serine-protein kinase ATM gene and reduce the level 
of ROS (Algire et al. 2012). The proposed pro-apoptotic effects of AMPK are 
produced by the mitochondrial complex-1 (Figure 20), and can confer the risk of 
mutagenesis (Algire et al. 2012). The inhibition of the mitochondrial complex 1 is 
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known to reduce the production of ROS, oxidative stress, DNA damage and thusly 
reducing the risk of mutagenesis (Algire et al. 2012).  
Within cancer, Metformin is described to lower systemic glucose and insulin levels, 
thusly decreasing insulin-mediated tumour growth and progression, whilst 
Metformin’s anti-inflammatory effects is said to potentially reduce the risk of 
developing cancer (Pollak et al. 2012, Pernicova and Korbonits 2014). From Figure 
20, activation of AMPK is known to activate the tumour suppressor gene TSC-2, 
which inhibits the mTORC1 activator RHEB, AMPK further inhibits and directly 
phosphorylates a member of the mTORC1 complex referred to as Raptor (Gwinn et 
al. 2008). The lowering of insulin levels via AMPK-dependent phosphorylation of 
IRS-1 is hypothesised to decrease the downstream signalling of IGF–1-insulin 
receptors, therefore inhibiting Akt and mTORC1 signalling (Gunton et al. 2003, Ning 
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Figure 20: The anticancer effects of Metformin are hypothesised to result from the 
combination of indirect (systemic) and direct effects. As summarised by Pernicova 
and Korbonits (2014) Metformin’s systemic influence can be demonstrated on 
metabolism and insulin – sensitive target tissues, whilst Metformin is known to lower 
system glucose and insulin levels, the decrease can result in the decrease in 
insulin–mediated tumour growth and progression. Metformin’s direct effects can 
stem from the ability to inhibit the mTORC1; the inhibition of mTORC1 is 
hypothesised to result in a reduction in cancer risk. Within Metformin–treated cancer 
cells, the activation of AMPK can act to restrain cancer cell growth; the resulting 
inhibition of TSC-2 inhibits the mTORC1 activator RHEB as well as AMPK directly 
inhibiting the member of mTORC1 protein Raptor. Moreover, the ability by 
Metformin to decrease signalling downstream of IGF-1–insulin receptors results in 
the inhibition of the Akt and mTORC1 signalling pathways (Pernicova and Korbonits 
2014). 
The focus on Metformin’s anticancer ability still remains divided as Metformin was 
shown to inhibit oxidative glycolysis in pre-neoplastic cells with an intact AMPK axis 
(Huang et al. 2008), however LKB1 and AMPK have been suggested to offer 
advantageous effects to tumour cells, in established tumours, protecting the cells 
against energetic stress (Jeon et al. 2012). The absence of either LKB1 or AMPK 
in established tumours was shown to result in a greater susceptibility to depleted 
ATP via Metformin, resulting from the impaired ability to restore the energy balance 
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(Algire et al. 2011). In acute myeloid leukaemia the LKB1-AMPK axis remains 
functional, however AMPK activation with Metformin demonstrated a full inhibition 
of mTORC1 activity, thereby reducing oncogenic protein synthesis (Green et al. 
2011). Incubation of leukaemia cancer cells with Metformin resulted in apoptotic cell 
death, whilst Metformin exerted significant anti-leukaemia activity in in-vivo mice 
transplanted with a human acute myeloid leukaemia cell line, highlighting the role 
of AMPK agonism for therapy (Green et al. 2010). From this, it would be interesting 
to see the potential anti-proliferative properties of Metformin during co-
administration with a chemotherapeutic agent such as Sunitinib in leukaemia cells.   
As discussed, Metformin has the ability to result in cancer cell death, we aim to 
investigate the potential for Metformin to be used in adjunctive treatment. Following 
this, we aim to investigate the anticancer properties of Metformin in Sunitinib-
induced cytotoxicity with the potential for Metformin to be used in combination with 
Sunitinib in chemotherapy treatment. Using information discussed, it can be 
suggested that Metformin has the potential to provide an anti-neoplastic effect alone 
but also in combination with existing chemotherapeutic agents, such as Sunitinib. 
However, the idea is not novel, as multiple studies have considered the anti-
neoplastic potential of Metformin when used in combination with cytotoxic therapies 
(Chen et al. 2012).  
Metformin has been shown to enhance the anticancer effect of chemotherapeutic 
agents (Liu et al. 2012, Shi et al. 2012, Chen et al. 2012, Nilsson et al, 2011, Hirsch 
et al. 2009, Erices et al. 2013). However, Metformin was able to antagonise 
Cisplatin-induced cytotoxicity in glioma, neuroblastoma, fibrosarcoma and 
leukaemia cell lines, believed to be via an AMPK-independent activation of Akt 
(Janjetovic et al. 2011).  The use of Metformin with Sunitinib co-treatment in diabetic 
patients with renal cell carcinoma indicated that patients receiving Metformin had a 
significantly higher 11-month increase in overall survival, following adjustments for 
known risk factors for poorer outcomes (Keizman et al. 2016). It was said that 
patients had an increase in clinical benefit and a decrease in primary treatment 
refractions, however progression-free survival was not deemed statistically 
significant against non-Metformin treated patients (Keizman et al. 2016). Moreover, 
despite mentioning potential pathways associated with the stated outcomes the 
authors were not able to perform any analysis in regards to evaluating the cellular 
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and anticancer hypotheses. Furthermore, the authors highlighted that the study 
performed was carried out with only 52 Metformin users and 56 non-Metformin 
users, whilst the patients only represented a heterogeneous group of patients and 
the study did not take into consideration the duration of Metformin therapy during 
Sunitinib treatment in patients (Keizman et al. 2016). The authors further stated that 
the significant decrease of LVEF, acute coronary syndrome and cerebrovascular 
accident during therapy was said to be similar between the groups of patients 
(Keizman et al. 2016), this would contradict existing reports highlighting Sunitinib’s 
ability to reduce LVEF as well as other cardiovascular events. It is worth addressing 
these issues when investigating the potential use of Metformin cotreatment with 
Sunitinib.  
In-vivo and in-vitro studies have demonstrated that Metformin may increase the 
efficacy of standard anticancer drugs (Vujic et al. 2015, Jang et al. 2014, Sliwinska 
et al. 2015). Metformin co-treatment was suggested to allow for chemotherapeutic 
dosage to be decreased without reducing effectiveness (Chen et al. 2015). 
Metformin was shown to accelerate WP 631-induced cell death, whilst enabling a 
dose reduction of WP 631 without the loss of the growth-inhibition effect on HepG2 
cells (Sliwinska et al. 2015). Sliwinska et al. (2015) commented that these results 
were in accordance with that shown by Chen et al. (2015) and Illiopoulos et al. 
(2011). The decrease in p53 levels in HepG2 cells, following WP 631 co-treatment 
with Metformin, was said to be the result of the activation of AMPK and NAD(+)-
dependent histone/protein deacetylase sirtuin 1 (SIRT1) (Nelson et al. 2012, 
Sliwinska et al. 2015). Nelson et al. (2012) indicated that Metformin increased 
susceptibility of p53 to ubiquitination by MDM2 via the activation of AMPK-SIRT1 
pathway, promoting the deacetylation of p53 (Sliwinska et al. 2015). HepG2 cells 
are said to be resistant to chemotherapeutic cytotoxic agents as a result of PTEN 
inactivation and Akt hyperactivity, whilst also possessing hyperactive Akt, which is 
said to be involved in the regulation of NFκB (Sliwinska et al. 2015). NFκB is 
responsible for the regulation of the genetic expression of cytokines, chemokines, 
growth factors, cell surface receptors, enzymes and acute phase proteins (Wardle 
2001, Rogalska et al. 2016). The NFκB signalling pathway is associated with cell 
survival, whilst affecting the course of pathways in cancer cells via the transcription 
of specific genes encoding proteins for the regulation of the cell cycle (cyclin D1, 
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growth arrest and DNA damage–inducible 45 (GADD45) and the tumour suppressor 
gene p161INK4A), apoptosis B cell lymphoma–XL (BclXL), x–linked inhibitor of 
apoptosis protein (XIAP), cellular inhibitor of apoptosis (cIAP) and oncogenesis 
(p53, vascular cell adhesion molecule (VCAM), intercellular adhesion molecule 
(ICAM) (Rogalska et al. 2016). However, reports indicate that NFκB is involved in 
both apoptotic and anti-apoptotic properties (Rogalska et al. 2016, Ueda and 
Richmond 2006, Aoki et al. 2001, Ismail et al. 2015).   
AMPK is a known sensor of cellular energy status and activation results in the 
switching on of catabolic pathways that generate ATP and switches off ATP-
dependent processes (Hardie 2004, Hasinoff et al. 2008). With this, AMPK is a 
critical regulator of energy homeostasis in metabolic processes and inhibits the rate-
limiting steps in lipogenesis, including SREBP-1 via mTOR in hepatic cells, 
repression of AMPK is suggested to negate the mentioned effects (Scott et al. 2004, 
Lv et al. 2015). As we’ve outlined previously, Metformin could improve hepatic 
steatosis by increasing AMPK phosphorylation (Hu et al. 2013, Lv et al. 2015). Lv 
et al. (2015) demonstrated that activation of AMPK was able to reverse the effects 
of TNF-α on lipid disposition in HepG2 cells. This supported the suggestion that 
TNF-α induced skeletal muscle insulin resistance is involved in AMPK signalling 
suppression (Lv et al. 2015). HepG2 cells are said to exhibit chromosomal and 
oncogenic gene abnormalities, as well as expressing wild-type p53 (Nelson et al. 
2012). Using this, the study by Nelson et al. (2012) demonstrated that addition of 2 
mM Metformin was able to decrease p53 protein concentration, under high glucose 
conditions. Furthermore, addition of Metformin in HepG2 cells was able to diminish 
systolic reactive oxygen species production in high glucose conditions (Nelson et 
al. 2012). The findings were said to be similar to studies involving AMPK activation 
in glomerular epithelial cells (Nelson et al. 2012, Eid et al. 2010).  
In-vitro studies for human myeloid leukaemia can be carried out involving the HL60 
cell line, originating from a female patient with acute myeloid leukaemia, an 
attractive model for studying cell differentiation and human myeloid cell 
differentiation (Birnie 1988). As outlined previously, we aim to investigate the 
potential role of Metformin in Sunitinib-induced cytotoxicity using the HL60 cell line. 
Based on knowledge involving Metformin treatment of HepG2 cells, we further aim 
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to investigate the role of Metformin with Sunitinib using the HepG2 cell line, 
providing a comparison to the potential use of Metformin together with Sunitinib.  
Using this information, we propose that Metformin has the potential to be used in 
co-administration with Sunitinib treatment. We have previously demonstrated in 
Chapters 3-4, that Metformin has the ability to reduce Sunitinib–induced cardiac 
myocyte death as well as reduce Sunitinib–induced increase in infarct percentage 
of the myocardium. However, with this we need to investigate whether Metformin is 
able to be used in combination with Sunitinib treatment, and if Metformin will result 
in a synergistic effect during co–administration in cancer cell lines. Moreover, we 
aim to demonstrate the potential role of AMPK signalling pathway during Metformin 
co–administration with Sunitinib. In doing so, we aim to use the MTT assay. HepG2 
and HL60 cells will be used to assess cell metabolic activity including NADPH–
dependent cellular oxidoreductase enzymes to reduce tetrazolium dye MTT to the 
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5.2. Methodology. 
5.2.1. Chemicals.  
Metformin hydrochloride (500 mg, MW 165.62 mg/mM) was purchased from Sigma 
Aldrich and dissolved in ultra-pure RO water. The Metformin stock solution was 
stored at -20oC.  
Sunitinib malate (25 mg, MW 532.56 mg/mM) was purchased from Sigma Aldrich 
and dissolved in DMSO. The Sunitinib stock solution was stored at -20oC and care 
was taken to avoid exposure to light and UV radiation.  
S-(4-Nitrobenzyl)-6-thioinosine (NBTI), 100 mg, MW 419.41 mg/mM) was 
purchased from Sigma Aldrich and was dissolved in DMSO. The NBTI stock solution 
was stored at -20oC.  
HepG2 and HL60 cancer cell lines were acquired from ATCC brought up from the 
Coventry University reserved stock.   
Penicillin-Streptomycin Solution (x100 concentration), Trypsin with EDTA (x10 
concentration) and L-Glutamine (200 mM, x100 concentration) were all purchased 
from LabTech International Ltd, East Sussex, United Kingdom. FBS, RPMI 1640 
Medium and DMEM with high glucose, L-Glutamine and Sodium Pyruvate w/o 
HEPES were all purchased from Thermo Fisher Life Technologies Ltd, Paisley, 
United Kingdom. Remaining reagents were standard laboratory reagents from 
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5.2.2. MTT Assay for HepG2 and HL60 Cell Viability.  
As mentioned in Section 2.5., the MTT assay with 3-(-4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide was performed using HepG2 and HL60 cancer 
cells for control and treatment groups (Section 2.5.). Cells were incubated with (i) 
Metformin (6-1000 µM), (ii) Sunitinib (0.1-100 µM), (iii) the combination (co–
treatment) of Sunitinib (0.1-100 µM) and Metformin (50 µM), (iv) NBTI (0.1–100 µM), 
(v) the combination (co–treatment and NBTI) of Sunitinib (0.1-100 µM) and 
Metformin (50 µM) and NBTI (1 µM).   
HepG2 and HL60 cells were investigated for assessing cell metabolic activity 
including NADPH–dependent cellular oxidoreductase enzymes to reduce 
tetrazolium dye MTT to the insoluble formazan product.  
HepG2 cells were plated and incubated at 37oC, 5 % CO2 for 48 hours, to allow 
attachment and 40%-60% confluency. Plates containing HL60 cells were incubated 
at 37oC, 5 % CO2 for 24 hours, to allow attachment and 40-60 % confluency 
Plates were incubated with required drug concentration for 24 hours. Following 
incubation with compounds, media was replaced with MTT media (concentration 5 
mg/ml). Plates were incubated for 6 hours minimum at 37oC, 5 % CO2. MTT-
containing media was removed gently and replaced with DMSO. Plates were read 
on microtiter plate reader at 595 nm/492 nm, reference 690 nm. Treatment groups 
were standardised to vehicle control for each plate. EC50 was generated from the 
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5.2.3. Statistical Analysis.  
The data were expressed as mean ± SEM of 4-6 wells for each treatment group and 
concentration. Sunitinib doses, the combination of Metformin and Sunitinib, and the 
combination of Metformin, Sunitinib and NBTI were assessed for the EC50 and 
statistical difference (p<0.05) using one-way ANOVA with LSD post hoc tests by 
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5.3.1. Results. 
Results from 90 successful experiments, consisting of 3 plates per replicate (n) for 
6 replicates, were included for the MTT assay study to assess the effect on MTT 
reductase activity levels during Sunitinib treatment at doses 0.1–100 μM (n6) 
(Figures 21a-21b), Metformin treatment at doses 6–1000 μM (n6) (Figures 22a–
22b), the combination (co–treatment) of Sunitinib at doses 0.1–100 μM and 
Metformin 50 μM (n6) (Figures 23a–23b), NBTI at doses 0.1–100 μM (n6) (Figures 
24a–24b) and the combination (co–treatment and NBTI) of Sunitinib at doses 0.1–
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5.3.2. The effects of Sunitinib on cell viability of HepG2 cells.    











Figure 21a: MTT assay for Sunitinib treatment dose–response on HepG2 cells 
following 24 hours of incubation using concentrations 0.1–100 µM (n=6). Treatment 
groups were standardised to control group for each individual plate.  
From Figure 21a Sunitinib at concentrations 1–100 µM demonstrated a significant 
decrease in cell viability of HepG2 cells compared to the control (p<0.05, EC50 15.4 
µM). Cell viability was demonstrated to be 88 ± 7 % following incubation with 
Sunitinib at 1 µM concentration, moreover cell viability was demonstrated to be 11 





198 | P a g e  
 
5.3.3. The effects of Sunitinib on cell viability of HL60 cells.    










Figure 21b: MTT assay for Sunitinib treatment dose–response on HL60 cells 
following 24 hours of incubation using concentrations 0.1–100 µM (n=6). Treatment 
groups were standardised to control group for each individual plate.  
From Figure 21b Sunitinib at concentrations 0.1–100 µM demonstrated a significant 
decrease in cell viability of HL60 cells compared to the control (p<0.05, EC50 10 
µM). Cell viability was demonstrated to be 86 ± 5 % following incubation with 
Sunitinib at 1 µM concentration, moreover cell viability was demonstrated to be 15 
± 2 % following incubation with Sunitinib at 100 µM concentration.  
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5.3.4. The effects of Metformin on cell viability of HepG2 cells. 
Figure 22a the effects of Metformin treatment on cell viability of HepG2 cells 










Figure 22a: MTT assay for Metformin treatment dose–response on HepG2 cells 
following 24 hours of incubation using concentrations 6–1000 µM (n=6). Treatment 
groups were standardised to control group for each individual plate.  
From Figure 22a Metformin at concentrations 6-1000 µM demonstrated no 
significant decrease in cell viability in HepG2 cells compared to the control group, 
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5.3.5. The effects of Metformin on cell viability of HL60 cells. 
Figure 22b the effects of Metformin treatment on cell viability of HL60 cells 










Figure 22b: MTT assay for Metformin treatment dose–response on HL60 cells 
following 24 hours of incubation using concentrations 30–1000 µM (n=6). Treatment 
groups were standardised to control group for each individual plate.  
From Figure 22b Metformin at concentrations 30-1000 µM demonstrated no 
significant decrease in cell viability of HL60 cells compared to the control group, 





































5.3.6. The effects of Sunitinib in the absence and presence of Metformin on 
cell viability of HepG2 cells    
Figure 23a the effects of Sunitinib in the absence and presence of Metformin 










Figure 23a: MTT assay for Sunitinib treatment dose–response on HepG2 cells 
following 24 hours of incubation using concentrations 0.1–100 µM (n=6) in the 
absence and presence of Metformin (50 µM) (n=6). Treatment groups were 
standardised to control group for each individual plate. Key: *=p<0.05 Co-treatment 
vs Sunitinib. 
From figure 23a the combination of Sunitinib at concentrations 0.1–100 µM and 
Metformin at 50 µM (co-treatment) demonstrated an overall significant increase in 
cell viability of HepG2 cells compared to the Sunitinib at concentrations 0.1–100 µM 
alone (p<0.05, EC50 34.7 µM for co–treatment vs. EC50 15.4 µM for Sunitinib). Figure 
23a demonstrated a right–shift of the curve for the Sunitinib and Metformin co–
treatment group when compared to the Sunitinib–treatment group alone. The co-
treatment of 50 µM Metformin with Sunitinib at 100 µM concentration demonstrated 
a significant increase in cell viability at compared to Sunitinib at 100 µM alone 
(p<0.05, 18 ± 3 % vs. 11 ± 2 %). 
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5.3.7. The effects of Sunitinib in the absence and presence of Metformin on 
cell viability of HL60 cells    
Figure 23b the effects of Sunitinib in the absence and presence of Metformin 









Figure 23b: MTT assay for Sunitinib treatment dose–response on HL60 cells 
following 24 hours of incubation using concentrations 0.1–100µM (n=6) in the 
absence and presence of Metformin (50 µM) (n=6). Treatment groups were 
standardised to control group for each individual plate. Key: *=p<0.05 Co-treatment 
vs Sunitinib. 
From Figure 23b the combination of Sunitinib at concentrations 0.1–100 µM and 
Metformin at 50 µM (co-treatment) demonstrated an overall significant increase in 
cell viability of HL60 cells compared to the Sunitinib at concentrations 0.1–100 µM 
alone (p<0.05, EC50 18.2 µM for co–treatment vs. 10 µM for Sunitinib). Figure 23b 
demonstrated a right–shift of the curve for the Sunitinib and Metformin co–treatment 
group when compared to the Sunitinib–treatment group alone. Co-treatment of 
Sunitinib at 100 µM concentration with 50 µM Metformin demonstrated a significant 
increase in cell viability compared to Sunitinib at 100 µM alone (p<0.05, 19 ± 2 % 
vs. 15 ± 2 %. Furthermore, Sunitinib at concentrations 30, 60 and 100 µM with 50 
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to Sunitinib 10µM (77 ± 3 % vs. 52 ± 3 %), 30 µM (46 ± 4 % vs. 20 ± 2 %) and 60 
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5.3.8. The effects of NBTI on cell viability of HepG2 cells.    











Figure 24a: MTT assay for NBTI treatment dose–response on HepG2 cells 
following 24 hours of incubation using concentrations 0.1–100 µM (n=6). Treatment 
groups were standardised to control group for each individual plate.  
From Figure 24a it was demonstrated that NBTI administration alone at 
concentrations 0.1–100 µM did not result in a significant decrease in cell viability on 
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5.3.9. The effects of NBTI on cell viability of HL60 cells. 











Figure 24b: MTT assay for NBTI treatment dose–response on HL60 cells following 
24 hours of incubation using concentrations 0.1–100 µM (n=6). Treatment groups 
were standardised to control group for each individual plate.  
From  Figure 24b it was demonstrated that NBTI administration alone at 
concentrations 0.1–100 µM did not result in a significant effect in cell viability on 
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5.3.10. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI on cell viability of HepG2 cells    
Figure 25a the effects of Sunitinib in the absence and presence of Metformin 









Figure 25a: MTT assay for Sunitinib treatment dose–response on HepG2 cells 
following 24 hours of incubation using concentrations 0.1–100 µM (n=6) in the 
absence and presence of Metformin (50 µM) (n=6) and NBTI (1 µM) (n=6). 
Treatment groups were standardised to control group for each individual plate. Key: 
*=p<0.05 Co–treatment+NBTI vs. Sunitinib. 
From Figure 25a the combination of Sunitinib at concentrations 0.1–100 µM, 
Metformin at 50 µM and NBTI 1 µM (co-treatment and NBTI) demonstrated an 
overall significant increase in cell viability of HepG2 cells compared to Sunitinib at 
concentrations 0.1–100 µM alone (p<0.05, EC50 43.3 µM for co–treatment and NBTI 
vs. 15.4 µM for Sunitinib) and an overall significant increase in cell viability when 
compared to the combination of Sunitinib and 50 µM Metformin (co–treatment) 
group alone (p<0.05, EC50 43.3 µM for co–treatment and NBTI vs. 34.7 µM for co-
treatment). Figure 25a demonstrated a right–shift of the curve for the co–treatment 
and NBTI group when compared to the co–treatment group and when compared to 
the Sunitinib treatment group. The combination of Sunitinib, Metformin 50 µM and 
* 
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NBTI 1 µM demonstrated a significant increase in cell viability when compared to 
the Sunitinib treatment group at 30 µM concentration group (p<0.05, 89 ± 6 % vs. 
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5.3.11. The effects of Sunitinib in the absence and presence of Metformin and 
NBTI on cell viability of HL60 cells  
Figure 25b the effects of Sunitinib in the absence and presence of Metformin 
and NBTI treatment on cell viability of HL60 cells  








Figure 25b: MTT assay for Sunitinib treatment dose–response on HL60 cells 
following 24 hours of incubation using concentrations 0.1–100 µM (n=6) in the 
absence and presence of Metformin (50 µM) (n=6) and NBTI (1 µM) (n=6). 
Treatment groups were standardised to control group for each individual plate. Key: 
*=p<0.05 Co–treatment+NBTI vs. Sunitinib. *=p<0.05 Co–treatment vs. Sunitinib. 
*=p<0.05 Co–treatment+NBTI vs. Co-treatment.  
From Figure 25b the combination of Sunitinib at concentrations 0.1–100 µM, 
Metformin at 50 µM and NBTI 1 µM (co-treatment and NBTI) demonstrated an 
overall significant increase in cell viability of HL60 cells compared to the Sunitinib at 
concentrations 0.1–100 µM alone (p<0.05, EC50 33 µM for co–treatment and NBTI 
vs. 10 µm for Sunitinib), and an overall significant increase in cell viability when 
compared to the Sunitinib and Metformin 50 µM (co–treatment) group (p<0.05, EC50 
33.3 µM for co–treatment and NBTI vs. 18.3 µM for co-treatment). Figure 25b 
demonstrated a right–shift of the curve for the co–treatment and NBTI group when 
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group. The combination of Sunitinib, Metformin 50 µM and NBTI 1 µM demonstrated 
a significant increase in cell viability compared to the co-treatment of Metformin 
50µM and Sunitinib at 60µM concentration (p<0.05, 59 ± 8 % vs. 30 ± 5 %). 
Moreover, the combination of Sunitinib, 50 µM Metformin and NBTI 1µM 
demonstrated a significant increase in cell viability compared to the Sunitinib 
treatment group at 30 µM concentration (p<0.05, 69 ± 10 % vs. 20 ± 2 %) and at 60 
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5.4. Discussion  
During cancer treatment, when the cancer is said to be incurable the improvement 
in overall survival via treatment with a potentially cardiotoxic agent will outweigh the 
associated safety risk (Mellor et al. 2010). Moreover, if the drug treatment can be 
used as an adjunctive form, the balance between risk and benefit will need to be 
examined carefully. To date, the TKI Sunitinib is administered, despite reports of 
adverse cardiac events, due to the drug being highly effective within settings where 
treatment is limited especially during oncology drug development where there is an 
issue in achieving anticancer efficiency is considered to be great, the risk of 
cardiotoxicity is considered on balance (Mellor et al. 2010).  
MTT assay results from Figures 21a and 21b demonstrated that Sunitinib resulted 
in a dose–dependent decrease in both HepG2 liver cancer cell viability and HL60 
human leukaemia cell viability. It can be said that cell viability was shown to be 
inhibited at Sunitinib concentrations greater than 10 µM (Figures 21a–21b). To 
support this, it is known that Sunitinib is able to inhibit angiogenesis of cancer cells, 
as well as immune modulation and induce apoptosis in order to mediate an anti–
tumour effect (Mena et al. 2010). Although the direct effect on tumour cells by 
Sunitinib is limited, using existing knowledge of chemotherapy-induced anti-tumour 
properties, it can be suggested that Sunitinib initiated a pro-apoptotic response 
involving mitochondria-mediated apoptosis (Yu and Zhang 2004). The proposed 
effect of Sunitinib can be deduced from Sunitinib’s mode of action binding to 
overexpressed pro–angiogenic growth factors VEGFR and PDGFR, both required 
for tumour cell angiogenesis (Faivre et al. 2007). The ability for Sunitinib to bind to 
VEGFRs, stem–cell factors and PDGFRs was demonstrated to result in a pro-
apoptotic response following the inhibition of the growth of human vein endothelial 
cells (Mendel et al. 2003). Sunitinib-induced activation of apoptosis in cancer cells 
was shown to be suppressed with an overexpression of the Bcl-2 homologue and 
anti-apoptotic protein ML1 myeloid cell leukaemia (MLC-1) (Sun et al. 2012, Fujise 
et al. 2000). In particular Sunitinib was demonstrated to activate PUMA expression 
in colon cancer cells, thusly resulting in the inhibition of Akt (Sun et al. 2012). PUMA 
is said to have an essential role in p53-dependent and independent apoptosis in 
human cancer cells, whilst also shown to activate mitochondrial-mediated apoptosis 
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via Bcl-2 family members Bax/Bak and suppressing anti-apoptotic Bcl-2 proteins 
(Sun et al. 2012, Yu et al. 2001, Yu et al. 2003, Ming et al. 2006). Moreover, DNA 
damage of tumour cells demonstrated p53-dependent induction of PUMA and 
apoptosis (Yu et al. 2003, Wang et al. 2007). Results from figures 21a and 21b can 
be suggested to be attributed to Sunitinib’s involvement in the PI3K/Akt pathway; in 
particular the activation of an apoptotic response (Sun et al. 2012).    
Previous studies demonstrated Sunitinib resulted in a concentration–dependent 
decrease in cell viability (Mendel et al. 2003). Results from the MTT assay dose-
response demonstrated that Sunitinib treatment produced an EC50 concentration of 
15.4 μM in HepG2 cells and 10 µM in HL60 cells in Figures 21a, 21b, 23a and 23b. 
The EC50 concentration demonstrated in our results is greater than the steady–state 
blood concentrations in patients undergoing Sunitinib treatment (Goodman et al. 
2007, Henderson et al. 2013). However, for Sunitinib to demonstrate a cytotoxic 
response, it was demonstrated in glucose and galactose-grown cancer cells that 
EC50 for Sunitinib was established to be 14 μM in glucose-grown cells and 14 μM in 
galactose-grown cells (Will et al. 2008), both concentrations were greater than the 
EC50 concentrations obtained in our study with HL60 cells but less than the EC50 
value achieved with HepG2 cells. As well as a pro–apoptotic response, results in 
Figures 21a–21b can also suggest that Sunitinib may be potentially initiating in an 
inhibition of ATP or the limiting of ATP to cancer cells. TKIs are known to compete 
with ATP for binding to various wild–type and mutated receptor TKs (Faivre et al. 
2007). The effect on ATP content following Sunitinib administration was 
demonstrated by Will et al. (2008) using the myoblast cell line H9c2, an in-vitro 
model to demonstrate cardiac related findings particularly direct mitochondrial 
functional impairment to cytotoxicity (L’Ecuyer et al. 2001, Sardao et al. 2008). 
Similar to our data in Figures 21a and 21b, the data generated by Will et al. (2008) 
suggests that a concentration greater than the clinically relevant dose of 1 µM is 
required to achieve cell death, whilst a concentration greater than 10 µM is needed 
to achieve 100 % inhibition of ATP content and conclude cell death. Sunitinib was 
also said to inhibit oxidative phosphorylation complexes at concentrations above 
clinical Cmax values (Will et al. 2008).  
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Moreover, we have previously demonstrated that Sunitinib treatment at 1 µM using 
the Langendorff system was able to result in a dephosphorylation of p-AMPK 
signalling in animal cardiac tissue following Western blot analysis. From this, it can 
be suggested that Sunitinib has the potential to inhibit ATP and result in the 
inactivation of AMPK phosphorylation, a possible anticancer approach by Sunitinib 
in Figures 21a and 21b. As mentioned previously, ATP is required for the regulation 
of cell growth, proliferation and activation of the AMPK signalling pathway; activated 
during cell starvation of energy to inhibit the biosynthetic pathways of lipid, protein 
and glycogen synthesis in mammals (Stapleton et al. 1996, Webster et al. 1999, 
Doenst et al. 2013, Gupta et al. 2009, Weiss et al. 2005, Ingwall 1993, Bolling et al. 
1991). To support this, as speculated by Force et al. (2007) and as shown by 
Laderoute et al. (2010), Sunitinib results in the inhibition of ATP and thusly 
contributing towards the prevention of AMPK activation and the release of AMPK-
associated downstream targets.  
However, the deregulation of mTOR is hypothesised to lead to cell growth and 
proliferation (Neshat et al. 2001), the signalling pathways associated with this are 
considered to be dysregulated in certain cancers, highlighting the AMPK signalling 
pathway as an area of interest in anti-cancer. For this, we incubated HepG2 and 
HL60 cell lines with Metformin at concentrations up to 1 mM in Figures 22a and 22b. 
The inhibition of the energy salvation pathway via AMPK activation and mTOR 
inhibition can potentially prevent and decrease cancer growth, an example of this is 
in breast cancer where the loss of expression of the tumour suppressor PTEN has 
been demonstrated to lead to uncontrolled activity of mTOR (Neshat et al. 2001, 
Petroulakis et al. 2006). An exposure to a growth inhibitory concentration of a drug, 
such as Metformin in order to indirectly activate AMPK signalling and result in mTOR 
inhibition can lead to decreased protein synthesis, blocking growth and proliferation 
of cancer cells (Zakilkhani et al. 2006, Dowling et al. 2007).  
In Section 4.1.-4.7., we demonstrated that Metformin was able to initiate a 
cardioprotective effect via the activation of the AMPK signalling pathway, as 
evidenced by the inhibition of adenosine with NBTI. In cancer cell studies, the 
addition of adenosine was shown to induce apoptosis in human epithelial cancer 
cells taken from the breast, the colon and the ovary via the intrinsic pathway (Barry 
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and Lind 2000, Schrier et al. 2001, Sai et al. 2006). Adenosine was taken up into 
cells via adenosine transporters, highlighting conversion to AMP by adenosine 
kinase (Barry and Lind 2000, Schrier et al. 2001, Sai et al. 2006). With this, it can 
be suggested that Metformin may be able to result in an anti–cancer effect via the 
use of adenosine particularly via the activation of AMPK. However, we 
demonstrated that up to a concentration of 1 mM, in Figures 22a and 22b, Metformin 
did not demonstrate any significant reductions in cell viability. In contrast to our 
approach, the study by Sai et al. (2006) demonstrated that extracellular adenosine 
activation of AMPK (5 mM) was able to increase apoptosis in rat astrocytoma cells 
and potentially induce cancer cell death, a concentration 5 times greater than the 
highest dose of Metformin used in our study, and 100 times greater than the 
concentration of 50 µM used in our animal studies to demonstrate cardioprotection, 
and therefore would be greater than clinically relevant doses of Metformin.  
As previously described, the primary use of Metformin is in the treatment of T2D 
mellitus, studies have highlighted the potential for Metformin reduce the risk of 
cancer via the involvement of the AMPK signalling pathway (Evans et al. 2005, 
Zakikhani et al. 2006, Ben Sahra et al.2008. Results from Figures 22a and 22b 
demonstrated that Metformin did not result in a significant decrease in live cell 
population or a reduction in cell viability, it was shown that in our MTT experiment 
Metformin at the highest concentration 1 mM did not induce apoptosis in HepG2 or 
HL60 cell lines. To support our results, the study by Ben Sahra et al. (2006) 
demonstrated that Metformin does not induce apoptosis but inhibit the cell cycle at 
the G0/G1 transition phase in DU145, PC–3, LNCaP and P69 cells at concentrations 
1 and 5 mM The study by Ben Sahra et al. (2008) demonstrated that Metformin had 
no effect on caspase-3 activity, whilst Metformin at 1 and 5 mM did not affect 
annexin V positive cells following annexin V-FITC labelling assay in DU145 and PC–
3 cells. Following this, it can be suggested that in order to demonstrate Metformin-
induced cell death in specific cancer cell lines a concentration greater than 1mM is 
required. Within the extrinsic pathway A2 adenosine receptors that are involved with 
G2 proteins are said to play a role in apoptosis in cancer cells including myeloid 
leukaemia cells (Sai et al. 2006). In contrast to A2 adenosine receptors being linked 
to an increase in apoptosis, little evidence exists suggesting A1 adenosine receptors 
are linked to apoptotic pathways, moreover A1 adenosine receptors were shown to 
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attenuate apoptotic cell death (Lee et al. 2004, Pingle et al. 2004, Regan et al. 
2003). The same study by Sai et al. (2006) demonstrated that activation of AMPK 
was able to reduce cell viability but did not enhance adenosine–induced cytotoxicity, 
the authors suggested that adenosine was able to induce cell death by a similar 
mechanism to that of AMPK-induced cell death. The activation of AMPK and 
agonism of adenosine receptors was shown to activate caspases-3 and -9, 
suggesting that adenosine is involved in activation of caspases-3 and -9 via A1 
adenosine receptors and the activation of AMPK (Sai et al. 2006).  
Metformin was shown to inhibit cyclin D1 expression and pRb phosphorylation 
independent of AMPK (Ben Sahra et al. 2008). Cancer cell proliferation and cell 
growth is controlled by cyclins and cyclin inhibitors, in particular one main 
checkpoint is the G1/S transition (Ben Sahra et al. 2008). Cyclin D1 is said to play 
an important role in proliferation by regulating cell cycle machinery, adjusting 
expression levels to that of the proliferative environment of the cell (Ben Sahra et 
al. 2008). Results from Figures 23a and 23b demonstrated that there was an overall 
statistical significance between Sunitinib and the co-treatment of Sunitinib and 
Metformin in both the HepG2 and HL60 cell lines. It was demonstrated in the HepG2 
cell line that the combination of Sunitinib with 50 µM Metformin (co–treatment) 
resulted in an increase in the EC50 concentration when compared to the Sunitinib 
treatment group alone (EC50 34.7 µM for co–treatment vs. 15.4 µM for Sunitinib). 
Moreover, it was also demonstrated in the HL60 cell line that the combination of 
Sunitinib with 50 µM (co-treatment) resulted in an increase in EC50 concentration 
when compared to the Sunitinib treatment group alone (EC50 18.2 µM for co–
treatment vs. 10 µM for Sunitinib).  
Moreover, in the HepG2 cell line, statistical significance was only demonstrated for 
the co–treatment of Metformin 50 µM and Sunitinib at 30 µM concentration against 
the Sunitinib at 30 µM concentration. This demonstrates that Metformin is potentially 
reducing Sunitinib’s anti–proliferative ability at this concentration but is not 
demonstrating a significant change at Sunitinib concentrations lower or greater than 
30 µM. From this, it can be suggested that in the HepG2 cell line the addition of 
Metformin at 50 µM is not having a significant effect on Sunitinib’s anti-proliferative 
properties at the relevant concentration of 1 µM Sunitinib, but at concentrations 
greater than 1 µM Sunitinib, hence the increase in EC50 concertation.  
215 | P a g e  
 
From Figure 25a, the addition of NBTI at 1 µM in combination with Sunitinib and 50 
µM Metformin demonstrated a statistical significant increase in cell viability, when 
compared to the co–treatment group of Metformin 50 µM and Sunitinib at 30 µM 
concentration, but not during other concentrations of Sunitinib. This suggests that 
inhibition of AMPK signalling, via the administration of NBTI, is not resulting in an 
increase in anti-proliferative properties of the co–treatment of Metformin at 50 µM 
with Sunitinib in the HepG2 cell line. However, as shown by Figure 25a a statistically 
significant increase in EC50 concentration was shown for the co–treatment and NBTI 
group (EC50 43.3 µM) when compared to the co–treatment group alone (EC50 34.7 
µM). To support this, the study by Ben Sahra et al. (2008) demonstrated that 
Metformin has the ability to activate AMPK in human prostate cancer cells but can 
mediate its effects independently of AMPK. Inhibition of AMPK was shown to not 
reverse the anti–proliferative properties of Metformin but rather the effects were 
mediated through the mTOR pathway independently of AMPK, suggesting an 
alternative approach (Ben Sahra et al. 2008). To investigate this we would need to 
investigate the role of mTOR signalling during the co-treatment of Sunitinib and 
Metformin, and during the co-treatment of Sunitinib and Metformin and NBTI.  
Similarly to the HepG2 cell line, the HL60 cell line from Figure 23b demonstrated 
that the addition of Metformin at 50 µM (co–treatment) was able to result in an 
increase in the EC50 concentration (EC50 18.2 µM for co–treatment) when compared 
to Sunitinib treatment alone (EC50 10 µM, p<0.05). Results from Figure 23b suggest 
that the addition of Metformin at 50 µM is resulting in a pro-cell proliferative effect 
during co–administration with Sunitinib. Moreover, Metformin at 50 µM in co–
treatment with Sunitinib at concentrations 10, 30, 60 and 100 µM demonstrated a 
statistical significant increase in cell viability when compared to Sunitinib treatment 
alone at concentration 10, 30, 60 and 100 µM (p<0.05). However, the addition of 
Metformin with Sunitinib at the concentration of 1 µM was not statistically significant 
when compared to Sunitinib at concentration of 1 µM alone (p>0.05). This suggests 
that Metformin is not resulting in an increase in cell viability during co–administration 
with Sunitinib at 1 µM but at Sunitinib concentrations greater than 1 µM. The addition 
of NBTI with Sunitinib and Metformin (co–treatment and NBTI) in Figure 25b 
demonstrated a statistically significant increase in EC50 concentration (33 µM) for 
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co–treatment and NBTI) when compared to the co–treatment group alone (18.3 µM, 
p<0.05).   
Many studies have demonstrated Metformin to have an anti-apoptotic effect, and as 
we have shown, Metformin can be used in co–administration with Sunitinib to 
reduce Sunitinib–induced cardiac myocyte damage in Section 4. From our previous 
chapter, it can be suggested that Metformin may be resulting in a similar anti–
apoptotic effect during Sunitinib co–treatment in the HL60 and HepG2 cell lines, 
potentially preventing Sunitinib to initiate an anti–cell proliferative effect in the HL60 
and HepG2 cell lines. However, the addition of NBTI at 1 µM with the combination 
of Sunitinib and Metformin at 50 µM resulted in an increase in the EC50 value and 
an increase in cell proliferation in both the HepG2 and HL60 cell line, when 
compared to the combination of Sunitinib and Metformin at 50 µM alone. This 
suggests that the activation of AMPK is having an involvement in preventing 
Sunitinib’s anti-proliferative properties. Moreover, the prevention of Sunitinib’s anti-
proliferative properties is having a greater effect in the HL60 cell line than in the 
HepG2 cell line. Moreover, results from Figures 23a-23b and 25a–25b suggest that 
although AMPK activation is occurring by the addition of Metformin, this is not 
resulting in a complete inhibition of Sunitinib’s anti-proliferative properties, as 
evidenced by the continued decrease in cell viability during co–administration with 
50 µM Metformin and the co–treatment with 50 µM Metformin and NBTI. The 
inhibition of AMPK signalling was previously suggested to be an indirect mode of 
Sunitinib’s anti-proliferative properties (Force et al. 2007). To support this, we 
previously highlighted that although Sunitinib was able to decrease phosphorylation 
of AMPK compared to non–treatment, Sunitinib did not result in a complete 
inhibition of AMPK signalling in Section 4. From this, previous reports and literature 
have highlighted that the inhibition of AMPK signalling is associated with the release 
of mTOR signalling and downstream–associated targets, (Laderoute et al. 2010, 
Force et al. 2007).  
mTOR, alongside the upstream PI3K/Akt signalling pathway, has been associated 
with proliferation and growth of certain cancer cells particularly leukaemia (HL60) 
cells (Liu et al. 2016, Xu et al. 2003, Pathania et al. 2013, Sun et al. 2011). The 
mTOR signalling pathway was reported to be upregulated in 40–50 % in 
hepatocellular samples, whilst inhibition of mTOR was reported to demonstrate 
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antitumoural activity (Liu et al. 2016, Sieghart et al. 2007, Sahin et al. 2004, 
Vilanueva et al. 2008, Gabrinksi et al. 2012). Inhibition of mTOR, and the associated 
down–stream targets, was demonstrated to result in a pro–apoptotic response of 
HL60 cells (Pathania et al. 2013). The over-activation of the PI3K/Akt/mTOR 
pathway is associated with the activation of HIF1α, required for the regulation of 
tumour genesis and angiogenesis (Semenza 2003, Hu et al. 2012, Soni and 
Padwad 2017, Sun et al. 2011, Liu et al. 2016, Zakikhani et al. 2006). It would be 
hypothesised that the inhibition of AMPK signalling, in Figures 25a and 25b, could 
have contributed towards the potential activation of mTOR signalling and thereby 
resulting in an increase in cancer cell proliferation in the HL60 and HepG2 cell lines, 
but not during incubation with the highest concentration of Sunitinib, however in 
order to demonstrate this an inhibitor of mTOR signalling such as Temsirolimus 
would need to be utilised in our study with the combination of Sunitinib and 
Metformin.  
It must be noted that Metformin is a biguanide and does not activate AMPK directly 
in cell free assays, unlike the compound AICAR, but rather indirectly via the 
inhibition of the complex -1 of the respiratory chain complex in order to increase the 
AMP: ATP ratio, the effect of Metformin could be from the result of ATP depletion 
rather than AMPK activation (Hardie 2003). As discussed, results from the MTT 
assay would suggest that Sunitinib is resulting in an ATP–decreasing effect in cell 
lines; the resulting effect would be counter-balanced by Metformin’s ability to restore 
energy deprivation levels via increasing AMP (Foretz and Viollet 2011, Winder and 
Hardie 1999). Nevertheless, it was demonstrated in the HepG2 and HL60 cell lines 
that co-administration of Sunitinib with Metformin resulted in an increase in the EC50 
concentration, however the co-administration did not result in an inhibition of 
Sunitinib’s anti-proliferative properties. The effects of Metformin could be potentially 
independent of AMPK in the cell lines (Ben Sahra et al. 2008), however further work 
would need carried out to determine the direct role of AMPK and mTOR down–
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5.5. Conclusion 
To conclude, results obtained in Section 5 have demonstrated the use of the MTT 
assay to investigate the cell proliferative ability of Sunitinib during co–administration 
with Metformin at 50 µM in HepG2 and HL60 cancer cell lines. Moreover, the 
combination of Sunitinib with Metformin was administered with the AMPK inhibitor 
NBTI to investigate the potential for the inhibition of AMPK during activation by 
Metformin. Results in Section 5.3.1 have demonstrated the increase in EC50 
concentration for the co–administration of Metformin with Sunitinib when compared 
to Sunitinib treatment alone, as well as a right-shift of the curve. However, the 
addition of Metformin did not result in a complete inhibition of Sunitinib’s anti–
proliferative ability; whilst the addition of Metformin had no statistically significantly 
effect on Sunitinib at 1 µM concentration, the concentration used in the Langendorff 
study in Sections 3-4. Metformin and NBTI alone did not demonstrate a significant 
decrease of cell viability in either HepG2 or HL60 cell lines. The introduction of NBTI 
demonstrated a statistically significance increase in EC50 concentration when 
compared to the co–treatment groups alone, however this may be resulting from 
several down-stream targets following AMPK inhibition, such as the proposed 
activation of mTOR signalling. However, despite causing an increase in EC50 
concentration, the use of NBTI was only shown to significantly increase cell viability 
for the co–treatment of Metformin and Sunitinib at 30 µM concentration in the 
HepG2 cell line, and significantly increased cell viability for the co–treatment of 
Metformin and Sunitinib at 60 µM concentration in the HL60 cell line. Results 
obtained could suggest an AMPK–independent effect of Metformin co-treatment, 
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Chapter Six: General Discussion. 
6.1. Summary of findings 
The aim of this study was to investigate the potential for Metformin to demonstrate 
cardioprotective properties when administered together with Sunitinib treatment 
whilst also investigating the associated intracellular mechanism involved in 
cardioprotection using ex-vivo modelling of the Langendorff system and primary 
isolated cardiac myocytes. Moreover, we further investigated the associated effects 
of both Metformin and Sunitinib administration in in-vitro cancer cell models 
involving HepG2 and HL60 cancer cell lines.   
In summary, our results demonstrated the effects of cardiotoxicity associated with 
Sunitinib administration using Langendorff perfused rat hearts and isolated cardiac 
myocytes. Sunitinib resulted in a significant decrease in haemodynamic function as 
evidenced by a significant decrease in LVDP in comparison to vehicle control. 
Moreover, Sunitinib resulted in a significant increase in infarct percentage when 
compared to vehicle control. The administration of Metformin together with Sunitinib 
was demonstrated to attenuate this increase in infarct percentage that was caused 
by Sunitinib administration alone. Moreover, the co-administration of Metformin was 
shown to restore changes in haemodynamic parameters of LVDP, similar to that of 
the vehicle control. However, it was further shown that the co-treatment of Metformin 
and Sunitinib demonstrated a significant decrease in CF at the 160 and 175 minute 
time points, demonstrating possible vasoconstrictive properties as discussed 
previously.   
Following this, we investigated the intracellular signalling and role of AMPK in 
Metformin-induced cardioprotection. The use of NBTI in combination with Metformin 
and Sunitinib inhibited the cardioprotective properties of Metformin, as evidenced 
by an increase in infarct percentage and a decrease of live cell population of isolated 
cardiac myocytes. The role of AMPK signalling was demonstrated using Western 
blot analysis of left atrium tissue following Langendorff perfusion. This was 
evidenced by an increase in phosphorylated AMPK signalling during co-
administration of Metformin with Sunitinib, compared to Sunitinib administration 
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alone. The increase in phosphorylated AMPK signalling was shown to be attenuated 
during the combination of Metformin, Sunitinib and NBTI.    
Furthermore, it was demonstrated that the combination of Metformin with Sunitinib 
resulted in an increase in the EC50 concentration when compared to Sunitinib 
treatment alone in both HepG2 and HL60 cancer cell lines. However, this adds to 
the risk-benefit balance debate, in regards to this the potential benefits of Metformin 
administration would need to be weighed up against the potential for Metformin to 
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6.2. Considerations and concluding remarks 
6.2.1. Mechanism of Sunitinib-induced cardiotoxicity 
The presented study warrants further research in regards to the direct mechanism 
of Sunitinib-induced cardiotoxicity. In particular the direct role of Sunitinib on AMPK 
signalling would need to be investigated further. It is worth considering if Sunitinib 
is resulting in a direct inhibition of AMPK signalling as suggested by a majority of 
literature, or if Sunitinib is resulting in an indirect reduction in AMPK signalling due 
to ATP-inhibiting properties. Moreover, this would also apply to Sunitinib-induced 
cardiotoxicity, this could suggest the inhibition of ATP via Sunitinib is resulting in a 
decrease in cardiac myocyte viability due to a reduction in ATP available, but not 
resulting in a direct activation of apoptosis or necrosis. For this, it is worth 
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6.2.2. Considerations for Metformin use 
When administering Metformin, it is worth considering the possibility of 
nephrotoxicity and lactic acidosis during ST-segment elevation myocardial infarction 
and reperfusion via primary percutaneous coronary intervention, as mentioned this 
can arise following prolonged AMPK activation (Bromage and Yellon 2015). In this 
regard, a risk-benefit balance will be required as well as precautionary safety profile 
when considering a level 2 study. Furthermore, it was noted by Hardie (2006) in his 
correspondence letter that the inhibition of the respiratory chain by biguanides 
accounts for the case of lactic acidosis and that this led to the withdrawal of 
Phenformin, with the side effect being more common with Phenformin than 
Metformin. The side effect may be more prominent due to the drug being able to 
enter cell more rapidly and can build up concentrations sufficient enough to result 
in a complete inhibition of the respiratory chain, with changes in cellular AMP: ATP 
more readily observed during incubation of cells with Phenformin but more difficult 
with Metformin (Hawley et al. 2005, Hawley et al. 2002, Hardie 2006). It must be 
reiterated that results observed in this study did not demonstrate toxicity properties 
during Metformin administration; however a significant decrease in CF was shown 
during Metformin coadministration with Sunitinib at the 160 and 175 minute time 
points compared to the vehicle control, highlighting that the use of Metformin as an 
adjunctive treatment is not without caution as suggested by previous studies 
discussed in section 3.4. These considerations of Metformin use would need to be 
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6.2.3. Concluding remarks  
As demonstrated, Sunitinib-induced cardiotoxicity was shown to be attenuated 
using the co-administration with Metformin. However further research is required in 
regards to the chronic administration of Sunitinib but also if Metformin is suitable for 
use in in-vivo experimentation. Although a good starting point, it is known that 
Langendorff studies involving coronary organs are not the same as in-vivo 
experimentation. For this, careful considerations need to account for factors such 
as the health of the animals, age, weight, hormonal and the effects of the 
administration of Metformin and Sunitinib on other organs. From this, the whole 
bodily processes such as intracellular stresses could contribute towards toxicity of 
Sunitinib, whilst liver health and activity in the liver could prevent the 
cardioprotective properties of Metformin following administration.  
When interpreting our data, it is important to understand that when administering 
Sunitinib and Metformin, a significant number of down-stream effects could be 
promoted and could contribute towards cell survival and overall survival for patients, 
however our research focussed primarily on the investigation of AMPK signalling in 
the heart and the co-administrative effects Metformin and Sunitinib in cancer cell 
lines. With this in mind, many studies exist regarding the investigation of several 
pathways, aside from AMPK signalling, with the respective effects on the heart. As 
touched in Sections 3.1.-5.5., it is always worth investigating the mechanisms of 
upstream and downstream signalling pathways and associated proteins in order to 
further evaluate the effects of Metformin when co-administered with Sunitinib. 
Nevertheless, it must be reiterated that our results demonstrated that Metformin was 
able to significantly reduce effects of Sunitinib-induced cardiotoxicity in SD rat 
hearts, associated with AMPK signalling. Although the co-administration was shown 
to result in an increase in the EC50 concentration of Sunitinib when compared to 
Sunitinib administration alone in cancer cell lines, Metformin did not result in a 
complete inhibition or prevention of Sunitinib’s anti-cancer properties. As mentioned 
in Section 6.1., this adds to the risk-benefit balance debate and the potential for 
Metformin to reduce the cytotoxic properties of Sunitinib treatment would need to 
be discussed in a wider context.  
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Chapter Seven: Appendix 
7.1. The effects of Sunitinib ± Metformin ± NBTI on haemodynamics in 7-8 
months female SD rat hearts.    
Figure i the effects of Sunitinib in the absence and presence of Metformin and 











Figure i: The effects of drug treatment on HR as a percentage of mean stabilisation: 
vehicle control (blue), Metformin (50 µM) (green), Sunitinib (1 µM) (red), the 
combination of Metformin (50 µM) and Sunitinib (1 µM) (co-treatment, purple), NBTI 
(1 µM) (turquoise), and the combination of Metformin (50 µM), Sunitinib (1 µM) and 
NBTI (1 µM) (co-treatment and NBTI, orange). Data is presented as mean ± SEM 
of 6 experiments (n=6).   
From figure i, it can be seen that there was no overall change in HR at set time 
points between all treatment groups. 
 
From figure i, single factor ANOVA and post-hoc Tukey and LSD demonstrated no 
statistical significant changes to HR during the treatment period for the Sunitinib 
group compared to vehicle control at selected time points (p>0.05). Moreover, the 
combination of Metformin and Sunitinib (cotreatment) group demonstrated no 
statistical significant changes to HR when compared to Sunitinib treatment at 
selected time points (P>0.05). Furthermore, the combination of Metformin, Sunitinib 
and NBTI (co-treatment and NBTI) group demonstrated no statistical significant 
Stabillisation 
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change to HR when compared to the combination of Metformin and Sunitinib (co-
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Figure ii The effects of Sunitinib in the absence and presence of Metformin 








Figure ii:  The effects of drug treatment on LVDP as a percentage of mean 
stabilisation: vehicle control (blue), Metformin (50 µM) (green), Sunitinib (1 µM) 
(red), the combination of Metformin (50 µM) and Sunitinib (1 µM) (co-treatment, 
purple), NBTI (1 µM) (turquoise), and the combination of Metformin (50 µM), 
Sunitinib (1 µM) and NBTI (1 µM) (co-treatment and NBTI, orange). Data is 
presented as mean ± SEM of 6 experiments (n=6). Key statistical significance: 
*=p<0.05 Sunitinib vs vehicle control.  *=p<0.05 Sunitinib vs Co-treatment. *=p<0.05 
Co-treatment vs Co-treatment and NBTI. 
From Figure ii, it can be seen that there is a decrease in LVDP for the Sunitinib 
treatment group compared to the vehicle control group at specific time points. 
Moreover, it can be seen that the combination of Metformin and Sunitinib (co-
treatment) group attenuated the Sunitinib-induced decrease in LVDP at specific 
time points 145, 160 and 175 minutes. Furthermore, the addition of NBTI with 
Metformin and Sunitinib (co-treatment and NBTI) decreased LVDP when compared 
to the Metformin and Sunitinib (co-treatment) group at the 160 and 175 minute time 
points.  
From Figure ii, single factor ANOVA with post-hoc Tukey and LSD demonstrated 
statistical significance for the Sunitinib treatment group against vehicle control at 
selected time points 115, 130, 145, 160 and 175 minutes (p<0.05, 115 minute; 91 
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± 3 % vs. 76 ± 4 %, 130 minute; 86 ± 3 % vs. 73 ± 4 %, 145 minute; 82 ± 4% vs. 68 
± 3 %, 160 minute; 82 ± 5 % vs. 67 ± 3 %, 175 minute; 64 ± 2 % vs. 78 ± 4 %). 
Moreover, single factor ANOVA and post-hoc Tukey and LSD demonstrated 
statistical significance for the Sunitinib and Metformin (co-treatment) group against 
the Sunitinib treatment group at selected time points 145, 160 and 175 minutes 
(p<0.05, 145 minute; 80 ± 3 % vs. 68 ± 3 %, 160 minute; 78 ± 4 % vs. 67 ± 3 %, 175 
minute; 78 ± 3 % vs. 64 ± 2 %). Furthermore, single factor ANOVA with post-hoc 
Tukey and LSD demonstrated statistical significance for the Sunitinib, Metformin 
and NBTI (co-treatment and NBTI) treatment group against the Sunitinib and 
Metformin (co-treatment) group at selected time points 160 and 175 minutes 
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Figure iii The effects of Sunitinib in the absence and presence of Metformin 













Figure iii: The effects of drug treatment on CF as a percentage of mean 
stabilisation: vehicle control (blue), Metformin (50µM) (green), Sunitinib (1µM) (red), 
the combination of Metformin (50µM) and Sunitinib (1µM) (co-treatment, purple), 
NBTI (1µM) (turquoise), and the combination of Metformin (50µM), Sunitinib (1µM) 
and NBTI (1µM) (co-treatment and NBTI, orange). Data is presented as mean ± 
SEM of 6 experiments (n=6). Key statistical significance: *=p<0.05 Sunitinib vs 
vehicle control. *=p<0.05 Sunitinib vs Co-treatment. *=p<0.05 Co-treatment vs Co-
treatment and NBTI. 
From figure iii, it can be seen that the Sunitinib treatment group decreased CF when 
compared to the vehicle control group at certain time points. Moreover, the 
Sunitinib-induced decrease in CF was shown to be attenuated at specific time points 
following the combination of Metformin and Sunitinib (co-treatment), when 
compared to the Sunitinib treatment group. Furthermore, the addition of NBTI with 
Metformin and Sunitinib (co-treatment and NBTI) was shown to decrease CF when 
compared to the Metformin and Sunitinib (co-treatment) group at specific time 
points.     
From figure iii, single factor ANOVA with post-hoc Tukey and LSD demonstrated 
statistical significance for the Sunitinib treatment group against vehicle control at 
// 
Stabillisation 
Drug added  
* * * 
* * * 
* * 
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selected time points 145, 160 and 175 minutes (p<0.05, 145 minute; 51 ± 5 % vs. 
70 ± 4 %, 160 minute; 48 ± 3 % vs. 68 ± 4 %, 175 minute; 48 ± 4 % vs. 67 ± 4 %). 
Moreover single factor ANOVA and post-hoc Tukey and LSD demonstrated 
statistical significance for the Sunitinib and Metformin (co-treatment) group against 
the Sunitinib treatment group at selected time points 145, 160 and 175 minutes 
(p<0.05, 145 minute; 70 ± 2 % vs. 51 ± 5 %, 160 minute; 69 ± 3 % vs. 48 ± 3 %, 175 
minute; 64 ± 1 % vs. 48 ± 4 %). Furthermore, single factor ANOVA with post-hoc 
Tukey and LSD demonstrated statistical significance for the Sunitinib, Metformin 
and NBTI (co-treatment and NBTI) treatment group against the Sunitinib and 
Metformin (co-treatment) group at selected time points 160 and 175 minutes 
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7.2. The effects of Sunitinib ± Metformin ± NBTI on infarct percentage in 7-8 
months female SD rat hearts.    
Figure iv the effects of Sunitinib in the absence and presence of Metformin 













Figure iv: The effects of vehicle control, Metformin (50µM), Sunitinib (1µM), the 
combination of Metformin and Sunitinib (Co-treatment), NBTI (1µM) and the 
combination of Metformin, Sunitinib and NBTI on infarct percentage (%). Data is 
presented as mean ±SEM of 6 experiments (n=6). Key statistical significance: 
***=p<0.001 Sunitinib vs vehicle control. #=p<0.05 Co-treatment vs Sunitinib, 
$=p<0.05 Co-treatment and NBTI vs Co-treatment. 
From figure iv, it can be seen that the Sunitinib treatment group resulted in an 
increase in infarct percentage when compared to the vehicle control. Moreover, the 
co-treatment group was shown to attenuate the Sunitinib-induced increase in infarct 
percentage. Furthermore, the addition of NBTI with Metformin and Sunitinib (co-
treatment and NBTI) was shown to attenuate the decrease in infarct percentage 
when compared to the co-treatment group.  
From figure iv, single factor ANOVA with post-hoc Tukey and LSD demonstrated 
statistical significance between the Sunitinib treatment group compared to the 
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was shown for the Metformin and Sunitinib (co-treatment) treatment group when 
compared to the Sunitinib treatment group (p<0.05, 18 ± 2 % vs. 33 ± 1 %). 
Furthermore, statistical significance was shown for the Metformin, Sunitinib and 
NBTI (co-treatment and NBTI) group when compared to the Metformin and Sunitinib 
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